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Patients with type 1 and type 2 diabetes have very different treatment and care 
requirements. Overlapping phenotypes and lack of clear classification 
guidelines make it difficult for clinicians to differentiate between type 1 and type 
2 diabetes at diagnosis. The rate of glycaemic deterioration is highly variable in 
patients with type 2 diabetes but there is no single test to accurately identify 
which patients will progress rapidly to requiring insulin therapy. Incorrect 
treatment and care decisions in diabetes can have life-threatening 
consequences. 
The aim of this thesis is to develop clinical prediction models that can be 
incorporated into routine clinical practice to assist clinicians with the 
classification and care of patient diagnosed with diabetes. We addressed the 
problem first by integrating features previously associated with classification of 
type 1 and type 2 diabetes to develop a diagnostic model using logistic 
regression to identify, at diagnosis, patients with type 1 diabetes. The high 
performance achieved by this model was comparable to that of machine 
learning algorithms.  
In patients diagnosed with type 2 diabetes, we found that patients who were 
GADA positive and had genetic susceptibility to type 1 diabetes progressed 
more rapidly to requiring insulin therapy. We built upon this finding to develop a 
prognostic model integrating predictive features of glycaemic deterioration to 
predict early insulin requirement in adults diagnosed with type 2 diabetes.  
The three main findings of this thesis have the potential to change the way that 




Use of the diagnostic model developed to identify patients with type 1 diabetes 
has the potential to reduce misclassification. Classifying patients according to 
the model has the benefit of being more akin to the treatment needs of the 
patient rather than the aetiopathological definitions used in current clinical 
guidelines. The design of the model lends itself to implementing a triage-based 
approach to diabetes subtype diagnosis.  
Our second main finding alters the clinical implications of a positive GADA test 
in patients diagnosed with type 2 diabetes. For identifying patients likely to 
progress rapidly to insulin, genetic testing is only beneficial in patients who test 
positive for GADA. In clinical practice, a two-step screening process could be 
implemented - only patients who test positive for GADA in the first step would 
go on for genetic testing. 
The prognostic model can be used in clinical practice to predict a patient’s rate 
of glycaemic deterioration leading to a requirement for insulin. The availability of 
this data will enable clinical practices to more effectively manage their patient 
lists, prioritising more intensive follow up for those patients who are at high risk 
of rapid progression. Patients are likely to benefit from tailored treatment. 
Another key clinical use of the prognostic model is the identification of patients 
who would benefit most from GADA testing saving both inconvenience to the 




Table of Contents 
 
Acknowledgments .............................................................................................. 5 
Abbreviations ...................................................................................................... 6 
 Introduction .................................................................................. 8 
 Development and validation of multivariable clinical diagnostic 
models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 
18 to 50  .................................................................................................. 54 
 Logistic regression has similar performance to optimised machine 
learning algorithms in a clinical setting: application to the classification of type 1 
and type 2 diabetes in young adults ............................................................... 103 
 A Type 1 Diabetes Genetic Risk Score can identify patients with 
GAD65 autoantibody positive type 2 diabetes that rapidly progress to insulin 
therapy  ................................................................................................ 137 
 Predicting early insulin requirement in adults diagnosed with type 
2 diabetes: development and external validation of a multivariable survival 
model  ................................................................................................ 171 
 Discussion ............................................................................... 217 
Appendix 1:  R Code for creating diabetes classification model shiny app ..... 249 
Appendix 2:  R Code for machine learning and logistic regression comparison







I am sincerely grateful to my supervisors Dr Angus Jones, Dr Beverley Shields 
and Professor Andrew Hattersley for giving me the wonderful and life changing 
opportunity to do this PhD. I would like to express my special appreciation to Dr 
Jones for sharing his diabetes expertise and guiding my statistical writing into 
something more interpretable for clinical audiences, and to Dr Shields for both 
sharing her knowledge so generously and providing mentorship on the 
statistical aspects of my PhD. I would also like to thank my pastoral tutor 
Professor David Richards for his time, encouragement and words of wisdom 
that kept me going during my low times.  
I have been privileged to work with amazing people in the diabetes research 
team and thank you all for your collaboration and friendship. I would particularly 
like to thank Dr John Dennis for being a role model, sharing his statistical 
expertise and always knowing which Stata or R function I should use, and to Dr 
Lauric Ferrat for sharing his passion for mathematical modelling with me.  
I am also very grateful to collaborators in Dundee, Oxford and The Netherlands 
for allowing me to use their data and being so helpful answering my queries, 
and to everyone in the Exeter NIHR Clinical Research Facility team for all their 
hard work helping me clean and understand the Exeter study data.  
Last but not least, to my wonderful husband Neil I send a very special heartfelt 
thank you for all your emotional and financial support during these past three 
years. I will be eternally grateful for your patience and encouragement, and for 





ADOPT A Diabetes Outcome Progression Trial 
AIC Akaike information criterion 
ALT Alanine Transaminase 
AUPRC Area Under the Precision Recall Curve 
BIC Bayesian information criterion 
BMI Body Mass Index 
CRF Clinical Research Facility 
DARE Diabetes Alliance for Research in England 
DCS Hoorn Diabetes Care System 
DPP4 inhibitor  Dipeptidyl peptidase-4 inhibitor 
eGFR:  estimated Glomerular Filtration Rate 
GADA GAD65 autoantibodies 
GBM Gradient Boosting Machine  
GLP-1 receptor 
agonist  
Glucagon-like peptide 1 receptor agonist 
GoDarts Genetics of Diabetes Audit and Research in Tayside 
Scotland 
HbA1c  Hemoglobin A1c 
HDL High-Density Lipoprotein 
HLA Human Leukocyte Antigen 
HOMA Homoeostatic Model Assessment 
IA-2 Islet Antigen 2 
IAA:  Insulin Autoantibodies 
ICA Islet Cell Antibodies   
KNN K-Nearest Neighbours  
LADA Latent Autoimmune Diabetes in Adults 
LDL Low-Density Lipoprotein 
LR Logistic Regression  
ML Machine Learning 
MODY Maturity-Onset Diabetes of the Young 
MRC Medical Research Council 
NICE National Institute for Health and Clinical Excellence 
NN Neural Network  
NPV Negative predictive value 
PPV Positive predictive value 
PRIBA Predicting Response to Incretin Based Agents in Type 2 
Diabetes 
PROMASTER PROspective Cohort MRC ABPI STratification and 
Extreme Response Mechanism in Diabetes 
RETROMASTER RETROspective Cohort MRC ABPI STratification and 
Extreme Response Mechanism in Diabetes 
RF Random Forest  
ROC AUC Area Under the Receiver Operating Characteristic Curve 
RP Royston-Parmar flexible parametric survival model 
SAID Severe AutoImmune Diabetes 
SGLT2 inhibitors Sodium-glucose co-transporter-2 inhibitors 




SNP Single-Nucleotide Polymorphism 
STARD Standards for the Reporting of Diagnostic Accuracy 
Studies 
StartRight Getting the Right Classification and Treatment From 
Diagnosis in Adults With Diabetes  
SVM Support Vector Machine 
T1D  Type 1 Diabetes 
T1D GRS Type 1 Diabetes Genetic Risk Score 
T2D GRS Type 2 Diabetes Genetic Risk Score 
TRIG Triglycerides 
TRIPOD Transparent Reporting of a multivariable prediction model 
for Individual Prognosis Or Diagnosis 
UCPCR:   Urinary C-peptide Creatinine Ratio 
UKPDS United Kingdom Prospective Diabetes Study 
VI Variable Importance 
WHO World Health Organisation 
YDX Young Diabetes in Oxford 














This chapter is divided into four parts. 
First the aims and structure of this thesis are stated. We then present the 
treatment and management challenges of type 1 and type 2 diabetes that can 
occur in clinical practice and review the current evidence on clinical features 
and biomarkers associated with classification and glycaemic progression. 
Next the challenges associated with the implementation of clinical prediction 
models into clinical practice are discussed and the key methodological 
approaches to diagnostic and prognostic model development and validation are 
reviewed. Finally we introduce the datasets used in subsequent chapters of this 
thesis. 
1.2 Aims and structure of thesis 
The overall aim of this thesis is to develop clinical prediction models that can 
assist with the classification and care of patient diagnosed with diabetes in 
clinical practice.  
The thesis is divided into six chapters.  
This chapter (chapter 1) presents an overview of the treatment and 
management challenges of type 1 and type 2 diabetes that can occur in clinical 
practice and the opportunity for the development of clinical prediction models. 
In Chapter 2, we investigate whether patient clinical features and biomarkers 
can be used to differentiate between different diabetes subtypes (type 1 and 
type 2) at diagnosis by applying logistic regression modelling, and validate our 




In chapter 3, we compare the performance of five different supervised machine 
learning algorithms and logistic regression using the diabetes subtype 
classification example from chapter 2.  
In chapter 4, we examine whether common type 1 diabetes genetic variants can 
predict rapid glycaemic deterioration (time to insulin therapy from diagnosis) 
over and above GADA testing in patients clinically diagnosed with type 2 
diabetes.  
In chapter 5, we apply flexible parametric survival analysis to investigate the 
use of clinical features and biomarkers of patients clinically diagnosed with type 
2 diabetes to predict rapid glycaemic deterioration (time to insulin therapy from 
diagnosis), and validate our findings with an independent dataset. 
Chapter 6 is a discussion of the main findings, conclusions, limitations and 
future work generated by each chapter. 
1.3 Treatment and management challenges of type 1 and type 2 
diabetes 
1.3.1 Overview of diabetes  
Diabetes is a disease in which the body’s ability to regulate sugar in the blood 
(glucose) is impaired leading to excess sugar in the blood (hyperglycaemia) 
which is a cause of serious health conditions such as diabetic retinopathy, 
nephropathy and neuropathy (1). Type 1 and type 2 are the two major subtypes 
of diabetes with type 2 being more common.  
1.3.2 Type 1 diabetes 
Type 1 diabetes is characterised by beta-cell destruction leading to rapid 




diagnosed with diabetes when they present with symptoms such as thirst or 
tiredness, or in a metabolic crisis.     
This severe insulin deficiency leads to acute glucose fluctuations which need to 
be controlled by continuous glycose monitoring and physiological insulin 
replacement administered by intensive insulin regimens (multiple daily injections 
or continuous subcutaneous insulin infusion therapy using an insulin pump) (3, 
6). Patients with type 1 diabetes need insulin treatment in the early stages of 
the disease; without insulin treatment they are at risk of acids building up in the 
blood (ketoacidosis) which can be life-threatening (7).  
1.3.3 Type 2 diabetes 
In contrast, type 2 diabetes is a progressive metabolic disease (also called 
metabolic disorder). Patients with type 2 diabetes can still produce insulin 
(unlike type 1 diabetes) but their body is unable to use it effectively, the beta 
cells become exhausted leading to a gradual reduction in the capacity of the 
beta cells to make insulin (8, 9). Patients with type 2 diabetes do not develop 
the severe insulin deficiency that is seen in patients with type 1 diabetes, they 
can usually be successfully treated initially with lifestyle changes or oral agents 
for many years (10-12) or can even achieve remission by maintained weight 
loss (13). However, due to this characteristic progressive reduction, many 
patients will eventually require insulin therapy to maintain glucose control (11). 
1.3.4 Importance of diabetes subtype classification for clinical management 
Severe insulin deficiency is the fundamental difference between type 1 and type 
2 diabetes and it is this deficiency that determines treatment requirements. To 
ensure that a patient receives the correct treatment it is therefore critical to 




diagnosis, based on a definition that closely aligns to their treatment 
requirement. However, correctly classifying patients is challenging (14, 15) 
because of the overlapping phenotypes of these diabetes subtypes (16, 17) and 
a lack of clear classification guidelines which tend to focus on the 
aetiopathological definitions rather than ones that relate to treatment 
requirements (2, 5, 18, 19).  
No clinical features and biomarkers provide perfect separation when used in 
isolation. Individual patients can have some features that would indicate type 1 
whilst their other features indicate type 2. Many of the tests that can assist 
classification are not routinely indicated in clinical practice and the lack of a 
single diagnostic test that can be used to classify diabetes robustly at diagnosis 
also makes classification challenging in clinical practice. There are no existing 
prediction models that can be used for classification of type 1 and type 2 
diabetes at diagnosis. All of these challenges combined contribute to the 
serious and common problem of misclassification in type 1 and type 2 diabetes 
(20-22). Incorrectly classifying patients with type 1 diabetes as type 2 can have 
life-threatening consequences; without insulin therapy, patients with type 1 
diabetes are at risk of ketoacidosis which left untreated can be fatal (7). Patients 
with type 2 diabetes incorrectly classified as type 1 will be treated un-
necessarily with insulin: as a result, patients may suffer unfounded negative 
quality of life impacts such as work restrictions and the health service treatment 




1.3.5 Clinical features and biomarkers associated with classification of type 1 
and type 2 diabetes 
Clinical features 
The use of age of diagnosis and BMI jointly predominates in clinical practice for 
diabetes classification, with younger age and lower BMI historically associated 
with type 1 diabetes; both of these features have strong evidence for utility at 
diagnosis (22) and are easily obtained. However these features are becoming 
less distinctive, type 2 diabetes is occurring in young patients as obesity levels 
increase (16) and type 1 diabetes can occur in adults (17).  
Presentation of symptoms such as glycaemia, weight loss or ketosis at 
diagnosis, glucose metabolism and family history of type 1 or type 2 diabetes in 
first-degree relatives are often used in clinical practice to classify patients but 
classification based on these features has little or no evidence base (22).  
Islet-autoantibodies 
The presence of one or more islet-autoantibodies (GAD65 autoantibodies 
(GADA) (23, 24), Islet Antigen 2 (IA-2) (23, 25), Zinc transporter 8 (ZnT8) (26), 
insulin autoantibodies (IAA) (23, 27) and Islet Cell Antibodies (ICA) (27)) is a 
marker of type 1 diabetes. GADA, IA-2 and ZnT8 are the three islet-
autoantibodies most often used in clinical practice. Testing for ICA has largely 
been superseded by testing for individual autoantibodies (GADA, IA-2 and 
ZnT8).  
There are limitations associated with the use of islet-autoantibodies to classify 
diabetes subtype that mean that widespread testing would not solve 
misclassification alone. The sensitivity of the tests for these markers performed 




life (27) and thus may have utility at diagnosis, islet-autoantibodies are not 
detectable at diagnosis in all patients with type 1 diabetes and longer durations 
post diagnosis are associated with higher negativity (28). The presence of 
multiple islet-autoantibodies increases the specificity of the tests (23, 27) but 
comprehensive testing is not routinely indicated in clinical practice.  
Other potential limitations are that the frequency of islet-autoantibody positivity 
may differ by ethnicity and/or sex although the evidence for these findings is 
weak as they are based on small studies (29-31) and IAA testing is only useful 
at first diagnosis since IAA is increased with exogenous insulin use (32).  
Whilst GADA is a marker of type 1 diabetes, many adult patients with type 2 
diabetes appear GADA positive (33, 34) but do not have the characteristics 
associated with type 1 diabetes. GADA is an imperfect diagnostic test: the 
likelihood of false positive result when testing in an adult population with low 
prevalence of type 1 diabetes will be high (35). This means that consideration of 
the prior probability of type 1 diabetes is important when interpreting the results 
of a single positive autoantibody result. The interpretation may be very different 
for a patient with low likelihood of type 1 diabetes based on other features such 
as their age and BMI compared to that of a patient clinically likely to have type 1 
diabetes. In the former situation, a positive results is more likely to be false 
positive result.  
Another consideration associated with the use of islet-autoantibodies for 
diagnostic purposes is the variation in specificity of the test between different 
laboratories. For example, the range of GADA specificity for the laboratories 
participating in the 2010 Diabetes Autoantibody Standardisation Programme 




assay formats and the use of different thresholds to define a positive result. 
Thresholds are usually defined using centiles of titres observed in a non-
diabetic population with higher titres increasing the specificity of the test. The 
97.5th or 99th centile is normally used but in some cases the assay lowest 
reportable value has been used. 
The limitations and considerations discussed above, and the substantial cost 
that would be incurred in testing everyone with diabetes for islet-autoantibodies 
are reasons why routine testing is not currently recommended in clinical 
practice.  
Genetics 
There is a strong genetic component to type 1 diabetes which is measurable by 
single nucleotide polymorphism (SNP) genotyping (37). These SNPs are 
located in the Human Leukocyte Antigen (HLA) and non-HLA regions with DR3 
and DR4-DQ8 alleles in the HLA region being the highest genetic determinants 
of type 1 diabetes (38, 39). A type 1 diabetes genetic risk score (T1D GRS) 
consisting of a combination of SNPs from both regions can discriminate 
between patients with type 1 and type 2 diabetes (37, 40). Advantages of using 
genotyping are that results do not change over time and susceptible genetic 
variants are common across ethnicities (41), but it is not currently routinely 
indicated in clinical practice. There are also common genetic variants 
associated with type 2 diabetes (42, 43) but a T2D GRS has far less 
discrimination power than the T1D GRS (37). 
C-peptide 
C-peptide is a substance made in the pancreas in equal amount to insulin and 




measured instead of insulin because it has a longer half-life and is not affected 
by exogenous insulin. C-peptide measurement is reliable and is widely available 
in clinical practice, more so than it has been in the past (22).  
C-peptide values measured in patients with longstanding diabetes provides a 
gold-standard test for classifying patients according to their treatment 
requirements (44). A low C-peptide value measured at any time post diagnosis 
(< 200 pmol/L (non-fasting)) confirms severe endogenous insulin deficiency (44, 
45), the key feature of type 1 diabetes. Patients with low C-peptide (< 200 
pmol/L)  will have the treatment requirements of type 1 diabetes - high glucose 
variability and lack of glycaemic response to non-insulin therapies whilst 
patients with high C-peptide (>600 pmol/L) do not have absolute insulin 
deficiency but may still require insulin for glucose management. However some 
patients with type 1 diabetes can retain significant amounts of endogenous 
insulin for 3 – 5 years (44, 46) particularly if they are obese. This means that 
there will be some overlap which limits the utility of the test at diagnosis.  
Suggested C-peptide threshold for classification of type 1 diabetes based on 
treatment requirement is < 200 pmol/L (non-fasting)) and > 600 pmol/L (non-
fasting) for type 2 diabetes (44, 47, 48). There will be uncertainty in the 
classification of patients whose C-peptide value is in the intermediate range 
(>=200 pmol/L and <=600 pmol/L). 
1.3.6 Glycaemic deterioration in patients with type 2 diabetes 
The clinical course of glycaemic deterioration is highly variable in patients with 
type 2 diabetes; some patients can be successfully treated without insulin for 




diagnosis (8, 9, 49). This variability may reflect differences in underlying 
pathophysiology which is highly heterogeneous in type 2 diabetes (50-54).  
In addition to correctly classifying patients, being able to correctly identify, at 
diagnosis, those patients with type 2 diabetes that are likely to have more rapid 
glycaemic deterioration may be helpful clinically. In clinical practice, the 
treatment and management of patients could then be personalised according to 
their individual risk. For example, patients likely to rapidly progress could be 
offered more frequent follow up, earlier treatment intensification or targeted 
treatment with interventions to delay glycaemic progression. In research, high 
risk patients could be targeted by clinical trials aimed at developing effective 
therapies to slow progression. 
1.3.7 Clinical features and biomarkers independently associated with 
glycaemic deterioration in patients diagnosed with type 2 diabetes 
A number of routinely indicated clinical features and biomarkers have been 
reported to be associated with glycaemic deterioration (Table 1) in patients with 
clinically diagnosed type 2 diabetes but some effect sizes are small and not all 
features investigated are independently associated (55). Despite differences in 
the definition of glycaemic deterioration, duration of diabetes at start of study, 
follow up times and cohorts between studies, the association findings for many 






Table 1: Studies identifying clinical features and biomarkers independently associated with glycaemic deterioration 
Study Definition of glycaemic deterioration Start point Independently associated clinical features 
and biomarkers 
Dennis et al. (51) HbA1c progression over time  Newly diagnosed Age at diagnosis 
Zhou et al. (55) Time to insulin therapy Diagnosis Age at diagnosis, TRIG, HDL, BMI 
Levy et al. (56) Time to failure of dietary therapy Newly diagnosed Fasting glucose, age at diagnosis, beta cell 
function (measured by OGTT)  
Turner et al. (34) Insulin therapy within six years of 
diagnosis 
Diagnosis GADA and beta-cell function (measured using 
HOMA) 
Matthews et al. (57) Sulphonylurea failure within six years 
of diagnosis 
Newly diagnosed Age at diagnosis, beta cell function (measured 
using HOMA), fasting glucose, drug treatment  





Age < 65 years, type of OAD treatment, HbA1c 
 
Cook et al. (59) Time until HbA1c >= 64 mm/mol (8.0%) 
or glucose-lowering therapy intensified 













Study Definition of glycaemic deterioration Start point Independently associated clinical features 
and biomarkers 
Pani et al. (60) HbA1c >= 53 mm/mol (7%) or medical 




HbA1c, age, weight gain  
Waldman et al. (61) Initiation of oral hypoglycaemic agents 
(OHAs) or insulin. 
Post diagnosis 
(median diabetes 
duration 5 years)  
HDL-C, HDL-C/apolipoprotein A-I  
Donnelly et al. (49) HbA1c progression over time Diagnosis GADA, age at diagnosis, BMI, HDL, year of 
diagnosis 
Pilla et al. (62) Time to insulin initiation Post diagnosis 
(mean diabetes 
duration 5.5 years)  
Age, ethnicity, HbA1c, number of drugs, BMI, 
smoking, hypertension, chronic kidney disease, 
cardiovascular disease and family history. 
Number of complications (cardiovascular 
disease, chronic kidney disease, diabetic 
neuropathy, and diabetic retinopathy), source of 
medical care. 
Schrijnders et al. (63) Time needed to treatment 




duration 5.5 years) 




Study Definition of glycaemic deterioration Start point Independently associated clinical features 
and biomarkers 





duration 1 year) 
First line drug 
In patients treated with metformin: eGFR, sex, 
source of medical care, history of stroke, 
prescription of diuretics and statins, age and 
diagnosed hyperlipidaemia 
In patients treated with sulfonylureas: high 
eGFR, diagnosed congestive heart failure and 
prescriptions of diuretics 
Gentile et al. (65) Insulin initiation within 5 years  First eGFR 
evaluation (mean 
diabetes duration 7 
years) 
Duration, HbA1c, TRIG, HDL ,age, drug 
(diabetes and lipid-lowering (statins)), 





Clinical features  
Multiple studies have shown that age at diagnosis (49, 51, 55-57, 63), and BMI 
(49, 62, 65) are independently associated with faster glycaemic deterioration. 
Findings for smoking status are conflicting with an independent association 
found in some studies (59, 62) but not in others (55, 60). Findings for sex were 
also inconsistent, some found an association with glycaemic progression, (59, 
64) but another did not (58). Black and Hispanic ethnicity have been associated 
with a lower risk of insulin initiation than white ethnicity whilst a family history of 
diabetes was associated with higher risk (62). All of the above features are 
easily obtained and have utility at diagnosis.  
Biomarkers 
There is strong evidence that high baseline HbA1c (58-60, 62, 63, 65) is 
associated with increased glycaemic deterioration, HbA1c is routinely measured 
in clinical practice and has utility at diagnosis. Hypertension (systolic blood 
pressure > 140 mmHg) (62) and higher fasting glucose (56, 57) are also 
associated with faster deterioration. Triglycerides (TRIG) (55, 65), Low-Density 
Lipoprotein (LDL) (65) and High-Density Lipoprotein (HDL) (49, 55, 61, 65) are 
independently associated with deterioration. Limitations of the use of these 
lipids tests are the strong collinearity between TRIG and HDL (55), and the 
requirement for patients to fast prior to TRIG measurement.  
Islet-autoantibodies 
The presence of islet-autoantibodies (GADA (34, 49) and IA-2 (66, 67)) have 
been independently associated with rapid glycaemic deterioration in participants 
with type 2 diabetes. In addition, the presence of GADA islet-autoantibodies in 
adult patients with a clinical diagnosis of type 2 diabetes has been used to 




view is that patients classified as LADA have a homogenous intermediate 
phenotype but there has recently been an opposing view that LADA is not in 
fact homogenous, rather LADA is likely to reflect a combination of two 
heterogeneous populations with very different phenotypes – true positives (type 
1 diabetes) and false positives (type 2 diabetes) (35).  
A limitation of the use of GADA and IA-2 for identifying patients likely to have 
more rapid glycaemic deterioration is that testing is not currently recommended 
in clinical practice so not all patients will be tested. As discussed in section 
1.3.5, the prior prevalence and specificity of the tests need to be considered 
when interpreting a positive result. 
Genetics 
It has previously been shown that genetic variants in the HLA region associated 
with type 1 diabetes may alter the risk of rapid progression to insulin in patients 
with type 2 diabetes who are GADA positive (72-74) and that high risk HLA is 
associated with low C-peptide in a type 2 diabetes cohort (74). There are no 
studies however that have specifically examined the association between T1D 
GRS, which includes HLA specific SNP’s, and rapid progression in patients with 
type 2 diabetes. Two studies found no association between glycaemic 
deterioration and gene variants associated with type 2 diabetes (55, 75). 
Other features that have been associated with glycaemic deterioration include: 
type of initial treatment (58), diabetes duration (65), drug therapy (62, 64, 65), 
diabetes complications (62, 64, 65), source of medical care (62, 64), estimated 
Glomerular Filtration Rate (eGFR) (64, 65) and serum creatinine (59) but these 
are not discussed further as they cannot be used and are not useful at 




tolerance tests (OGTT) (56) have been associated with glycaemic deterioration 
but the former test is not routinely available in clinical practice and the latter is 
now only measured for the diagnosis of gestational diabetes.  
1.3.8 Conclusion 
There is evidence that many clinical features and biomarkers are associated 
with classification of type 1 and type 2 diabetes and glycaemic progression in 
patients with type 2 diabetes. The diagnostic or prognostic accuracy of these 
clinical features and biomarkers used in isolation may be improved by the use 
of a holistic approach in which these clinical features and biomarkers are 
combined. 
The most effective approach is to combine these features in multivariable 
prediction models as is now common in many areas of clinical practice. There 
are however, currently no diagnostic or prognostic prediction models to help 
clinicians distinguish between type 1 and type 2 diabetes subtypes or to predict 
rapid progression in patients with type 2 diabetes. 
1.4 Clinical prediction model concepts, and methods used for 
development, validation and reporting 
1.4.1 Overview of clinical prediction models 
Clinical prediction models have a grounding in evidence-based medicine. They 
provide clinicians with external evidence of the probability of a particular 
outcome for an individual patient that can be taken into consideration when 
making treatment or testing choices. This outcome may be the presence or 
absence of a disease or condition (diagnostic) or the future development of a 




Literature on prediction models has increased over time (77), in 2010 there 
were 101 publications listed on PubMed with the terms “prediction model” or 
“prognostic model” compared to 410 listed in 2018. In all areas of medicine, 
including diabetes, clinical prediction models have been implemented as 
websites and applications, and many incorporated into clinical guidelines (78-
87). Models associated with diabetes include a diagnostic model to identify 
monogenic forms of diabetes in patients with young-onset diabetes prognostic 
models (88) and prognostic models to predict the risk of type 2 diabetes (89-91) 
and the risk of glycaemic deterioration (49, 65). A classification tool based on 
five diabetes clusters (50) has also been developed.  A model to identify 
undiagnosed type 2 diabetes (92) has been incorporated into NICE guidance. A 
search for “Diabetes Mellitus” disease on MDCalc (93) returned 23 medical 
apps. 
However, the number of models actually implemented into clinical practice is 
very low compared to the number of models developed and published. It has 
been suggested that between 1993 and 2011, models for diabetes were being 
published at a rate of about one every three weeks (89). There are several 
plausible explanations for this low implementation rate; the inclusion of 
predictors that are not routinely indicated in clinical practice render models 
unusable and a lack of clinical credibility and evidence reduces confidence in 
the model (94). Chapter 1 has already discussed the clinical utility of various 
features with prior evidence of an association with diabetes classification and 
progression. Clinical credibility is concerned with the validity of the model 
development including adherence to model assumptions and interpretability of 
the model whilst evidence is concerned with the performance and accuracy of 




1.4.2 Reporting guidelines for diagnostic and prognostic studies  
There are a number of systematic reviews that have performed critical 
appraisals of the development, validation and reporting of clinical prediction 
models (95-102). The identification of shortcomings in many of the studies 
evaluated in these reviews has led to the introduction of reporting guidelines 
(103). Adherence to these guidelines is now included in the author instructions 
for most journals when submitting papers addressing development and/or 
validation of prediction models. The relevant reporting guidelines for diagnostic 
and prognostic models are Standards for the Reporting of Diagnostic Accuracy 
Studies (STARD) (104) and transparent reporting of a multivariable prediction 
model for individual prognosis or diagnosis (TRIPOD) (105-107). STARD was 
first published in 2003 and updated in 2015; its objective is to “improve the 
completeness and transparency of reporting of studies of diagnostic accuracy, 
to allow readers to assess the potential for bias in the study (internal validity) 
and to evaluate its generalisability (external validity).” (108). The TRIPOD 
statement was published in 2015 and has the reporting of model development, 
validation or updates as its focus. 
1.4.3 Statistical model concepts 
The focus of this thesis is multivariable models (multiple predictors) developed 
using clinical study data.  
Logistic regression 
In situations where the outcome of interest is binary, the most commonly 
applied statistical model is binary logistic regression (LR). The technical details 
of LR have been well documented (109-114). In brief, LR is a form of 




on the log odds scale. As this is a linear model, linearity (linear relationship 
between any continuous predictors and the logit of the outcome variable) is a 
strong assumption. There are various methods to deal with non-linearity (simple 
transformations, restricted cubic splines, fractional polynomials (77)) although, 
to reduce the risk of overfitting, dealing with non-linearity is only recommended 
for strong predictors or in predictors where non-linearity is known to be likely 
(77).  Overfitting arises from either model or parameter uncertainty and is a 
significant issue in regression modelling (77). A model that is over-fitted will 
have lower performance when it is applied to subjects outside the study data.   
Survival models 
Cox proportional hazards regression (115) is the most well-known and 
commonly applied model for time-to-event (survival) outcomes in medical 
studies where there is censored data. There are however limitations of its use 
for individual patient predictions including; 1) it requires a strong proportional 
hazards assumption of no time/predictor interaction, 2) it requires a non-
parametric estimate for the baseline hazard to obtain survival/failures 
probabilities over time for individual patients, 3) the non-parametric baseline 
hazard is a noisy step function and 4) the model is fitted very closely to the data 
so may not perform well in external data (116). An alternative model that deals 
with these limitations is a Royston-Parmar flexible parametric survival model 
(RP) (116, 117). The main feature of this model is the use of restricted cubic 
splines to flex the Weibull baseline hazard function allowing for complex 
baseline hazards (118). These models can also be extended to incorporate 
time-dependent effects (predictors whose regression coefficients vary over 
time). The parametric nature of these models make them preferable when 




prognostic studies is currently very limited, only 12 studies were identified in a 
systematic review covering the period 2001 to 2016 (119). Other considerations 
in survival models are the choice of endpoint, censoring, restricting follow-up 
times and dealing with competing risks (120, 121). 
1.4.4 Machine learning applications 
Logistic regression and Cox proportional hazards regression are well 
established statistical models with strong theoretical backgrounds but in recent 
years there has been an increased interest in the use of machine learning 
algorithms as an alternative for developing clinical prediction models. 
Supervised machine learning algorithms have been used to develop diagnostic 
and prognostic clinical prediction models in medical applications such as 
predicting diabetes, assessing fracture risk, fibromyalgia diagnosis, genetics 
and cancer mortality (122-127).  The advantages of using these machine 
learning algorithms over classic statistical models are their ability to process 
vast amounts of data such as medical images, biobank and electronic health 
care records, and their ability to deal with complex interactions and non-
linearity. Estimation biases resulting from mis-specified statistical models are 
avoided by the use of machine learning algorithms since they are non-
parametric (128) and they have greater modelling flexibility through the use of 
tuning parameters (129). However the main disadvantage with the use of 
machine learning is the lack of transparency which makes them difficult to 
interpret (130), limiting their clinical credibility.  
There have been many applied studies comparing the performance of machine 




142). Many of the comparison studies have limitations that render them at high 
risk of bias (143). 
1.4.5 Key methodological approaches to diagnostic and prognostic model 
development and validation 
In an attempt to improve the methodological standard of the development and 
validation of prediction models, several studies and books have published 
frameworks (76, 144-147) or recommendations (77, 148) for best practice. This 
thesis provides a brief overview of the key methodological approaches to 
diagnostic and prognostic model development and validation. 
Missing data 
Many real world datasets used for developing prediction models will have 
missing data. The most common approach to missing data is to use a complete-
case analysis whereby all observations that have missing values for the 
variables of interest are excluded from the analysis. This approach may be 
acceptable when the amount of missing data is either low (149) or when the 
data is assumed to be missing completely at random (MCAR) (77). The main 
disadvantage with this approach is that the sample size is reduced and bias is 
introduced if the assumption of MCAR is not valid. More complex approaches 
for dealing with missing data may be required in situations where bias is likely 
(150-153). 
Effective sample size 
An effective sample size is to some extent, governed by the complexity of the 
research question (77). To avoid overfitting, the minimum training data size for 
different model types is determined by the number of events rather than the 




variable (EPV) (154) but there is much debate over the rationale for this number 
(155, 156). An alternative approach for determining the EPV in binary outcome 
models based on the number of predictors, total sample size and events 
fraction has been proposed (155). To achieve the effective sample size, data 
reduction techniques can be applied to adjust the number of predictors. 
Selection and coding of predictors  
There are various strategies for selecting predictors for inclusion in the model 
(157). Univariate screening is often used for pre-selecting predictors prior to 
multivariable modelling but is generally not recommended (158) whilst selection 
of predictors for inclusion in the model based on previous evidence and expert 
clinical knowledge, regardless of their statistical significance in the model, has 
been recommended (149). Another strategy that is often used is a significance 
criteria strategy that is based on hypothesis testing; predictors are included or 
excluded from the model using iterative stepwise selection methods. An 
approach that uses a significance criteria strategy but forces predictors with 
prior evidence or expert knowledge into the model has also been previously 
used (159). An alternative approach is to use an information criteria strategy 
that is based on selecting the best model from a set of several models using 
Akaike information criterion (AIC) or Bayesian information criterion (BIC) where 
more complex models are penalized.  
In the development of clinical prediction models, testing for non-linearity in 
continuous predictors has become standard practice. Dichotomisation or 
grouping of continuous predictors often occurs in medical research but leads to 
a loss of information (160). This practice is appropriate in some situations, for 
example to replicate use of test results in clinical practice. It is not however 




simple transformations, restricted cubic splines (77, 149) or fractional 
polynomials (77, 161). A comparison of AIC or BIC between models developed 
using linear and different non-linear functions can be used to determine the 
most appropriate relationship. 
In multivariable models there is the possibility of interactions between the 
variables, for example age may have a stronger effect for males compared to 
females or an interaction including time in survival models. Interaction terms 
can be included in the model (time-dependent effects for survival models) but 
their use can lead to overfitting and overly complex models. 
Model performance  
There are several performance measures that can be used to assess the quality 
of the model, these fall into three main aspects; overall performance (distance 
between predictions and actual outcomes), discrimination (separation of 
patients with and without the outcome) and calibration (predictions versus 
observed outcomes). A summary of common performance measures used in 





Table 2: Summary of performance measures (adapted from Steyerberg) (76) 
Measure Advantages  Disadvantages 
Overall performance  
R2 
 
Commonly used to express amount of explained 
variation.  
Can be used to for model comparison. 
R2D available for RP models (162). 
 
 Cannot be used to compare models from different 
populations/datasets. 
Difficult to interpret. 
Many different calculations available (e.g. Cox-
Snell and Nagelkerke’s R2). 
Can be used for survival models. 
Nagelkerke’s R2 severely penalizes false 
predictions close to 0% and 100%. 
Brier score 
 
Less severe in penalizing false predictions close to 
0% and 100% than Nagelkerke’s R2. 
 
 Interpretation of score depends of the prevalence 
but can be scaled between 0% and 100%. 
Calibration component of the Brier score can be 
tested using Spiegelhalter’s z-test. 
Cannot be calculated for survival models. 
Discrimination  
Concordance (c) 
statistic (C-index) for 
logistic regression 
 
Rank order statistic insensitive to prevalence. 
Can be visualized using ROC curve. 
Well established. 
 Related to variance of predictors (163). 
Interpretation varies by clinical area and is based 
on artificial concept. 
Harrell’s C-statistic for 
survival models 
Indicates the rank order of the proportion of all 
pairs that can be ordered. 
 Some pairs cannot be ordered. 
Cannot be used if time-dependent effects are 





Measure Advantages  Disadvantages 
D-statistic for survival 
models (162) 
Can be used to calculate a R2D which is easier to 
interpret.  
 Hard to interpret. 
Interpretation is based on two created groups 
(based on the model output) and the model scale. 




Calibration in the large 
 
Can be visualized in a calibration plot. 
Indicates if predictions are systematically too low 
or too high. 
Statistical testing of the difference in log odds 
between predictions and observed outcomes is 
possible 
 Accurate by design in apparent validation 
Calibration slope 
 
Can be visualized in a calibration plot. 
Indicates under or over fitting. 
Statistical testing of the deviation of the slope from 
1 (miscalibration) is possible. 
 Accurate by design in apparent validation 
Hosmer and Lemeshow  
 
Can be visualised. 
Goodness of fit test for logistic regression. 
 Sensitive to sample size and number of groups. 
Limited power in small samples. 
Interpretation is difficult.  
Cannot be calculated for survival models. 
Ratio of expected and 
observed number of 
events (E/O) 
Easy to calculate. 
Can be used for survival models using expected 
and observed event probabilities rather than 
number of events. 






Assessment of overly influential observations 
All observations used to develop a model will influence the fit to some extent but 
it is possible that some observations will overly influence the model. This may 
be related to the data quality such as insufficient observations, data errors and 
extreme predictor values or it may be the case that the data may contain 
unusual observations where the relationship between the predictors and 
outcome differ from that observed in the majority of observations (149).  In 
regression models, diagnostic statistics can be used to identify influential 
observations (165, 166) however the values used to classify an observation as 
influential are subjective. Careful consideration is also needed on how to deal 
with influential observations; removing such observations is not generally 
recommended as this may artificially inflate the predictive accuracy of the model 
(149).  
Clinical usefulness  
Clinical usefulness has been defined as the improvement in classification 
derived from the use of a prediction model above some default position or rule 
that does not use the said model (77). Clinical usefulness measures fall into two 
main types; traditional methods using a set threshold selected using either an 
intuitive or optimal approach, or those that are derived using a decision-analytic 
approach (77). Measures using the former approach are often used to evaluate 
prediction modes and are well embedded in clinical use but there are no defined 
thresholds to indicate clinical usefulness (167). The latter approach involves 
incorporating the harm and benefit of a decision based on the prediction model 
into the assessment of clinical usefulness. An example of a harm is an un-
necessary operation or medication and a benefit is correct diagnosis of a 




including capturing the clinical consequences of the prediction model in the 
assessment (167) and the use of decision curves to consider a range of 
thresholds but quantifying the harms and benefits is a significant limitation. 
Model validation  
The purpose of model validation is to provide evidence for the performance and 
accuracy of the model. Model validation comprises of two aspects; internal and 
external validation.    
Internal validation 
Internal validation is where the model performance is assessed using the same 
dataset that was used to develop the model. Several techniques exists for 
internal validation, the difference between them being the specification of the 
samples used to both develop and validate the model (77). Apparent validation 
is a technique where the entire dataset is used to develop the model, the same 
dataset used to develop the model is then used to assess the model 
performance. The advantages of this method is that the development sample 
size is maximised and the assessment of performance is stable but the 
performance estimate will be overly optimistic. Calibration in the large and 
calibration slope validation tests are not useful when using apparent validation 
as they will be accurate by design (77).  
Another internal validation technique that is often used in medical research is 
split-sample validation. The model is developed using a random or stratified 
subset of the original dataset (classically 50 - 70%) and the model performance 
assessed using the remaining data. There are numerous issues with the use of 
this method related to variance and bias (149). With the availability of more 




not now generally recommended (77, 168). Cross-validation is an internal 
validation technique that is related to split-sample validation but has an 
advantage of using a larger subset of the original dataset for model 
development. It uses the same approach of developing the model on a random 
subset of the original dataset and evaluating the model on the remaining data 
but this process is repeated several times so that every patient in the original 
dataset is included at least once in the model assessment. To achieve stable 
results, the whole cross-validation process may have to be repeated as many 
as 50 times (77). Ten-fold cross-validation is the most common cross-validation 
method where the original data is divided into ten equal sized groups or folds; 
the first group is used to validate the model and the other nine groups are used 
to develop the model. This process is repeated ten times with a different group 
used each time for the validation, the performance estimate is an average of the 
estimates from each round of validation. Jack-knife cross validation is an 
extreme version of the ten-fold cross validation where only one patient at a time 
is left out of the development group, this method is not efficient with large 
number of patients and can underestimate model variability (77).  
Bootstrap validation is much the preferred internal validation technique having 
many advantages over the other techniques such as dealing with model 
uncertainty and estimate stability. In bootstrap validation, samples are drawn 
with replacement from the original dataset. For each bootstrapped sample, a 
model is developed and then evaluated in both the same bootstrapped sample 
(apparent validation) and the original dataset (test validation). The difference 
between the two sets of results indicates the amount of optimism which can be 





External validation is considered the best quality validation technique in a 
suggested hierarchy of various validation techniques (149). External validation 
involves evaluating the model using a separate dataset from the dataset used to 
develop the model, in which the patients are different in some respect from the 
patients used to develop the model. The nature of the external validation can be 
temporal (model validated on new patients recruited to the study), geographic 
(model validated on patients from another study centre) or fully independent 
(model validation undertaken by independent researchers) (77). 
1.4.6 Conclusion 
Clinical prediction models are a valuable commodity in clinical practice. Many 
different diagnostic and prognostic models have been developed in all areas of 
medicine using both traditional statistical methods and machine learning but the 
number actually implemented into clinical use is comparatively low. The lack of 
clinical uptake can be due to the inclusion of predictors that are not routinely 
indicated in clinical practice but also a lack of clinical credibility and evidence. 
Reporting guidelines have been introduced to address the lack of clinical 
credibility and evidence in the development and validation of clinical prediction 
models. Several studies and books have published frameworks and 
recommendations for best methodological approaches to model development 






1.5 Data overview 
This section provides an overview of the different datasets used in the 
subsequent chapters of this thesis. All of the datasets were obtained from 
existing diabetes studies that recruited adults with a clinical diagnosis of either 
type 1 or type 2 diabetes.  
1.5.1 Datasets  
Diabetes Alliance for Research in England (DARE)  
DARE (2007 - 2017) was a cross-sectional study designed to explore the 
causes and complications of diabetes (169). Patients with any type of diabetes 
were recruited from primary and secondary care in eight diabetes research 
regions across England. Clinical measurements and blood were collected at 
recruitment and ongoing biochemical data collected from pathology 
laboratories. Within the dataset, data were accessible for approx. 6,000 Exeter-
recruited participants.  
Predicting Response to Incretin Based Agents in type 2 Diabetes (PRIBA)  
PRIBA (2011 – 2013) was a prospective study of 957 adult participants with a 
clinical diagnosis of type 2 diabetes starting DPP4 inhibitors or GLP-1 receptor 
agonist treatment as part of their normal care. Patients were recruited from 
primary or secondary care in South West England. The primary analysis was 
the relationship between insulin secretion (measured by blood C-peptide or 
Urinary C-peptide Creatinine Ratio (UCPCR)) and glycaemic response 
(measured by HbA1c) (170). Clinical measurements and blood were taken at the 






MRC PROspective Cohort MRC ABPI STratification and Extreme Response 
Mechanism in Diabetes (PROMASTER) 
PROMASTER (2013 – 2015) was an observational study of 820 adult 
participants with clinically diagnosed type 2 diabetes starting second or third line 
glucose lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, 
SGLT2 inhibitors, Glitazone or insulin) as part of their normal care (171). 
Patients were recruited from primary or secondary in South West England, 
Tayside, Oxford, Glasgow, London and Newcastle. The primary outcome of the 
study was a comparison of two groups of participants; those who showed a 
good response to the treatment and those who had a poor treatment response. 
Clinical measures, fasting blood and urine samples were taken at first visit and 
repeated at second visit approx. six months after starting the new treatment to 
measure response. 
MRC Retrospective Cohort MRC ABPI STratification and Extreme Response 
Mechanism in Diabetes (RetroMASTER) 
RetroMASTER (2013 – 2015) is an observational study of 562 participants with 
clinically diagnosed type 2 diabetes that were being treated with a second or 
third line glucose lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R 
agonists, SGLT2 inhibitors, Glitazone or insulin) as part of their normal care for 
at least four months (172). Participants were grouped according to their rate of 
diabetes progression (rapid or slow progression to insulin therapy (<7, >7 years 
respectively)). Participants were recruited from primary and secondary care in 
Exeter, Oxford and Dundee. The primary outcome of the study was to compare 
the clinical characteristic of the two groups of participants. Fasting blood, urine 






Crossover (2013 -2015) was an intervention study of 143 adult participants 
clinically diagnosed with type 2 diabetes and treated with sulphonylurea tablets 
as their normal care (173). Patients were recruited in Exeter and Tayside. The 
primary outcome of the study was to understand individual variation in altered 
glycaemic response to two different treatments. The study had a cross-over 
model where patients were randomised to be treated for periods of four weeks 
with Gliclazide (DPP-IV thera) or Sitagliptin (sulphonylurea) in a crossover 
fashion. Clinical measurements were collected and a mixed-meal test was 
performed at baseline and at each study drug visits. Fasting blood was 
collected at each cross-over. 
Genetics of Diabetes Audit and Research Tayside Study (GoDarts) 
GoDarts is an observational case-control study comprising of patients with a 
clinical diagnosis of type 2 diabetes recruited from primary and secondary care 
in the Tayside area of Scotland since 1998. The primary aim of GoDarts is to 
provide a database which can be used to investigate the genetics, 
complications and treatment of type 2 diabetes (174). Cross-sectional baseline 
data, including a blood sample and clinical and lifestyle factors, collected in the 
study is linked to individual electronic medical records which includes laboratory 
data, prescription history and hospital admissions making GoDarts a 
longitudinal cohort (175). Data is available on approx. 10,000 participants.  
Young Diabetes in Oxford (YDX)  
YDX is a cross-sectional study of participants diagnosed with diabetes (of any 
type) up to the age of 45 years. Participants were recruited from primary and 
secondary care in Oxfordshire. One of the aims of the study was to identify 




Onset Diabetes of the Young (MODY) for genetic testing. Data was accessible 
for 1,200 participants screened between 2005 and 2017. 
Hoorn Diabetes Care System (DCS) 
DCS is a prospective cohort study representing the data of over 12,000 
participants clinically diagnosed with type 2 diabetes in West-Friesland, 
Netherlands since 1998 (176). The longitudinal dataset contains baseline 
clinical measurements and annual follow-up visit data. Additional health data, 
including prescription history and cause-specific mortality, is collected using 
electronic medical record linkage. 
A Diabetes Outcome Progression Trial (ADOPT) 
ADOPT (2000 – 2006) was an intention to treat randomised drug efficacy trial in 
adult patients who had been recently diagnosed with type 2 diabetes (177-179). 
Patients were recruited in 488 centres in the US, Canada and Europe, a total of 
4,360 participants underwent randomisation (179). The study was designed to 
compare glycaemic control (long-term blood glucose) of participants treated 
with alternative therapies (thiazolidinedione (rosiglitazone), metformin and 
sulfonylurea (glibenclamide)). The primary outcome was time to monotherapy 
failure defined by confirmed level of fasting plasma glucose of more than 180 
mg/dl (10.0 mmol/l) (177). Baseline data collected included biomarkers such as 
lipids and GADA (179).  
1.5.2 Data preparation 
Each dataset was supplied individually by the study and imported into Stata/SE 
15.1 (StataCorp, College Station, TX) except for the ADOPT data which was 
accessed through the Clinical Trial Data Transparency Portal under approval 




In DARE, additional data including C-peptide, HbA1c and islet-autoantibodies 
was obtained from electronic patient medical records where available. Islet-
autoantibody testing and genotyping were requested and performed for those 
DARE participants where these data were missing but whose blood serum had 
been stored. 
Some participants had been recruited to more than one of the studies included 
in this thesis. Duplicate participant observations were removed where the 
analysis was performed on a merged dataset, DARE data took precedence 
when this occurred.  
Potential data errors or inconsistencies identified in the Exeter-based datasets 
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To develop and validate multivariable clinical diagnostic models to assist 
distinguishing between type 1 and type 2 diabetes in adults aged 18 to 50. 
Research design and methods 
Multivariable logistic regression analysis was used to develop classification 
models integrating five pre-specified predictor variables, including clinical 
features (age of diagnosis, BMI) and clinical biomarkers (GADA and Islet 
Antigen 2 islet-autoantibodies, Type 1 Diabetes Genetic Risk Score), to identify 
type 1 diabetes with rapid insulin requirement using data from existing cohorts. 
The study population consisted of 1,352 (model development) and 582 (external 
validation) participants diagnosed with diabetes between the age of 18 and 50 
years of white European origin, recruited from primary and secondary care in 
the United Kingdom. 
Type 1 diabetes was defined by rapid insulin requirement (within 3 years of 
diagnosis) and severe endogenous insulin deficiency (C-peptide <200pmol/L). 
Type 2 diabetes was defined by either a lack of rapid insulin requirement or, 
where insulin treated within 3 years, retained endogenous insulin secretion (C-
peptide >600pmol/L at ≥5 years diabetes duration). Model performance was 
assessed using area under the receiver operating characteristic curve (ROC 
AUC), and internal and external validation. 
Results 
Type 1 diabetes was present in 13% of participants in the development cohort. 




type 1 diabetes (p<0.001 for all) with individual ROC AUC ranging from 0.82 to 
0.85. Model performance was high: ROC AUC range 0.90 [95%CI 0.88, 0.93] 
(clinical features only) to 0.97 [0.96, 0.98] (all predictors) with low prediction 
error. Results were consistent in external validation (clinical features and GADA 
ROC AUC 0.93 [0.90, 0.96]). 
Conclusions 
Clinical diagnostic models integrating clinical features with biomarkers have 
high accuracy for identifying type 1 diabetes with rapid insulin requirement, and 
could assist clinicians and researchers in accurately identifying patients with 




Making the correct diagnosis of type 1 and type 2 diabetes is crucial for 
appropriate management, with guidelines for these conditions recommending 
very different glucose-lowering treatment and education (1-3). These 
differences are predominantly driven by the rapid development of severe 
endogenous insulin deficiency in type 1 diabetes (1). This means that patients 
with type 1 diabetes need rapid insulin treatment and are at risk of life-
threatening ketoacidosis without insulin treatment. They develop a requirement 
for physiological insulin replacement (e.g. multiple injections, carbohydrate 
counting and pumps) due to the very high glycaemic variability associated with 
severe insulin deficiency (4, 5) and have poor glycaemic response to most 
adjuvant glucose-lowering therapies (6). In contrast, patients with type 2 
diabetes continue to make substantial endogenous insulin even many decades 
after diagnosis (7). Glycaemia is therefore usually managed initially with lifestyle 
change or oral agents (4, 8) and, if insulin treatment is needed, a combination of 
simple insulin regimens and adjuvant non-insulin therapies (4, 5, 8, 9).  
Correctly distinguishing between diabetes subtypes at diagnosis is often difficult 
and misclassification therefore common (10-12). Current guidelines focus on 
aetiopathological definitions without giving clear criteria for clinical use (1, 13). 
In clinical practice, clinical features are predominantly used to determine 
diabetes subtype but only age at diagnosis and BMI have evidence for utility at 
diabetes onset, whereas other features used by clinicians such as symptoms at 
diagnosis, weight loss or ketosis do not have an evidence base (14). Increasing 
obesity rates mean that many patients with type 1 diabetes will be obese and 
type 2 diabetes is occurring in the young (15). Type 1 diabetes has been 
recently shown to occur at similar rates in those aged above and below 30 (16). 




accurately diagnose diabetes type for many patients (1, 10). Similarly, there is 
no single diagnostic test that can be used to classify diabetes robustly at 
diagnosis. While measurement of islet-autoantibodies can assist classification, 
many patients with type 1 diabetes are islet-autoantibody negative and many 
patients with the clinical phenotype of type 2 diabetes, without rapid insulin 
requirement, are islet-autoantibody-positive (17). A type 1 genetic risk score has 
been recently shown to assist diagnosis of diabetes type but this provides 
imperfect discrimination in isolation (18).  
In order to classify diabetes a suitable “gold standard” is necessary.  As the key 
factor driving differences in treatment decisions between the two subtypes is the 
lack of endogenous insulin secretion, direct measurement of endogenous 
insulin secretion  in longstanding insulin-treated diabetes (>3-5 years), using C-
peptide, provides a robust classification that closely relates to treatment 
requirements (19); patients with severe endogenous insulin deficiency (low C-
peptide) have the high glucose variability, absolute insulin requirement, and lack 
of response to non-insulin glucose-lowering therapies that are characteristic of 
type 1 diabetes, regardless of their clinical characteristics and clinician’s 
diagnosis (7, 11, 19-23). However, this test may have limited utility at diagnosis, 
as patients with recent onset type 1 diabetes may have retained endogenous 
insulin secretion (21, 24). 
Clinical prediction models offer a way of combining multiple patient features and 
biomarkers to improve accuracy of diagnosis or prognosis. In diabetes, 
diagnostic models combining clinical features are available to predict the risk of 
prevalent or incident type 2 diabetes (25) and there is a model to identify 
monogenic forms of diabetes in patients with young-onset diabetes (26). 




type 2 diabetes at diagnosis. We therefore aimed to develop and validate 
multivariable clinical diagnostic models that combine clinical features and 
biomarkers to identify type 1 diabetes (defined by rapid insulin requirement and 
severe endogenous insulin deficiency) in patients aged between 18 and 50 
years at diabetes diagnosis.  
Methods 
We used logistic regression to model the relationship between each of clinical 
features and biomarkers, and type 1 diabetes defined by rapid insulin 
requirement and severe endogenous insulin deficiency (see below). We 
assessed the performance of the models using both internal validation and 
external validation. 
Study population – development cohort 
To maximise the sample size and to create a development cohort reflecting the 
general population prevalence of type 1 diabetes, participants were identified 
from four Exeter, UK-based cohorts (27-30) and combined into a single dataset. 
Combining the four Exeter cohorts was considered appropriate given that the 
assessment of both their clinical features and laboratory measurements were 
consistent across them. 
These cohorts comprised of participants with clinically diagnosed diabetes 
recruited from primary and secondary care. Summaries of the cohorts including 
recruitment and data collection methods, and the number of type 1 diabetes in 
each cohort are shown in Supplementary Table 1.  
Participants were eligible for the study (model development or validation) if they 
had a clinical diagnosis of type 1 or type 2 diabetes between the ages of 18 and 




known disorder of the exocrine pancreas (32), were excluded. All participants 
included in this study were of white European origin. 
Study population - external validation cohort 
Participants meeting the study inclusion criteria were identified in the Young 
Diabetes in Oxford (YDX) study (33). YDX is a cross-sectional study of 
participants diagnosed with diabetes (of any type) up to the age of 45 years, 
recruited from primary and secondary care in the Thames Valley region, UK. 
Participants with known secondary, pancreatic or monogenic diabetes were 
excluded. 
Model outcome: type 1 and type 2 diabetes definition 
Type of diabetes was defined by the presence or absence of rapid insulin 
requirement and severe endogenous insulin deficiency after a diagnosis of 
diabetes, as follows:  
Type 1 diabetes: Insulin treatment within <= 3 years of diabetes diagnosis and 
severe insulin deficiency (non–fasting C-peptide < 200pmol/L) (21).  
Type 2 diabetes: Either 1) no insulin requirement for 3 years from diabetes 
diagnosis or 2) where insulin was started within 3 years of diagnosis, substantial 
retained endogenous insulin secretion (C-peptide >600pmol/L ) at >=5 years 
diabetes duration. 
Cohort participants not meeting the above criteria or with insufficient information 
were excluded from analysis, as type of diabetes and rapid insulin requirement 







Five pre-specified predictor variables were assessed, based on prior evidence 
and availability: age at diagnosis (14), BMI (14), GADA and IA-2 islet-
autoantibodies (17, 34), and a Type 1 diabetes Genetic Risk Score (T1D GRS) 
(18).  
Assessment of clinical features 
At study recruitment visit, clinical history including time to insulin and age at 
diagnosis were self-reported by participants in an interview with a research 
nurse. Height and weight were measured for calculation of BMI. 
Laboratory Measurement 
C-peptide 
In the development cohort, C-peptide was measured on stored EDTA taken at 
study visits (non-fasting random (35), fasting, or at 90 minutes in a post-mixed-
meal tolerance test (majority 87% non-fasting)). With specific additional 
consent, C-peptide was also measured on post-recruitment non-fasting EDTA 
samples collected as part of routine clinical care. Fasting C-peptide values were 
multiplied by 2.5 to non-fasting equivalent (21). The median C-peptide value 
was used where more than one eligible C-peptide value was available (62% of 
participants requiring this measure for outcome definition). C-peptide was 
measured using an electrochemiluminescence immunoassay on a Roche 
Diagnostics E170 analyser (Roche, Mannheim, Germany) by the Academic 
Department of Blood Sciences at the Royal Devon and Exeter Hospital. In the 
external validation cohort, C-peptide measurement was performed in the 




chemiluminescence immunoassay on an ADVIA Centaur analyser (Siemens 
Healthcare Diagnostics Ltd). 
Islet-autoantibodies 
In the development cohort, GADA and IA-2 were measured on EDTA taken at 
recruitment or obtained from local laboratory records. Both islet-autoantibodies 
were measured using the RSR Ltd ELISA assays (RSR Ltd, Cardiff, UK) on the 
Dynex DS2 ELISA Robot (Dynex Technologics, Worthing, UK) by the Academic 
Department of Blood Sciences at the Royal Devon and Exeter Hospital. The 
department participates in the International Autoantibody Standardization 
Programme. The cut-off for positivity for GADA was ≥11 units/ml and IA-2 was 
≥15 units/ml, based on the 97.5th centile of 1,559 controls without diabetes 
(34).  
In the external validation cohort, GADA was measured by a radioimmunoassay 
using 35S-labeled full-length GAD65 by the Department of Clinical Science, 
University of Bristol, Bristol, U.K. Results were expressed in World Health 
Organization (WHO) units per millilitre derived from a standard curve calibrated 
from international reference material (National Institute for Biological Standards 
and Control code 97/550). The cut-off for positivity for GADA was 13 WHO 
Units/mL initially, using a local assay (samples measured n=218, DASP2010 
sensitivity 88% at 93% specificity) and changed to 33 DK Units/mL later in the 
study (standard assay, DASP2010 sensitivity 80%, specificity 97%). 
Type 1 Diabetes Genetic Risk Score (T1D GRS) 
The T1D GRS was calculated on the development cohort as previously 
described (18). In brief, T1D GRS consists of 30 common type 1 diabetes 




HLA loci; each variant is weighted by its effect size on type 1 diabetes risk from 
previously published literature, with weights for DR3/DR4-DQ8 assigned based 
on imputed haplotypes (Supplementary Table 2). All SNPs had an INFO > 0.8. 
The combined score represents an individual’s genetic susceptibility to type 1 
diabetes. T1D GRS calculation was not performed if genotyping results were 
missing for either of the two alleles with the greatest weighting (DR3/DR4-DQ8 
or HLA_DRB1_15) or if more than two of any other SNPs were missing. For 
ease of clinical interpretation the score is presented in this article as the score 
and centile position of the distribution in the Wellcome Trust Case Control 
Consortium type 1 diabetes population (36).  
Missing data 
Models were developed using complete case analysis. The percentage of 
participants in the development data meeting our inclusion criteria but excluded 
due to missing data was 10% (Supplementary Table 2). The missing data for 
the majority of these participants was related to the model outcome, 11 
participants were excluded due to missing BMI. These missing data were never 
collected (not by design). The nature of the missing data (missing data 
mechanism) was not investigated for these data due to the low amount of 
missing data (BMI), the sample size was considered sufficient to give unbiased 
estimates using complete-case analysis and the missing outcome data is highly 
unlikely to depend on the values of the predicted variables.  
Missing data for the remaining predictor variables (GADA, IA-2 and T1D GRS) 
were never collected (by design). These missing data were handled by use of a 
staged model development sequence which was considered a suitable method 




the appropriateness of this approach, we first looked at the missing data 
patterns to describe the missing data. 70% of the participants had complete 
data and only 4% had missing data for all three predictor variables. The missing 
data mechanism for these variables was investigated by regressing a binary 
missing variable on the other variables. If no variables predict whether a given 
variable is missing, then it is plausible that the data is missing completely at 
random (MCAR) and a complete cases analysis is appropriate. If the data is not 
MCAR, then the complete case may not be a random sample and may produce 
biased estimates. Postive IA-2 was a significant predictor of missing GADA and 
vice versa, GADA was also a significant predictor of missing T1D GRS. 
Although these results suggest that the data may not be MCAR, there is no 
reason to assume that the missing values are distributed significantly differently 
from the non-missing values i.e. the data appears to be missing at random and 
multiple imputation was not considered. 
Statistical analysis 
Model development 
We used logistic regression analysis to develop the models.  
Clustering of data by cohort origin was not adjusted for in the models since 
cohort origin was inherently associated with type of diabetes (Supplementary 
Table 1).  
Age at diagnosis, BMI and T1D GRS were modelled as continuous variables 
and transformations used to ensure linearity on the logit scale (37) 
(Supplementary Figures 1A and 1B). GADA and IA-2 were both dichotomized 
into negative or positive based on the cut-off for positivity in line with how the 




minimal Events Per Variable (EPV) criteria (>=10) (38) and square root of the 
mean squared prediction error (rMPSE) (39) and were considered sufficient for 
reliable diagnostic modelling. 
Models were built and validated in four stages, this staged development 
sequence was selected in order of clinical availability of the predictors and, as 
some participants had missing diagnostic test data, to maximise the sample 
size at each stage: 1) model including only clinical features (age at diagnosis 
and BMI); 2) Addition of GADA to the linear predictor from model 1; 3) Addition 
of both GADA and IA-2 to the linear predictor from model 1; 4) Addition of T1D 
GRS to model 3 linear predictor.  
Evaluation of model performance: Internal validation 
Three internal validation techniques were used to assess the discrimination and 
calibration performance of the models: 1) directly using the data used to 
develop the model (apparent validation, ROC AUC); 2) Jack-knife cross-
validation; 3) Bootstrapping (with replacement method) (37). 
Evaluation of model performance: External validation 
Performances of model 1 (clinical features) and model 2 (clinical features + 
GADA), were evaluated in the YDX study cohort. We were unable to externally 
evaluate models 3 and 4 as IA-2 autoantibodies and T1D GRS were not 
available in the YDX study. 
Model comparisons 
Four nested replica models were built on the subset of participants with 
complete data on all predictor variables (n = 943). The predictive information of 




Unitless Index of Adequacy (37), log likelihood ratio test (37), Net 
Reclassification Improvement and Integrated Discrimination Improvement (40). 
Sensitivity analysis 
Model development of all 4 models was repeated on 943 participants with 
complete data. To assess performance of biomarker models in those difficult to 
classify on clinical features alone model AUC ROC was repeated for each 
model in participants with intermediate age of diagnosis (range 25-35 years 
(inclusive)) and BMI (range 25-35 kg/m2 (inclusive)). 
All statistical analyses were performed using STATA version 15, STATA Corp, 
Texas, USA (unless otherwise stated). 
Results 
1,352 (type 1 diabetes n = 179) participants met analysis inclusion criteria for 
the clinical features model with 943 participants having all predictor variables 
measured. A flow diagram describing the flow of participants through the study 
is shown in Supplementary Figure 2. The majority of participants (n = 904 
(67%)) were identified from DARE which is an unselected cohort enriched for 
type 1 diabetes due to some secondary care recruitment (type 1 diabetes 
prevalence 19.6%). The inclusion of 448 participants from the other three 
Exeter cohorts, which are type 2 diabetes focused, resulted in an overall cohort 
prevalence of type 1 diabetes very similar to that in published population 
cohorts (41) meaning that model probabilities are more likely to be relevant to 
the general population than those obtained using DARE alone. 
Only 37 (2.7% of the cohort) had an undefinable outcome due to intermediate 




diagnosis). The remaining exclusions were due to either missing data or short 
duration of diabetes. The characteristics and type 1 diabetes outcome 
prevalence of the included participants were similar in all four development 
samples (Supplementary Table 3). There were no clinically relevant differences 
in the characteristics of the participants who were excluded from the fourth 
model development stage (n = 409) (Supplementary Table 4). Islet-
autoantibodies and C-peptide were measured at median 13 years and 16 years 
post-diagnosis respectively.  
Clinical features or biomarkers in isolation overlap substantially between 
diabetes types (Figure 1).Participants with type 1 diabetes and rapid insulin 
requirement were diagnosed younger compared to the participants with type 2 
diabetes (median 27 vs 44 years, p < 0.001) and had a lower BMI (median 26 vs 
34 kg/m2, p < 0.001). Positive autoantibodies (GADA, IA-2 or both) were more 
common in the participants with type 1 diabetes (71% of participants with type 1 
diabetes vs 5% of participants with type 2 diabetes, p < 0.001). Patients with 
type 1 diabetes had a higher T1D GRS (median 0.27 vs 0.23 (equivalent to 40th 
and 4th centile of the Wellcome Trust Case Control Consortium population with 
type 1 diabetes (36), p < 0.001). These features overlapped substantially 
between participants meeting criteria for type 1 and type 2 diabetes (Figure 1 (A 
– D)) with AUC ROC for these features in isolation: 0.82 (age at diagnosis), 





Figure 1: Density plots for (A) age at diagnosis, (B) BMI and (D) T1D GRS. Stacked bar chart 
(C) showing percentages of participants (total n = 943 (stage 4 model development sample)) by 
actual type 1 diabetes outcome and GADA/IA-2 status. Dashed line shows the distribution for 
type 2 diabetes (T2D) (n = 815), solid line shows the distribution for type 1 diabetes (T1D) (n = 
128) of participants included in the stage 4 model development.   
 
 
Combining clinical features using a diagnostic model improves model 
discrimination 
In model 1, age at diagnosis and BMI were both significant independent 
predictors of type 1 diabetes, with the odds of having type 1 diabetes increasing 
with younger age at diagnosis and lower BMI. Combined, these features 
provided excellent discrimination (ROC AUC=0.904, perfect test = 1) (Figure 
2a), with low probabilities capturing the majority of participants with type 2 
diabetes and type 1 diabetes being very unlikely (Figure 2b; sensitivity, 
specificity, and positive and negative predictive values at various probability cut-
offs are reported in Table 1). In successive models adding in GADA (model 2 
(figures 2c and 2d)), then IA-2 (model 3 (figures 2e and 2f)) and then T1D GRS 




model resulted in significant improvements in discrimination (Supplementary 
Table 5) and model fit (Supplementary Tables 6 and 7). In sensitivity analysis, 
results were similar when restricting all models to only the 943 participants with 





Figure 2: Development sample validation results. Plots are the results from the validation of the 
models. First row (a and b): clinical features logistic regression model (n = 1,315). Second row 
(c and d): clinical features + GADA logistic regression model (n = 1,036). Third row (e and f): 
clinical features + GADA + IA-2 logistic regression model (n = 1,025). Fourth row (g and h): 
clinical features + GADA + IA-2 + T1D GRS logistic regression model (n =943). Plots (a), (c), 
(e), & (g) are ROC curves showing discrimination ability of the models. Plots (b), (d), (f) & (h) 








Table 1: Model performance at different cut-offs for classifying type 1 diabetes for all four 
logistic regression models (development cohort). Positive and negative predictive values 
assume prevalence for type 1 diabetes: Model 1 = 13%, Model 2 = 14%, Model 3 = 13%, Model 
4 = 14% 
* Youden’s Index - best trade-off between sensitivity and specificity (sensitivity+specificity – 1). 
Model 1: Clinical features (n = 1,352) 
 Probability (%) cut-off  
 10 30 50 70 90 12 * 
Sensitivity/specificity (%) 85/79 64/95 49/98 35/99 15/100 83/83 
Accuracy (%) 80 90 91 90 89 83 
PPV (%) 38 64 79 83 90 42 
NPV (%) 97 95 93 91 89 97 
 
Model 2: Clinical features + GADA (n = 1,036) 
 Probability (%) cut-off  
 10 30 50 70 90 16 * 
Sensitivity/specificity (%) 90/88 80/96 66/97 52/99 31/100 86/92 
Accuracy (%) 89 94 93 92 90 92 
PPV (%) 55 75 80 85 92 64 
NPV (%) 98 97 95 93 90 98 
 
Model 3: Clinical features + GADA + IA-2 (n = 1,025) 
 Probability (%) cut-off  
 10 30 50 70 90 12 *  
Sensitivity/specificity (%) 91/91 80/96 69/98 57/99 37/100 90/92 
Accuracy (%) 91 94 94 93 92 92 
PPV (%) 59 75 81 85 92 62 
NPV (%) 99 97 96 94 92 98 
 
Model 4: Clinical features + GADA + IA-2 + T1D GRS  (n = 943) 
 Probability (%) cut-off  
 10 30 50 70 90 14 * 
Sensitivity/specificity (%) 92/90 84/96 74/98 63/99 41/100 91/93 
Accuracy (%) 90 95 94 94 92 93 
PPV (%) 59 78 83 88 93 67 






In further sensitivity analysis restricting analysis to those most difficult to classify 
on clinical features alone due to both intermediate BMI (range 25-35 kg/m2 
(inclusive)) and age of diagnosis (range 25-35 years (inclusive)), model 
performance remained high for models incorporating biomarker measurement 
(clinical features + islet-autoantibodies AUC ROC 0.89, clinical features + islet-
autoantibodies + T1D GRS AUC ROC 0.95) (Supplementary Table 9). This 
compares to AUC ROC of 0.72 for GADA and IA-2 measurement alone, and 
0.89 for T1D GRS measurement alone in this sub population (n = 71). 
Internal validation suggests robust model performance 
Results of the internal validation bootstrap (Supplementary Table 5) indicate 
good model discrimination, with very similar model performance in bootstrapped 
samples (near identical ROC AUC for all models (max decrease = 0.0018)), 
high calibration indicating the predicted probabilities closely fit the observed 
probabilities (calibration slope range 0.98 - 1.00 (0.9 – 1.1 is indicative of good 
calibration)), and very low levels of optimism suggesting little error due to 
overfitting.   
Model performance remains high in an external validation cohort with 
different characteristics 
582 participants in the YDX study met criteria for external validation 
(Supplementary Figure 3). Compared to the participants in the Exeter model 
development cohort, the participants in the YDX study were younger at 
diagnosis (consistent with the narrower age range in YDX (18-45y) (median 37 
years vs 43 years, p < 0.001)), had a lower BMI (median 31 kg/m2 vs 33 kg/m2, 




a higher prevalence of type 1 diabetes by study definition (22% vs 14%, p < 
0.001) (see Supplementary Table 10 for participant characteristics). 
There was a small decrease in performance of the model 1 (clinical features) 
and model 2 (clinical features and GADA) when they were applied to the 
external validation samples but both still showed high levels of discrimination 
despite differences in the two cohorts (ROC AUC = 0.865 and 0.930 for models 
1 (Figures 3a, 3b and 3c) and 2 (Figures 3d, 3e and 3f) respectively 
(Supplementary Table 11). Both models slightly over estimated type 1 diabetes 
prevalence but there was no evidence of miscalibration (Figures 3b and 3e, 
Supplementary Table 11). Sensitivity and specificity in the validation cohort are 





Figure 3: External validation results. Plots on the first row (a, b, c) are the results from the external validation of the clinical features logistic regression model applied 
to participants in the YDX study (n = 582). The second row of plots (d, e, f) are the results from the external validation of the clinical features + GADA logistic 
regression model applied to participants in the YDX study (n = 549). Plots (a) & (d) are ROC curves showing discrimination ability of the models, dashed line 





Participants with high model probability type 1 diabetes but type 2 
diabetes outcome have the characteristics of type 1 diabetes but took > 3 
years to commence insulin therapy. 
Supplementary Table 13 shows the characteristics of 12 participants in the 
external validation cohort with >80% model type 1 diabetes probability, but an 
actual model outcome of type 2 diabetes. These participants had the clinical 
characteristics associated with type 1 diabetes with GADA positivity and low C-
peptide in the majority of cases (median C-peptide 120 pmol/L). However the 
time to insulin was > 3 years in GADA positive cases, suggesting slow onset 
autoimmune diabetes. In contrast, the 6 participants who had a low model type 
1 diabetes probability (< 16%) but an actual model outcome of type 1 diabetes 
(Supplementary Table 14) had features associated with type 2 diabetes. 
Online calculator 
The four models have been incorporated into an online calculator (beta version 
available at https://www.diabetesgenes.org/t1dt2d-prediction-model/). An 
additional four models with different combinations of the five predictor variables 
were also developed for the online calculator, to allow every combination of 
clinical features plus the other biomarkers as optional. As expected, ROC AUC 
and prediction error results for these four additional models were intermediate 
between the basic clinical features model and the full model with all features 
(Supplementary Table 15). 
Supplementary Tables 16 - 23 inclusive show the β coefficients and odds ratios 
for all models. The regression equations for the online calculator are shown in 






We have developed, evaluated and validated clinical diagnostic models 
combining age at diagnosis, BMI, GADA, IA-2, and T1D GRS to provide 
estimates of a patient’s risk of having type 1 diabetes requiring rapid insulin 
therapy from diagnosis. These models show high performance, and could 
potentially assist classification of diabetes in clinical practice and provide a tool 
for evidence based classification in research cohorts. 
Model performance was optimised in the model combining all five predictors 
(ROC AUC 0.97). However, all models performed well with ROC AUC > 0.9 and 
low cross-validated prediction errors in development. The results of the external 
validation provide additional confidence in model performance. This was 
undertaken in a distinct dataset with different type 1 diabetes prevalence and 
biochemical assays.  
This is the first study developing clinical diagnostic models for classification of 
type 1 and 2 diabetes. Key strengths of this study include our systematic 
approach to model development including robust internal and external validation 
(42). Our staged approach to model development means that we have 
maximised the information gained from each predictor. Our model is 
parsimonious, we have used only five predictors previously shown to be 
associated with type 1 diabetes. This, in combination with large datasets, mean 
we have a high number of events per variable and very low risk of overfitting, a 
common problem with diagnostic models of this nature. Our use of 
predominantly population-based cohorts recruited largely from a primary care 
setting (for model development) means our results are likely to reflect true 




defined type 1 diabetes of 13% in our development dataset is close to the 11% 
reported type 1 diabetes prevalence at diagnosis in a UK population aged 20-50 
(41). 
A limitation of our study is the cross-sectional nature of our cohorts meaning 
that age at diagnosis and time to insulin were self-reported at a single visit.  
Insulin commencement was also based on clinical decision-making rather than 
a trial protocol. BMI and antibodies were measured at median 13 years after 
diagnosis. BMI, and GADA and IA-2 antibodies change modestly over time in 
adult onset diabetes, with previous research suggesting an approximately 18% 
lower combined GADA and IA-2 prevalence after 13.5 years diabetes duration 
in this age group (43), and BMI having higher discrimination for diabetes 
classification when measured at diagnosis (44). The potential impact on the 
results of BMI and islet-autoantibodies having been measured some years post 
diagnosis is that the predictions may be under-estimated. The lack of 
information at diagnosis also meant we were unable to assess whether other 
features available at diagnosis may assist classification, such as presentation 
glycaemia, ketosis, or weight loss. A prospective study to validate these 
models, and assess whether other features may assist classification is therefore 
ongoing (https://clinicaltrials.gov/ct2/show/NCT03737799). 
A further limitation is that this model has been developed and tested in a white 
European population with young onset diabetes, extension of this work to non-
white populations and older age groups is therefore a priority for future 
research.  
These models have the potential to help robustly classify diabetes in research 




available, a common situation in many biobanks. They may also assist clinical 
decision making, with the important caveats that this evidence can only be 
applied to patients aged 18-50, of white ethnicity, and that these models are 
intended to act as a decision aid in conjunction with other information which a 
clinician may use to inform treatment decisions (for example severity of 
hyperglycaemia): they do not replace expert clinical opinion. A web-based 
calculator and smartphone app could be used to display the estimate of the 
patient’s probability of having type 1 diabetes based on the predictor variable 
values entered. The models can be used with age of diagnosis and BMI as a 
minimum; users will then have a choice to add results of GADA, IA-2 and T1D 
GRS in any combination. This could therefore be used by clinicians as a triage-
based approach to diabetes subtype diagnosis. For example, probabilities 
calculated on clinical features could be used as the basis for antibody testing, or 
the additional value likely to be gained from antibody or genetic testing could be 
assessed by inputting dummy results into the model. We propose providing the 
continuous probability outcome of the models rather than giving a threshold. 
This is because the decision made on whether to commence insulin for a given 
probability of type 1 diabetes will vary enormously due to other factors. For 
example temporary insulin treatment may be appropriate regardless of likely 
classification where hyperglycaemia is severe, and in some circumstances it 
may be appropriate to trial oral therapy even where type 1 diabetes has a high 
probability, for example where a person’s occupation would be affected by 
insulin treatment and they can be carefully monitored for glycaemic 
deterioration.  
In conclusion clinical diagnostic models integrating clinical features with 




requirement in white participants aged 18 to 50 at diabetes diagnosis, and may 
assist clinicians in identifying patients with type 1 diabetes in clinical practice.  
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Supplementary material  
Supplementary Table 1: Cohort recruitment and data collection methods summary. *Included in the clinical features model stage 1 development.    
 DARE  PRIBA  MRC Pro/RetroMaster  MRC crossover 
Included participants* 904  368  72  8  
Type 1/Type 2 diabetes n (%) 177 (19.6%)/727 (80.4%) 2 (0.5%)/366 (99.5%) 0 (0.0%)/72 (100%) 0 (0.0%)/8 (100%) 
Data collection period 2007 to 2017 2011 to 2013 2013 to 2015 2013 to 2015 
Study design Cross-sectional Longitudinal Cross-sectional Interventional Crossover 
Setting Primary and secondary 
care in eight diabetes 
research regions, 
England and retinal 
screening clinics. 
Primary and secondary 
care in South West 
England 
Primary and secondary care 
sites  South West England, 
Tayside, Oxford, Glasgow, 
KCL and Newcastle, U.K. 
Exeter and Tayside,U.K. 
Inclusion criteria Clinical diagnosis of 
diabetes (any type). 
Clinical diagnosis of 
type 2 diabetes. 
Clinician determined 
requirement for DPP-IV 




Clinical diagnosis of type 2 
diabetes non-insulin treated 
within 6 months of diagnosis. 
Participants were selected on 
the basis of rapid or slow 
progression to insulin therapy 
(<7, >7 years).  Age 18-90 
inclusive.  
Clinical diagnosis of type 2 
diabetes, currently treated 
with sulphonylurea tablets 
and no change in treatment 
in previous 3 months, Last 
HbA1c (within previous 12 
months) ≥42 and ≤75 
mmol/mol (6-9%).  
Age 19-79 inclusive. 
Data collection Clinical measurements 
and blood sample 
collected at visit. 
Ongoing biochemical 
data collected from 
pathology laboratories. 
Clinical measurements 
and blood taken at 
initial visit. Follow up 
clinical measurements 
and blood collected at 
three and six months. 
Clinical measures and fasting 
blood sample taken at visit. 
MMT at baseline & MMT on 
each study drug visits. Three 





Supplementary Table 2: Type 1 diabetes SNPs included in the genetic risk score with weights. 









DR3/DR4 48.18 3.87  
 
DR3/DR3 21.12 3.05  
DR4/DR4 21.98 3.09  
DR4/X 7.03 1.95  
DR3/X 4.53 1.51  
rs1264813 HLA_A_24 1.54 0.43  T 
rs2395029 HLA_B_5701 2.50 0.92  T 
rs3129889 HLA_DRB1_15 14.88 2.70  A 
rs2476601 PTPN22 1.96 0.67  A 
rs689 INS 1.75 0.56  T 
rs12722495 IL2RA 1.58 0.46  T 
rs2292239 ERBB3 1.35 0.30  T 
rs10509540 C10orf59 1.33  0.29  T 
rs4948088 COBL 1.30 0.26  C 
rs7202877   1.28 0.25  G 
rs12708716 CLEC16A 1.23 0.21  A 
rs3087243 CTLA4 1.22 0.20  G 
rs1893217 PTPN2 1.20 0.18  G 
rs11594656 IL2RA 1.19 0.17  T 
rs3024505 IL10 1.19  0.17  G 
rs9388489 C6orf173 1.17  0.16  G 
rs1465788   1.16 0.15  C 
rs1990760 IFIH1 1.16 0.15  T 
rs3825932 CTSH 1.16 0.15  C 
rs425105   1.16 0.15  T 
rs763361 CD226 1.16 0.15  T 
rs4788084 IL27 1.16 0.15  C 
rs17574546   1.14 0.13  C 
rs11755527 BACH2 1.13 0.12  G 
rs3788013 UBASH3A 1.13 0.12  A 
rs2069762 IL2 1.12 0.11  A 
rs2281808   1.11 0.10  C 





Supplementary Figure 1: Relationship between age at diagnosis (A) and BMI (B) and response modelled using restricted cubic splines (k = 3, 4 and 5) and a 
simple log transformation. Age at diagnosis and BMI did not predict linearly, the graphs of fitted splines and log transformation suggested that a simple log 





Supplementary Figure 2: Flow diagram of participants through the model development stages. 




























Unable to assign outcome excluded participants (n = 342) 
Diabetes duration <=36 months and not insulin 
treated: 223 
Diabetes duration at C-peptide measurement <5 
years, insulin treated <=36 months and C-peptide 
>200 pmol/L: 82   
Diabetes duration at C-peptide measurement >=5 
years, insulin treated <=36 months and C-peptide 
>=200 pmol/L and <=600 pmol/L: 37 
  
Participants from Exeter studies meeting eligibility criteria (clinical diagnosis 
of T1D or T2D and age between 18 and 50 years) (n = 1,892) 
 
Participants selected for model development (n = 1,352, T1D = 179) 
DARE: 904 
PRIBA: 368 
MRC MASTERMIND: 80 
 
 
Excluded - GADA not tested: 316 
Model development stage 2 (n = 1,036, T1D = 140) 
Excluded - IA-2 not tested: 11 
Missing data excluded participants (n = 198) 
 Time to insulin or duration not available: 103 
Insulin treated <=36 months and C-peptide not 
measured: 84 
 BMI not available: 11 
 
Excluded - T1D GRS not tested: 82 
Model development stage 4 (n = 943, T1D = 128) 




Supplementary Table 3: Characteristics of the Exeter, U.K. study participants included at each model development stage. Model 1 – Clinical features (Age at 
diagnosis & BMI), Model 2 – Clinical features + GADA, Model 3 - Clinical features + GADA + IA-2, Model 4 - Clinical features + GADA + IA-2 + T1D GRS. Median 
(IQR) or % or *Geometric mean [95% CI] for transformed variables. †Measured at recruitment (median 13 years post diagnosis). Minimum and maximum values for 
each continuous predictor variable used in the models 
 
 Model 1 
development 
n = 1,352  
Model 2 development 
n = 1,036 
Model 3 development 
n = 1,025 
Model 4 development 
n = 943 
Characteristic     
Sex (% Male)  59% 59% 59% 59% 
Age at diagnosis (years)* 40 [39, 41] 40 [39, 40] 40 [39, 40] 40 [39, 40] 
Age at diagnosis (years) min, 
max 
18, 50 18, 50 18, 50 18, 50 
BMI (kg/m2)*† 33 [32, 33] 33 [32, 33] 33 [32, 33] 33 [32, 33] 
BMI (kg/m2)*† min, max 17.5, 70.2  17.5, 70.2 17.5, 70.2 17.5, 70.2 
Duration of diabetes (years)  13 (8, 20) 13 (8, 20) 13 (8, 20) 13 (8, 20) 
Type 1 diabetes  13% 14% 13% 14% 
HbA1c (%)†  8.2 (7.1, 9.6) 8.3 (7.3, 9.8) 8.3 (7.3, 9.8) 8.2 (7.2, 9.7) 
HbA1c (mmol/mol)† 66 (54, 81) 67 (56, 84) 67 (56, 84) 66 (55, 83) 
GADA positive (%)  - 12% 12% 12% 
IA-2 positive (%) - - 4% 4% 
T1D GRS - - - 0.24 (0.22, 0.26) 
T1D GRS centile - - - 5.8 (1.2, 23.7) 







Supplementary Table 4: Comparison of characteristics for participants included in the model 4 development and participants included 
in model 1 development but excluded from model 4. Median (IQR) or % or *Geometric mean [95% CI] for transformed variables. 
†Measured at recruitment (median 13 years post diagnosis). 
 
 Model 4 development 
n = 943  
Model 4 development exclusions 
n = 409 
p value for comparison 
Characteristic    
Sex (% Male)  59% 60% >0.1 
Age at diagnosis (years)* 40 [39, 40] 41 [40, 42 ] 0.04 
BMI (kg/m2)*† 33 [32, 33] 33 [32, 33] > 0.1 
Duration of diabetes (years)  13 (8, 20) 13 (7, 20) > 0.1 
Type 1 diabetes  14% 12% > 0.1 
HbA1c (%)†  8.2 (7.2, 9.7) 8.0 (6.9, 9.3) 0.009 













Supplementary Table 5: Model performance results for the internal validation performed at each development stage. * P value for Brier score is Spiegelhalter’s z-
test used to evaluate the calibration component of the Brier score, significant p-values indicate poor calibration. †Result reported as raw cross-validation estimate of 
prediction error with misclassification cost function (cut-off 0.5). cv.glm function in R version 3.3.3.  
Performance parameter Development sample validation Internal validation (bootstrap 500) Optimism 
Apparent (SD) test (SD) 
Clinical features model (n = 1,352) 
ROC [95% CI] 0.90 [0.88, 0.93] 0.9056 (0.013) 0.9038 (0.0005) 0.0018 
Calibration-in-the-large  0 0.0000 (0.000) 0.0003 (0.1072) -0.0003 
Calibration slope (bL) 1 1.0000 (0.000) 0.9977 (0.0678) 0.0023 
Brier Score 0.07 (p = 0.50) - - - 
Hosmer-Lemeshow p =  0.95 - - - 
Jack-knife cross validation† 0.09 - - - 
Clinical features + GADA model (n = 1,036) 
ROC [95% CI] 0.96 [0.95, 0.97] 0.9595 (0.0070) 0.9586 (0.0010) 0.0009 
Calibration-in-the-large  0 0.0000 (0.0000) -0.0019 (0.1472) 0.0019 
Calibration slope (bL) 1 1.0000 (0.0000) 0.9850 (0.0787) 0.015 
Brier Score  0.05 (p = 0.35) - - - 
Hosmer-Lemeshow p = 0.39 - - - 
Jack-knife cross validation† 0.07 - - - 
Clinical features + GADA + IA-2 model (n = 1,025) 
ROC [95% CI] 0.96 [0.95, 0.98] 0.9622 (0.007) 0.9633 (0.0015) 0.0011 
Calibration-in-the-large  0 0.0000 (0.000) 0.0055 (0.1567) -0.0055 
Calibration slope (bL) 1 1.0000 (0.000) 0.9780 (0.0707) 0.022 
Brier Score 0.04 (p = 0.31) - - - 
Hosmer-Lemeshow p = 0.14 - - - 
Jack-knife cross validation † 0.06 - - - 
Clinical features + GADA + IA-2 + T1D GRS model (n = 943) 
ROC [95% CI] 0.97 [0.96, 0.98] 0.9718 (0.0060) 0.9710 (0.0006) 0.0008 
Calibration-in-the-large  0 0.0000 (0.0000) 0.0084 (0.1675) -0.0084 
Calibration slope (bL) 1 1.0000 (0.0000) 0.9880 (0.0810) 0.0124 
Brier Score 0.04 (p = 0.35) - - - 
Hosmer-Lemeshow p = 0.84 - - - 




Supplementary Table 6: Unitless index of adequacy is the proportion of log likelihood explained by each model 
stage with reference to the end model containing all predictors. Based on replica models developed using stage 4 
development sample (n = 943). 
 
Model LR 2   Adequacy 
Clinical features 324.7 (df 2) 0.67 
Clinical features + GADA 418.7 (df 3) 0.87 
Clinical features + GADA + IA-2 447.6 (df 5) 0.93 
Clinical features + GADA + IA-2 + T1D GRS 481.8 (df 6) 1.00 
 
 
Supplementary Table 7: Model fit comparisons of nested models developed using stage 4 development sample (n = 943). Null hypothesis for Likelihood Ratio test: 
Additional predictor(s) has no predictive information. Net Reclassification Improvement (NRI) calculated using 50% classification cut-off. IDI = Integrated 
Discrimination Improvement 
 
Model comparison Likelihood Ratio test NRI IDI 
Adding GADA to Clinical features model LR 2 (1) = 94.02 p <0.001 0.12, p = 0.01 0.13, p < 0.001 
Adding IA-2 to Clinical features + GADA model LR 2 (2) = 28.82 p < 0.001 0.14, p = 0.004 0.15, p < 0.001  
Adding T1D GRS to Clinical features + GADA + IA-2 model LR 2 (3) = 34.20 p < 0.001 0.06, p = 0.04 0.06, p < 0.001 
 
 
Supplementary Table 8: Model performance comparison with replica models developed using stage 4 development sample (n = 943).  
 
Model Clinical features Clinical features + GADA Clinical features + GADA + IA-2 
 ROC AUC ROC AUC ROC AUC 
Development sample 1 (n = 1,352)  0.90 [0.88, 0.93] - - 
Development sample 2 (n = 1,036) - 0.96 [0.95, 0.97] - 
Development sample 3 (n = 1,025) - - 0.96 [0.95, 0.98] 




Supplementary Table 9: ROC AUC calculated including only patients aged 25-35 years 
(inclusive) at diagnosis and with BMI 25-35 kg/m2 (inclusive). 
Model ROC AUC [95% CI] n 
Clinical Features 0.72 [0.61, 0.83] 104 
Clinical Features + GADA 0.89 [0.80, 0.98] 78 
Clinical Features + GADA + IA2 0.89 [0.80, 0.98] 77 






Supplementary Figure 3: Flow diagram of participants through the model external validation 

















Unable to assign outcome excluded participants  
(n = 187) 
Diabetes duration <=36 months and not 
insulin treated: 91 
Insulin treated <=36 months and missing  
C-peptide: 72   
Insulin treated <=36 months and C-peptide 
>=200 pmol/L and <=600 pmol/L: 24 
  
Participants from Young Diabetes in Oxford study studies meeting eligibility criteria (clinical 
diagnosis of T1D or T2D and age between 18 and 50 years) (n =856) 
 
Participants selected for clinical features model external validation (n = 582, T1D = 134) 
 
Missing data excluded participants (n = 87) 
 Missing C-peptide: 9 
 Treatment not known: 18 
Time to insulin or duration not available: 50 
 BMI not available: 10 
 
Excluded - GADA not tested: 33 
Participants selected for clinical features + GADA model external validation  





Supplementary Table 10: Baseline characteristics comparison of the development and validation data sets for: Model 1 – Clinical features (Age at diagnosis & BMI) 
and Model 2 – Clinical features + GADA. *Measured at recruitment (median 13 years and 14 years post diagnosis in development data sets and validation data 
sets). Kruskal-Wallis used for comparison testing continuous variables, chi-square for categorical variables. 
 Model 1 development 
n = 1,352  
Model 1 validation 
n = 582  
comparison p 
value 
Model 2 development 
n = 1,036  
Model 2 validation 




Sex (% Male)  59% 61% >0.1 59% 61% > 0.1 
Age at diagnosis (years) 43 (36, 48) 37 (30, 41) <0.001 43 (36, 48) 37 (30, 41) < 0.001 
BMI (kg/m2)* 33 (28, 38) 31 (27, 36) <0.001  33 (28, 38) 31 (27, 36) < 0.001 
Duration of diabetes (years)* 13 (8, 20) 14 (8, 23) 0.03 13 (8, 20) 13 (8, 23) > 0.1 
Type 1 diabetes 13% 23% <0.001 14% 22% < 0.001 
HbA1c (%)* 8.2 (7.1, 9.6) 8.1 (7.2, 9.3) >0.1 8.3 (7.3, 9.8) 8.1 (7.2, 9.4) 0.08 
HbA1c (mmol/mol)* 66 (54, 81) 65 (55, 78) >0.1 67 (56, 84) 65 (55, 79) 0.08 





Supplementary Table 11: Model performance results for the external validation of the clinical 
features and clinical features+ GADA models. * P value for Brier score is Spiegelhalter’s z-test 
used to evaluate the calibration component of the Brier score, significant p-values indicate poor 
calibration. 
Performance parameter External validation  
Clinical features model (n = 582) 
ROC [95% CI] 0.86 [0.83, 0.90] 
Expected/Observed 1.06 
Calibration-in-the-large (𝑎|𝑏𝐿=1) -0.14 
Calibration slope (bL) 0.85 
Overall misclassification -0.14 p = 0.05  
Brier Score* 0.11 (p = 0.14) 
Clinical features + GADA model (n = 549) 
ROC [95% CI] 0.93 [0.90, 0.96] 
Expected/Observed 1.08 
Calibration-in-the-large (𝑎|𝑏𝐿=1) -0.23 
Calibration slope (bL) 0.90 
Overall misclassification -0.10 p > 0.1  





Supplementary Table 12: Classification table comparing the development and validation samples at different cut-offs for probability of type 1 diabetes using the 
clinical features and clinical features + GADA logistic regression models. 
PPV and NPV assume prevalence for type 1 diabetes: Clinical features model – 13% (development) and 23% (validation), Clinical features + GADA model - 14% 
(development) and 22% (validation).  
 
Clinical features Development (n = 1,352) Validation (n = 582) 
 Probability cut-off  Probability cut-off  
 10 30 50 70 90 10 30 50 70 90 
Sensitivity/specificity (%) 85/79 64/95 49/98 35/99 15/100 91/62 73/85 59/93 45/96 13/99 
Accuracy (%) 80 90 91 90 89 69 82 85 84 79 
Positive predictive value (PPV) (%) 38 64 79 83 90 42 59 71 77 77 
Negative predictive value (NPV) (%) 97 95 93 91 89 96 91 88 85 79 
 
Clinical features + GADA Development (n = 1,036) Validation (n = 549) 
 Probability cut-off  Probability cut-off  
 10 30 50 70 90 10 30 50 70 90 
Sensitivity/specificity (%) 90/88 80/96 66/97 52/99 31/100 97/75 86/89 75/93 55/96 42/97 
Accuracy (%) 89 94 93 92 90 80 88 88 87 85 
Positive predictive value (PPV) (%) 55 75 80 85 92 53 69 73 80 81 










Supplementary table 13: Characteristics of participants with probability of Type 1 diabetes > 80% but with type 2 diabetes actual outcome *Non fasting equivalent, 
measured > 5 years post diagnosis (unless < 200 pmol/L prior to 5 years). † C-peptide measured at single screening visit. ‡Clinical features + GADA model applied to 
participants in the YDX study. 








Insulin Treated Time to insulin 
(months) 




Probability of type 
1 diabetes‡ (%) 
18 26 0 775 1 Immediate 15 Type 2 diabetes 80 
21 23 0 868 1 Immediate 10 Type 2 diabetes 82 
27 29 1 - 0 - 3 Type 2 diabetes 88 
38 22 1 550 1 48 10 Type 2 diabetes 88 
36 22 1 175 1 72 12 Type 2 diabetes 89 
23 32 1 25 1 48 29 Type 2 diabetes 90 
30 25 1 25 1 36 30 Type 2 diabetes 91 
29 25 1 225 1 48 12 Type 2 diabetes 93 
23 28 1 50 1 120 28 Type 2 diabetes 95 
33 21 1 65 1 96 47 Type 2 diabetes 95 
34 20 1 25 1 120 22 Type 2 diabetes 96 






Supplementary table 14: Characteristics of participants with probability of Type 1 diabetes < 16% (Youden’s Index cut-off) but with type 1 diabetes actual outcome 
*Non-fasting equivalent, measured > 5 years post diagnosis (unless < 200 pmol/L prior to 5 years). † C-peptide measured at single screening visit. ‡Clinical features 
+ GADA model applied to participants in the YDX study. 








Insulin Treated Time to insulin 
(months) 




Probability of type 1 
diabetes (%)‡ 
41 40 0 50 1 12 41 Type 1 diabetes 0.6 
40 34 0 198 1 12 34 Type 1 diabetes 1.8 
43 31 0 125 1 3 1 Type 1 diabetes 2.1 
39 33 0 25 1 24 17 Type 1 diabetes 2.5 
38 25 0 68 1 Immediate 19 Type 1 diabetes 12.7 




Supplementary table 15: Model performance results for the four additional models in the online calculator. * Result reported as raw cross-validation estimate of 
prediction error with misclassification cost function (cut-off 0.5). cv.glm function in R version 3.3.3 
 
Model ROC [95% CI] Jack-knife cross validation * 
Clinical features + IA-2 0.93 [0.90, 0.95] 0.07 
Clinical features + T1D GRS 0.93 [0.90, 0.95] 0.08 
Clinical features + IA-2 + T1D GRS  0.95 [0.93, 0.97] 0.06 





Supplementary Table 16: Clinical features logistic regression model (model 1). * Log 
transformed. Linear Predictor mean -2.96, sd 1.98  
Included β (SE) Odds Ratio [95% CI] p value 
Constant (intercept) 37.94 (2.67) - - 
Age at diagnosis (years) * -5.09 (0.41) 0.006 [0.003, 0.014] <0.001 




Supplementary Table 17: Clinical features + GADA logistic regression model (model 2). 
Linear Predictor mean -3.37, sd 2.53 
Included β (SE) Odds Ratio [95% CI] p value 
Constant (intercept) -0.98 (0.19) - - 
Model 1 linear predictor  0.94 (0.08) 2.57 (2.18, 3.03) < 0.001 





Supplementary Table 18: Clinical features + GADA + IA-2 logistic regression model (model 3).  
Linear Predictor mean -3.55, sd 2.58 
 
Included β (SE) Odds Ratio [95% CI] p value 
Constant (intercept) -1.28 (0.21) -  
Model 1 linear predictor  0.92 (0.09) 2.50 [2.10, 2.98] < 0.001 
Antibody status - GADA positive only 3.08 (0.35) 21.81 [11.06, 43.02] < 0.001 
Antibody status - IA-2 positive only 3.49 (0.78) 32.93 [7.11, 152.64] < 0.001 




Supplementary Table 19: Clinical features + GADA + IA-2 + T1D GRS logistic regression model (model 4). T1D GRS standardized using mean 0.2356997, sd 
0.0363499. Linear Predictor mean -3.74, sd 2.89. 
Included β (SE) Odds Ratio [95% CI] p value 
Constant (intercept) -0.67 (0.24) - - 
Model 3 linear predictor  0.88 (0.08) 2.40 [2.06, 2.80] < 0.001 
T1D GRS (per 1 SD change) 1.08 (0.21) 2.93 [1.96, 4.39] < 0.001 
 
 
Supplementary Table 20: Clinical features + IA-2 logistic regression model. Linear Predictor mean -3.17, SD 2.28 
Included β (SE) Odds Ratio [95% CI] p value 
Constant (intercept) -0.36 (0.17) - - 
Model 1 linear predictor  0.99 (0.08) 2.70 [2.30, 3.16] < 0.001 






Supplementary Table 21: Clinical features + T1D GRS logistic regression model. T1D GRS standardized using mean 0.2360879, sd 
0.0358468. Linear Predictor mean -3.180108, sd 2.401089. 
 
Included β (SE) Odds Ratio [95% CI] p value 
Constant (intercept) -0.65 (0.18) - - 
Model 1 linear predictor  0.87 (0.07) 2.39 [2.09, 2.74] < 0.001 
T1D GRS (per 1 SD change) 1.22 (0.15) 3.38 [2.51, 4.54] < 0.001 
 
 
Supplementary Table 22: Clinical features + IA-2 + T1D GRS logistic regression model. T1D GRS standardized using 
mean 0.235673, sd 0.0363399. Linear Predictor mean -3.537275, sd 2.79395. 
Included β (SE) Odds Ratio [95% CI] p value 
Constant (intercept) -1.12 (0.23) - - 
Model 1 linear predictor  0.87 (0.09) 2.40 [2.02, 2.84] < 0.001 
T1D GRS (per 1 SD change) 1.36 (0.20) 3.89 [2.64, 5.74] < 0.001 
IA-2 positive 2.95 (0.65) 19.17 [5.33, 68.81] < 0.001 
 
 
Supplementary Table 23: Clinical features + GADA + T1D GRS logistic regression model. T1D GRS standardized using mean 
0.2359649, sd 0.0363407. Linear Predictor mean - 3.596086, sd 2.868552. 
Included β (SE) Odds Ratio [95% CI] p value 
Constant (intercept) -1.50 (0.24) - - 
Model 1 linear predictor  0.85 (0.09) 2.33 [1.97, 2.76] < 0.001 
T1D GRS (per 1 SD change) 1.12 (0.20) 3.05 [2.09, 4.46] < 0.001 








Supplementary Table 24: *To convert to probability use exp(lp)/(1+exp(lp)). †Dummy variable: negative = 0, positive = 1 ‡Dummy variables: false = 0, true = 1, 
AntiStatus1 = GADA positive only, AntiStatus2 = IA-2 positive only, AntiStatus3 = Both GADA and IA-2 positive. 
Model  Linear predictor (lp) regression equation* 
Clinical features 37.94 + (-5.09 * log(age)) + (-6.34 * log(BMI)) 
Clinical features + GADA† 34.8057844720 + (-4.801441792 * log (Age)) + (-5.980577792 * log(BMI)) + 
(2.937107976 * GADA†) 
Clinical features + GADA + IA-2 33.49649577 + (-4.665598345 * Log(Age)) + (-5.81137397 * Log(BMI)) + (3.082366 * 
AntiStatus1‡) + (3.494462 * AntiStatus2‡) + (4.350717 * AntiStatus3‡) 
Clinical features + GADA + IA-2 + 
T1D GRS 
21.57649882 + (-4.086215772 * Log(Age)) + (-5.096252172 * Log(BMI)) + (2.702010666 
* AntiStatus1‡) + (3.063255174 * AntiStatus2‡) + (3.813850704 * AntiStatus3‡) + 
(30.11052 * T1D GRS) 
Clinical features + IA-2 37.26905033 + (3.194096 * IA-2† ) + (-5.047657308 * Log(Age)) + (-6.287258808 * 
Log(BMI)) 
Clinical features + T1D GRS 24.46138054 + (-4.443506884 * Log(Age)) + ( -5.534741384 *Log(BMI)) + (33.93968 * 
T1D GRS) 
Clinical features + IA-2 + T1D GRS  23.2151829 +(2.953142 * IA-2†) + (-4.446784844 *Log(Age))+(-5.538824344 * Log(BMI)) 
+ (37.40205 * T1D GRS) 
Clinical features + GADA + T1D GRS 23.20924904 + (2.63093 * GADA†) + (-4.303557843 * Log(Age)) + (-5.360423718  
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There is much interest in the use of prognostic and diagnostic prediction models 
in all areas of clinical medicine. The use of machine learning to improve 
prognostic and diagnostic accuracy in this area has been increasing at the 
expense of classic statistical models. Previous studies have compared 
performance between these two approaches but their findings are inconsistent 
and many have limitations. We aimed to compare the discrimination and 
calibration of six models built using logistic regression and optimised machine 
learning algorithms in a clinical setting, where the number of potential predictors 
is often limited, and externally validate the models. 
Research design and methods 
We trained models using logistic regression and five commonly used machine 
learning algorithms to classify diabetes (type 1 versus type 2) based on three 
pre-specified predictor variables (Age, BMI and GADA islet-autoantibodies) 
using a UK cohort of adult participants (aged 18–50 years) with clinically 
diagnosed diabetes recruited from primary and secondary care (n = 1,036). 
Discrimination performance (ROC AUC and AUPRC) and calibration of each 
approach was compared in a separate external test dataset (n = 549).  
Results 
Average performance obtained in model training was similar in all models (ROC 
AUC >= 0.94). In external validation, decreases in performance were observed 
in all models. Calibration tests showed that all models overstated predicted risk 





Logistic regression performed as well as optimised machine algorithms to 
classify patients with type 1 and type 2 diabetes. This study highlights the utility 
of comparing traditional regression modelling to machine learning, particularly 






There is much interest in the use of prognostic and diagnostic prediction models 
in all areas of clinical medicine including cancers (1, 2), cardiovascular disease 
(3, 4) and diabetes (5, 6). These models are increasingly being used as web-
calculators (7-9) and medical apps for smartphones (10-12), and many have 
been incorporated into clinical guidelines (13-22). 
There are many different approaches that can be used for developing these 
models. Classic statistical models such as logistic regression are commonly 
applied but there is increasing interest in the application of machine learning to 
improve prognostic and diagnostic accuracy in clinical research (23-26) with 
many examples of their use (27-33). Machine learning (ML) is a data science 
field dealing with algorithms in which computers (the machines) adapt and learn 
from experience (data), these algorithms have the ability to process the vast 
amounts of data, complex interactions and non-linearity. Supervised Learning is 
the most widely employed category of machine learning. In Supervised 
Learning, the machine predicts the value of an outcome (either binary or 
continuous) trained on a set of predictor variables.  
There are many applied studies comparing the performance of classic models 
to different machine learning algorithms (34-45) but their findings are 
inconsistent. Many such comparison studies have limitations; not all use non-
default parameter settings (hyperparameter tuning) or have validated 
performance on external data (46). Discrimination, as measured by area under 
the receiver operating characteristic curve, is almost always provided but 





We aimed to use a methodological approach to explore and compare 
performance of machine learning and a classic statistical modelling approach 
using an example of a diabetes classification model. Classification of diabetes 
offers an interesting case study as it is an area where there is considerable 
misclassification in clinical practice. Type 1 diabetes and type 2 diabetes can be 
hard to distinguish between, particularly in adults aged between 18 and 50.  
Methods 
We focus on the capacity of each machine learning algorithm in a specific 
context using real data as the basis for our comparisons. An alternative method 
of comparing machine learning algorithms is to use simulation. Whilst simulation 
studies are interesting, the choice of model used to generate the simulation 
data can introduce bias. Our use of real data avoids this potential bias. In 
addition, our use of a real data allows us to test the algorithms in an external 
dataset with different data collection methods, simulated data is unable to 
capture such differences. In summary, our decision to use real data ensures 
that we are comparing the performance of the algorithms in a setting 
representative of clinical practice. 
Sample size was checked using events per variable. For machine algorithms it 
has been suggested that over ten times as many events per variable is required 
to achieve stable results compared to traditional statistical modelling. For three 
predictors, this means that 300 events are required. 
We selected a classic model and five supervised machine learning algorithms 
that 1) were appropriate for classification problems and 2) had been used 
previously in medical applications: Logistic Regression, Gradient Boosting 




Nearest Neighbours, Neural Network and Random Forest machine learning 
algorithms. We trained models using each algorithm, incorporating 
hyperparameter tuning, and compared the performance of the optimised models 
on a separate external test dataset. 
Study population – training 
Participants with clinically diagnosed diabetes were identified from Exeter, UK-
based cohorts (47-50). Summaries of the cohorts including recruitment and data 
collection methods are shown in Supplementary Table 1. Only participants that 
had a clinical diagnosis of type 1 or type 2 diabetes between the ages of 18 and 
50 years were eligible.  
Study population – external test dataset 
Participants were identified from the Young Diabetes in Oxford (YDX) study 
(51).  Participants were recruited in the Thames Valley region, UK, and 
diagnosed with diabetes up to the age of 45 years. The same eligibility criteria 
were applied to this cohort. 
All participants included in this study (training and test datasets) were of white 
European origin.  
Model outcome (dependent variable): type 1 and type 2 diabetes definition 
We used a binary outcome with values type 1 or type 2 diabetes. Type 1 
diabetes was defined as having insulin treatment within <= 3 years of diabetes 
diagnosis and severe insulin deficiency (non–fasting C peptide < 200pmol/L). 
Type 2 diabetes was defined as either 1) no insulin requirement for 3 years from 
diabetes diagnosis or 2) where insulin was started within 3 years of diagnosis, 




>=5 years diabetes duration. Participants not meeting the above criteria or with 
insufficient information were excluded from analysis, as type of diabetes and 
rapid insulin requirement could not be robustly defined (n = 342).   
Predictor variables 
We used three pre-specified predictor variables, age at diagnosis, BMI and 
GADA islet-autoantibodies. All three predictor variables have evidence for utility 
at diabetes diagnosis (52-54). Age at diagnosis was self-reported by the 
participant. Height and weight was measured at study recruitment by a research 
nurse to calculate BMI. Age at diagnosis and BMI were modelled as continuous 
variables and were standardised (55). GADA islet-autoantibodies were 
dichotomized into negative or positive based on clinically defined cut-offs, in 
accordance with clinical guidelines (56). 




All models were trained using the entire training dataset.  We evaluated six 
classification algorithms; Logistic Regression (LR), Support Vector Machine 
(SVM), Gradient Boosting Machine (GBM), Neural Network (NN), K-Nearest 
Neighbours (KNN) and Random Forest (RF). For SVM we used the Radial 
Basis Function kernel parameter (55) and for NN we used the most commonly 
used single-hidden-layer neural network (55) trained using Quasi-Newton back 
propagation (BFGS) (57) optimisation method. There are no clear guidelines 




of each in specific clinical settings. A brief summary of each algorithm is shown 








Table 1: Algorithm description and references  
Algorithm Description References 
Logistic Regression A classic statistical algorithm for binary 
outcomes that uses maximum likelihood 
estimation. It is fully parametric but has a 
number of assumptions that need to be 
satisfied such as weak collinearity between 
the variables. There are no model 
parameters to be set. Coefficients are 
adjusted to allow for dependence between 
the characteristics. Is useful for inference, 




An artificial intelligence based method. It is 
a quadratic optimisation problem involving 
minimising penalties and maximizing margin 
width, the two classes are separated by 
constructing nonlinear decision boundaries 
(hyperplanes) using kernel trick that 
maximise the margin between them. It is 
non-parametric and requires penalty and 
kernel function parameters to be set.  
(55, 61, 62) 
Gradient Boosting 
Machine 
An ensemble learning technique similar to 
random forest in the sense they average a 
large number of decision trees to make 
prediction. The difference between the two 
is the application of gradient boosting. In 
gradient boosting, the decision trees are 
trained sequentially with the weights of each 
successive model adjusted based on 
reducing the errors of the previous model. 
After few steps of the algorithm, the new 
decision trees are able to handle hard to fit 
data. Finally, the predicted class is 
determined from the average estimated 
class probability (or majority vote of 
predicted class) calculated over the 
ensemble of trees.  
(55, 63, 64) 
Neural Network An artificial intelligence based method using 
an adaptive and non-sequential approach to 
learning that mimics a biological neural 
network. It is a non-parametric technique, it 
uses all the predictor variables resulting in 




A model-free method; it is a type of 
instance-based learning or lazy learning in 
which there is no training phase, instead the 
algorithm memorises the training data. 
Based on the principle that observations 
located close together in n-dimensional 
space will have the same outcome, the 
classification process involves a search the 
entire dataset for the k training points 
closest in Euclidean distance (k-
neighbours), the predicted class is 
determined based on a majority vote of the 
actual class among these k-neighbours. 




Algorithm Description References 
Random Forest A popular artificial intelligence based 
algorithm that grows a large ensemble of 
classification trees on bootstrapped 
samples using a random selection of the 
predictor variables and performs bagging for 
class selection; after all the trees have been 
grown, the predicted class is determined 
from the average estimated class probability 
(or majority vote of predicted class) 
calculated over the ensemble of trees.  
(55, 71, 72) 
 
 
All models were trained using 5 repeats of 10-fold cross validation resampling 
method. We applied Synthetic Minority Over-Sampling Technique (SMOTE) 
inside of cross-validation to deal with imbalanced data (73). While real-world 
data medical applications are likely to be unbalanced, the use of sampling 
methods such as SMOTE can improve model prediction performance. We used 
a grid search to tune the model parameters (hyperparameter tuning) (74), i.e. 
optimize the performance of the machine learning algorithm. The 
hyperparameter metrics applied in the grid searches are shown in 
Supplementary Table 2. Optimal models were selected using the maximum 
mean area under the receiver operating characteristic curve (ROC AUC) 
calculated in the cross-validation.  
Model performance measures  
We used ROC AUC (75) and precision recall curve (AUPRC) as the summary 
metrics to evaluate model discrimination. The ROC AUC quantifies the 
probability that the risk scores from a randomly selected pair of individuals with 
and without this condition are correctly ordered. AUPRC is a more sensitive 
performance metric when dealing with strongly imbalanced data (unequal 
percentage in each class); it evaluates the performance of the model in regard 




identify the second class (76-78). For both measures, a value of 1 indicates a 
perfect test. 
We assessed calibration visually using calibration plots and statistically using 
calibration tests (calibration slope). 
External testing 
For each optimal model developed in the training dataset, external performance 
was evaluated in the YDX study cohort and compared to the internal (cross-
validation resampling) performance. Calibration was investigated using 
calibration curves. We also checked for correlation in the predictions from each 
model.  
Variable Importance 
We assessed and compared the predictor variable importance (VI) in the 
optimal models (79). The VI model-specific metrics were scaled to derive values 
proportional to the most important predictor having value 100. VI metrics were 
not available for the SVM or KNN models.  
Software 
All analysis was performed using R software (version 3.5.2). Model training, 
internal evaluation and variable importance were performed using the Caret R 
package (79-83). VI model specific metrics were obtained using the Caret 
VarImp function.  
Code 
In Appendix 2 we share the code to allow reproduction of similar comparisons of 




Results   
1,036 participants in the Exeter cohort met inclusion criteria and were included 
in the training dataset, of whom 140 (14%) were classified as having type 1 
diabetes. 549 participants (type 1 diabetes n = 122 (22%)) in the YDX cohort 
met criteria and were included in the external validation test dataset. Compared 
to the participants in the Exeter cohort, the participants in the YDX cohort were 
younger at diagnosis (consistent with the narrower age range in YDX (18-45y) 
(median 37 years vs 43 years, p < 0.001)), had a lower BMI (median 31 kg/m2 
vs 33 kg/m2, p < 0.001), had a higher percentage of GADA (20% versus 12%, p 
< 0.001) and a higher prevalence of type 1 diabetes by study definition (22% vs 
14%, p < 0.001) (Supplementary Table 3 for participant characteristics). 
The average (mean) performance ROC AUC for the optimal models obtained in 
the resampling was high in all six models (ROC AUC >= 0.94) (Table 2 
(resampling ROC AUC column)) with no difference in performance between 
models. Supplementary Table 2 includes the final model tuning parameters 




Table 2: ROC AUC [95% CI] and AUPRC performance comparison of the six optimal models applied to the resampling and test datasets. 
 
Model Resampling ROC AUC Test ROC AUC Test AUPRC 
Gradient Boosting Machine 0.96 [0.92, 1.00] 0.93 [0.90, 0.95] 0.88 
Logistic regression 0.96 [0.90, 1.00] 0.93 [0.90, 0.96] 0.76 
Support Vector Machine  0.96 [0.91, 1.00] 0.93 [0.90, 0.96] 0.75 
Neural Network 0.96 [0.90, 1.00] 0.93 [0.90, 0.96] 0.84 
Random Forest 0.94 [0.89, 0.99] 0.91 [0.89, 0.94] 0.87 
K-Nearest Neighbours 0.95 [0.89, 1.00] 0.92 [0.89, 0.95]  0.88 
 
 
Table 3: Calibration test results on test dataset. 





Gradient Boosting Machine 1.328 -0.738 0.328, p = 0.003   
Logistic regression 0.808 -0.784 -0.192, p = 0.008 
Support Vector Machine  0.776 -0.845 -0.224, p = 0.001   
Neural Network 0.886 -0.746 -0.114, p = 0.138 
Random Forest 0.359 -0.783 -0.641, p < 0.001 






There was a decrease in the ROC AUC of all models when they were applied to 
the external test dataset (Table 2 (test ROC AUC column)) but all still showed 
high levels of performance (ROC AUC >= 0.90, Figure 1). When model 
performance on the external test dataset was assessed using AUPRC, there 
was a clear difference in performance of LR and SVM, and the other models 
(Supplementary Figure 1 and Table 2 (test AUPRC column)). Model predictions 
were highly correlated across models (Supplementary Table 4).   
Figure 1: ROC AUC plots obtained using external validation dataset for six prediction models 
Legend:  
Solid lines: black = Support Vector Machine, dark grey = Logistic Regression, light grey = 
Random Forest 
























In the calibration tests performed on the external test dataset, all models over-
estimated type 1 diabetes prevalence (Figure 2 and Table 3 (calibration in the 
large values < 0 indicate over-estimating risk)) and there was evidence of 
miscalibration (significant overall misclassification p values indicate 
miscalibration) in all models (often due to an underestimation of type 1) except 




Figure 2: Calibration plots obtained using external validation dataset for prediction models: A: Logistic Regression B: Support Vector Machine C: Random Forest D: 
Gradient Boosting Machine E: K-Nearest Neighbours F: Neural Network. 





Although performance was similar, variable importance differed by model in the 
training dataset (Supplementary Figure 2). Relative to other predictors, Age at 
diagnosis was more important in the LR, GBM and RF models than the neural 
network model, BMI was very important only in the GBM. GADA had similar 
high importance in all the four models assessed.  
Conclusions 
We found similar performance when applying logistic regression and five 
optimised machine learning algorithms to classify type 1 and type 2 diabetes, in 
both training and test datasets. Performance was high for all models. In 
calibration tests, all models overstated predicted risk and most had evidence of 
miscalibration. The choice of algorithm in this study made very little difference to 
the discrimination performance of the models.  
Strengths of our study include the use of a systematic approach to model 
comparison dealing with limitations from previous studies (46, 84) including: 1) 
use of different datasets to train and test models, 2) use of default tuning 
parameters (35, 41) and 3) calibration (23). We have used the same dataset to 
train all our models; since model performance will differ between settings, use 
of the same dataset is crucial for valid model comparisons. The choice of tuning 
parameters will affect the performance of the model (74), we have optimised our 
models by applying hyperparameter tuning using a recognised grid search 
approach. We have increased the validity of our results by using an external 
test dataset. 
We have compared several machine learning algorithms that have been 
selected for their suitability to our setting. The use of only three predictor 




three predictors may also be considered as a limitation of our study since these 
machine learning algorithms are designed to deal with larger datasets and more 
variables. Working with a few meaningful predictors is common in clinical 
settings and knowing the performance of machine learning models using low 
numbers of predictors is important. It is possible with more variables, machine 
learning approaches may prove more discriminative. However, we have 
achieved excellent performance using just these three predictors. Another 
limitation of our study is that we judge the model only on its performance. In real 
practice we would want to consider ease of implementation and interpretation 
when selecting the ‘best’ model. 
For machine learning algorithms it has been suggested that over ten times as 
many events per variable is required to achieve stable results compared to 
traditional statistical modelling (85). Although we did not have the sufficient 
number of events per variable to meet this criteria (140 actual events compared 
to 300 suggested), the results of the external validation suggest stability was 
achieved.  
The performance ranking of the models differed when ordering by each of the 
two discrimination performance measures (ROC AUC and AUPRC), it is 
therefore important that the performance measure being reported is the most 
appropriate for the individual clinical setting. In our study, ROC AUC is 
appropriate as we place equal weight on each type of misclassification error. In 
this setting LR, SVM and NN are the best models.  If accuracy of estimated 
probability were an importance factor NN would come at the best approach. If 
wrongly identifying type 1 diabetes for type 2 diabetes was important then KNN 




of best model is context dependent but in this study the models perform 
similarly. 
The observed decrease in ROC AUC when assessed in the external test data 
highlights the importance of external validation to test the transportability of 
models. Indeed, all of the algorithms underperformed in the test set. The 
models fit on the training data set might be over-fitted and their performance 
could be overestimated despite a rigorous internal validation. Other reasons 
might be that the test dataset used different GADA and C-peptide assays, and 
the different populations – this may diminish performance and does not 
necessarily mean over-fitting. 
The performance of LR on both training and test datasets shows that classic 
algorithms can perform as well as more advanced algorithms even when 
disadvantaged by assuming linearity in the predictors. LR models are relatively 
easy to use and understand compared to machine learning algorithms where 
usage is limited by the difficultly of interpreting the model, often referred to as a 
“black boxes”. LR models also have a strong theoretical background which lead 
to the possibility of using well defined statistical tests to explore the statistical 
significant of the variables. There is an increasing number of studies 
demonstrating that LR can perform as well if not better, in a large number of 
settings (46). However we could not find a study that compared machine 
learning algorithms with optimised hyperparameters versus LR on an external 
dataset as we have done in this study which shows again that LR performs as 
well as more complex approaches. 
We have shown through this study that machine learning performs similarly, 




database is unique and there is no ‘free lunch’, i.e. if an algorithm performs well 
on a certain class of problems then it necessarily pays for that with degraded 
performance on the set of other problems (46, 84). It is thus important to test 
different algorithms benchmarked against logistic regression to identify if one 
algorithm outperforms the other; if performance is similar then the simplest and 
most interpretable model can be used.  
In a diabetes classification setting with three strongly predictive variables, a 
classic logistic regression algorithm performed as well as more advanced 
machine algorithms. This study highlights the utility of comparing traditional 
regression modelling to machine learning, particularly when using a small 
number of well understood, strong predictor variables. Furthermore, this article 
highlights once again the need to perform external validation when selecting 
models as we demonstrate that all algorithms can underperform on external 
data. 
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Supplementary Table 1: Cohort recruitment and data collection methods summary (training dataset).   
 
 DARE  PRIBA  MRC Pro/RetroMaster  MRC crossover 
Included participants 614 353 61 8 
Data collection period 2007 to 2017 2011 to 2013 2013 to 2015 2013 to 2015 
Study design Cross-sectional Longitudinal Cross-sectional Interventional Crossover 
Setting Primary and secondary 
care in eight diabetes 
research regions, 
England and retinal 
screening clinics. 
Primary and secondary 
care in South West 
England 
Primary and secondary 
care sites  South West 
England, Tayside, 
Oxford, Glasgow, KCL 
and Newcastle, U.K. 
Exeter and Tayside,U.K. 
Inclusion criteria Clinical diagnosis of 
diabetes (any type). 
Clinical diagnosis of 
type 2 diabetes. 
Clinician determined 
requirement for DPP-




Clinical diagnosis of 
type 2 diabetes non-
insulin treated within 6 
months of diagnosis. 
Participants were 
selected on the basis of 
rapid or slow 
progression to insulin 
therapy (<7, >7 years).  
Age 18-90 inclusive.  
Clinical diagnosis of type 2 
diabetes, currently treated with 
sulphonylurea tablets and no 
change in treatment in 
previous 3 months, Last 
HbA1c (within previous 12 
months) ≥42 and ≤75 
mmol/mol (6-9%).  
Age 19-79 inclusive. 
Data collection Clinical measurements 
and blood sample 
collected at visit. 
Ongoing biochemical 
data collected from 
pathology laboratories. 
Clinical measurements 
and blood taken at 
initial visit. Follow up 
clinical measurements 
and blood collected at 
three and six months. 
Clinical measures and 
fasting blood sample 
taken at visit. 
MMT at baseline & MMT on 
each study drug visits. Three 






Supplementary Table 2: Model training details including the R training method used and grid search parameters applied in hyperparameter tuning, and model 
parameters for the optimal model selected using largest ROC AUC value. There are no model parameters for logistic regression. Hyperparameter tuning was not 
used for Random Forest due to the low number of predictor variables. Descriptions for search parameters are available in reference. Seed choice was set to 7 in 
model training. 
 
Model R train method Grid Search parameter values Final values used for 
the optimal model  
Logistic Regression glm N/A N/A 
Gradient Boosting machine gbm (180) n.trees = (50,100,150,500,2000) 
interaction.depth = (1, 3, 6, 9, 10) 
shrinkage = (from 0.0005 to 0.1 by 
0.001) 
n.minobsinnode = (5,10,15,20) 
n.trees = 50,  
interaction.depth = 3  
shrinkage = 0.0515  
n.minobsinnode = 20 
Support Vector Machine 
(with Radial Basis Function 
Kernel) 
svmRadial (181) sigma = (0.01, 0.1, 1, 10, 100) 
C = (from 0.1 to 1 by 0.05) 
sigma = 0.01 
C = 0.7 
K-Nearest Neighbours knn (182) k = (from 1 to 100 by 1) k = 99 
Neural Network nnet (182) size = (from 1 to 10 by 1)                       
decay = (0.5, 0.1, 0.01, 0.001, 
0.0001, 0.00001, 0.000001, 
0.0000001) 
size = 7 
decay = 0.5 











Supplementary Table 3: Characteristics of the Exeter, U.K. study participants included in the model training and Young Diabetes in Oxford participants included in 
the model external testing. Median (IQR) or %. *Measured at recruitment (median 13 years post diagnosis). Minimum and maximum values for each continuous 
predictor variable used in the models. 
 
Characteristic Training dataset 
n = 1,036 
External validation 
dataset n = 549 
comparison  
p value 
Sex (% Male)  59% 61% > 0.1 
Age at diagnosis (years) 40 [39, 40] 37 [30, 41] < 0.001 
Age at diagnosis (years) min, max 18, 50 18, 49 NA 
BMI (kg/m2)* 33 [32, 33] 31 [27, 36] < 0.001 
BMI (kg/m2)* min, max 17.5, 70.2 15.3, 87.7 NA 
Duration of diabetes (years)  13 (8, 20) 13 (8, 23) > 0.1 
Type 1 diabetes  14% 22% < 0.001 
HbA1c (%)*  8.3 (7.3, 9.8) 8.1 (7.2, 9.4) 0.08 
HbA1c (mmol/mol)* 67 (56, 84) 65 (55, 79) 0.08 





Supplementary Figure 1: Precision-Recall curves derived from test dataset. 
Legend: 
Solid lines: black = Support Vector Machine, dark grey = Logistic Regression, light grey = 
Random Forest 





















     
Support Vector Machine  0.97 1.00 
    
K-Nearest Neighbours  0.94 0.96 1.00 
   
Neural Network  0.97 0.99 0.97 1.00 
  
Random Forest  0.94 0.93 0.90 0.93 1.00 
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Progression to insulin therapy in clinically diagnosed type 2 diabetes is highly 
variable. The presence of GADA is associated with faster progression, but its 
predictive value is limited. We aimed to determine if a Type 1 Diabetes Genetic 
Risk Score (T1D GRS) could predict rapid progression to insulin treatment over 
and above GADA testing.  
Research Design and Methods 
We examined the relationship between T1D GRS, GADA (negative or positive) 
and rapid insulin requirement (within 5 years) using Kaplan-Meier survival 
analysis and Cox regression in 8,608 participants with clinical type 2 diabetes 
(onset >35 years, treated without insulin for ≥6 months). T1D GRS was 
analysed both continuously (as standardized scores) and categorized based on 
previously reported centiles of a type 1 diabetes population (<5th (low), 5th-50th 
(medium), >50th (high)).  
Results 
In GADA positive participants (3.3%), those with higher T1D GRS progressed to 
insulin more quickly:  Probability of insulin requirement at five years [95% CI]: 
47.9% [35.0%, 62.78%] (high T1D GRS) vs 27.6% [20.5%, 36.5%] (medium 
T1D GRS) vs 17.6% [11.2%, 27.2%] (low T1D GRS), p=0.001. In contrast T1D 
GRS did not predict rapid insulin requirement in GADA negative participants 
(p=0.4). In Cox regression analysis with adjustment for age of diagnosis, BMI 
and cohort, T1D GRS was independently associated with time to insulin only in 





A Type 1 Diabetes Genetic Risk Score alters the clinical implications of a 
positive GADA test in patients with clinical type 2 diabetes, and is independent 





Type 2 diabetes is a progressive disease due to a gradual reduction in the 
capacity of the pancreatic islet cells (beta cells) to produce insulin (1). The 
clinical course of this progression is highly variable with some patients 
progressing very rapidly to requiring insulin treatment, whilst others can be 
successfully treated with lifestyle changes or oral agents for many years (1; 2). 
Being able to identify patients likely to rapidly progress may have clinical utility 
in prioritization monitoring and treatment escalation, and in choice of therapy.  
It has previously been shown that many patients with clinical features of type 2 
diabetes have positive GADA and that the presence of this autoantibody is 
associated with faster progression to insulin (3; 4). This is often termed Latent 
Autoimmune Diabetes in Adults (LADA) (5; 6). However the predictive value of 
GADA testing is limited in a clinical type 2 diabetes population, with many 
GADA positive patients not requiring insulin treatment for many years (4; 7). 
Previous research has suggested that genetic variants in the Human Leukocyte 
Antigen (HLA) region associated with type 1 diabetes are associated with more 
rapid progression to insulin in patients with clinically defined type 2 diabetes and 
positive GADA (8).  
We have recently developed a Type 1 Diabetes Genetic Risk Score (T1D GRS), 
which provides an inexpensive £56 in our local clinical laboratory, £16 where 
DNA has been previously extracted), integrated assessment of a person’s 
genetic susceptibility to type 1 diabetes (9). The score is composed of 30 type 1 
diabetes risk variants weighted for effect size, and aids discrimination of type 1 
diabetes from type 2 diabetes. The T1D GRS has advantages over HLA typing 
alone, as it includes more genetic information, is cheaper than conventional 
HLA typing, and represents a continuous scale of likelihood of type 1 diabetes 




predict insulin dependence and is independent of and additive to islet-
autoantibodies and clinical features (9).  It is not known if the T1D GRS will 
improve the prediction of insulin requirement by GADA in clinically defined type 
2 diabetes. 
We aimed to determine if the T1D GRS could predict rapid progression to 
insulin (within 5 years of diagnosis) over and above GADA testing in patients 
with a clinical diagnosis of type 2 diabetes treated without insulin at diagnosis.  
Methods 
We examined the relationship between GADA, T1D GRS and progression to 
insulin therapy using survival analysis in 8,608 participants with clinical type 2 
diabetes initially treated without insulin therapy. 
Study population  
Included participants had a clinical diagnosis of type 2 diabetes after the age of 
35 years, and were treated without insulin for the first 6 months from diagnosis 
and were of white European origin. 
To achieve a sufficient number of GADA positive participants, participants were 
identified in the following cohorts: Genetics of Diabetes Audit and Research 
Tayside Study (GoDARTS) (10), Hoorn Diabetes Care System (DCS) (11), 
Diabetes Alliance for Research in England (DARE) (12), Predicting Response to 
Incretin Based Agents in Type 2 Diabetes (PRIBA) (13), and MRC 
MASTERMIND Progressors (14) and combined into a single dataset. These 
cohorts were studies of participants with a clinical diagnosis of type 2 diabetes 
recruited from primary and secondary care, and are population based with the 




<10% of participants. Summaries of the cohort recruitment and data collection 
methods are shown in Supplementary Table 1, a flow diagram of sample 
selection is shown in Supplementary Figure 1. 
Participants known to have had GADA testing performed either in clinical 
practice or prior to diagnosis (through review of electronic laboratory records) 
were excluded due to the risk of the result influencing the clinician’s treatment 
decision. 
In the GoDarts cohort, participants diagnosed with diabetes before 1st January 
1994 were excluded; due to insufficient prescribing information we were unable 
to define time to insulin prior to this date. In the DARE cohort, only the 
participants recruited in the Exeter Centre with saved serum were included. 
Assessment of diabetes progression (time to insulin)  
For GoDarts and DCS cohorts, time to insulin was defined from electronic 
prescription records. For Exeter Cohorts (DARE, PRIBA and MRC 
MASTERMIND Progressors), insulin treatment, date of commencing insulin and 
date of diagnosis were self-reported at a single visit.   
Laboratory Measurement  
The Academic Department of Blood Sciences at the Royal Devon and Exeter 
Hospital measured GADA for all five cohorts at a median diabetes duration of 
6.1 years, using the same assay from biobanked samples stored at -80C. 
GADA was performed using the RSR Limited ELISA assay (RSR Ltd, Cardiff, 
UK) on the Dynex DS2 ELISA Robot (Dynex Technologics, Worthing, UK). The 
cut-off for positivity was ≥11 units/ml, based on the 97.5th centile of 1,500 




was 5.0 units/ml. The laboratory participates in the International Autoantibody 
Standardization Programme. 
The HbA1c value at latest follow up (closest available result, median 10.6 years 
diabetes duration) was obtained from electronic healthcare records or 
measured on a research sample by the Academic Department of Blood 
Sciences at the Royal Devon and Exeter Hospital. 
Assessment of T1D GRS 
The development of the T1D GRS has been described previously (9).  In brief, 
T1D GRS consists of 30 common type 1 diabetes genetic variants (single 
nucleotide polymorphisms (SNPs)) from HLA and non-HLA loci; each variant is 
weighted by their effect size on type 1 diabetes risk from previously published 
literature, with weights for DR3/DR4-DQ8 assigned based on imputed 
haplotypes. The combined score represents an individual’s genetic 
susceptibility to type 1 diabetes. Variants used to derive the score are shown in 
Supplementary Table 2. For ease of clinical interpretation the score is 
presented in this article as the centile position of the distribution in the 
Wellcome Trust Case Control Consortium type 1 diabetes population (16).  
In the Exeter cohorts, genotyping was performed using the KASP genotyping 
assay by LGC Genomics (Hoddesdon, UK) as previously described (9). 
Genotyping in the GoDarts cohort was performed using custom genotyping 
arrays (including Immunochip, Cardio-Metabochip (Metabochip) and Human 
Exome array) from Illumina as previously described (17). Genotyping in the 
DCS cohort was performed with Illumina’s HumanCoreExome Array and 
imputed using IMPUTE2 (18) into the 1000 Genomes March 2012 reference 




T1D GRS calculation was not performed if genotyping results were missing for 
either of the two alleles with the greatest weighting (DR3/DR4-DQ8 or 
HLA_DRB1_15) or if more than two of any other SNPs were missing.  
Statistical analysis 
We assessed the relationship between time to insulin treatment and each of 
GADA and T1D GRS using survival analysis. For this analysis, T1D GRS was 
categorized based on centiles of a type 1 diabetes population (Wellcome Trust 
Case Control Consortium (16)): <5th centile (< 0.234 (low)), 5th-50th centile (>= 
0.234 & <= 0.280 (medium)), >50th centile (> 0.280 (high)) as previously 
reported (9; 19). GADA was dichotomized into negative or positive based on the 
cut-off for positivity. Participants were then classified into six risk groups from 
these categories 1) GADA negative, low T1D GRS  2) GADA negative, medium 
T1D GRS  3) GADA negative, high T1D GRS  4) GADA positive, low T1D GRS  
5) GADA positive, medium T1D GRS  6) GADA positive, high T1D GRS.  
Time to insulin data was censored at five years (or the latest available time 
point not on insulin, if earlier). Survival distributions for time to insulin, stratified 
by risk groups, were estimated using the Kaplan-Meier product limit estimator 
(20). The proportional hazard assumption was checked visually and failed. 
Differences in time to insulin between risk groups were therefore compared 
using the Wilcoxon (Breslow) test. Positive predicted values were obtained from 
the product limit estimator which makes allowances for censored observations. 
To assess whether clinical characteristics were different across risk groups we 
performed Wilcoxon test for trend (21) on the continuous variables and Pearson 




To assess whether GADA, T1D GRS (as a continuous covariate), age of 
diagnosis and BMI (closest available to diagnosis, median 3 years diabetes 
duration) are independent predictors of rapid progression to insulin we 
performed multivariate Cox proportional hazards regression analysis (22). 
When T1D GRS was used as a continuous covariate, the proportional hazard 
assumption was satisfied. T1D GRS and GADA were added in as separate 
variables and as an interaction term. The log-linearity assumption was checked 
by examining Martingale-based residual plots and was considered valid. Study 
of origin was included as a strata variable to control for effects of cohort 
differences. 
As a 10 SNP T1D GRS combining the 10 alleles with the greatest weightings 
ordered by published odds ratios (Supplementary Table 3) has also been 
proposed for clinical practice, we repeated survival analysis using T1D GRS 
defined by this 10 SNP score using the same centile cut-offs for categorization 
(9). We also estimated survival distributions for risk groups based on imputed 
HLA DR3/DR4 genotypes, individually and grouped by number of copies of at 
risk alleles.  
Median follow-up time was calculated using the reverse Kaplan-Meier method 
(23). All analysis was performed in Stata/SE 15.1 (StataCorp, College Station, 
TX).  
Results 
We identified 8,608 participants with a clinical diagnosis of type 2 diabetes 
meeting all of our inclusion criteria, Table 1 shows the characteristics for these 
participants. 79.9% (n = 6,879) had been followed for at least five years; median 




latest follow up), was 10.5 [95% CI 10.3, 10.6] years. 7.8% (n = 533) of those 
participants with over five years follow up had progressed to insulin <= 5 years. 
3.3% (n = 280) of participants were GADA positive (measured at a median 6.1 
years diabetes duration). The distribution of participants by low, medium and 
high TID GRS category was 53.2% (n = 4,580), 40.7% (n = 3,504) and 6.1% (n 
= 524) respectively.  
Table 1: Participant characteristics. Median (IQR) or % (n = 8 608). *Closest to diagnosis 
(median 3 years diabetes duration). †Percentage of participants observed for at least five years. 
‡At latest follow up. §Centile of participants with type 1 diabetes from the Wellcome Trust Case 
Control Consortium. 
 
Characteristic  Value 
Sex (% Male)   56.4% 
Age at diagnosis (years)  60 (52, 68) 
BMI (kg/m2)*  30.4 (27.2, 34.7) 
Duration of diabetes (years) at latest follow up   10.6 (6.0, 14.3) 
Duration of diabetes (years) at GADA  6.1 (3.3, 10.0) 
Insulin treated within 5 years (%)†  7.8% 
HbA1c (%)‡  7.0 (6.4, 8.0) 
HbA1c (mmol/mol)‡  53 (46, 64) 
GADA positive (%)   3.3% 
T1D GRS centile§  4.2 (0.6, 16.1) 
 
 
Characteristics of the participants stratified by the individual cohorts are shown 
in Supplementary Table 4. Statistically significant differences in GADA 
prevalence, diabetes duration and HbA1c between cohorts were evident and 
survival distributions differed between studies. These cohort differences were 
adjusted for by including study of origin as a strata variable in the Cox 
proportional hazards regression analysis. Year of diagnosis for the participants 
ranged over a fairly long period (from 1967 to 2015) over which management 
and treatment practices are likely to have changed. Supplementary Figure 2 
shows a reasonable distribution between 1994 and 2015 but with a long tail 




High T1D GRS is associated with markedly higher rates of rapid insulin 
requirement in participants with positive GADA, but is not associated in 
those who are GADA negative 
T1D GRS was strongly predictive of rapid insulin requirement in participants 
with positive GADA (Figure 1). In GADA positive participants, those with higher 
T1D GRS progressed to insulin more quickly (p=0.001): probability of requiring 
insulin at five years post diagnosis (positive predictive value) [95% CI]: 47.9% 
[35.0%, 62.78%] (high T1D GRS) vs 27.6% [20.5%, 36.5%] (medium T1D GRS) 
vs 17.6% [11.2%, 27.2%] (low T1D GRS).   
T1D GRS was not associated with rapid insulin requirement in GADA negative 
participants. For the GADA negative participants, the probability of requiring 
insulin at five years post diagnosis was similar across all risk groups (p=0.4): 
7.4% [5.3%, 10.3%] (high T1D GRS) vs 7.3% [6.5%, 8.3%] (medium T1D GRS) 













Figure 1: Kaplan-Meier plot of probability of requiring insulin therapy during 5-year follow-up by 
risk group of T1D GRS. Solid lines represent GADA positive groups, dashed lines represent 
GADA negative groups. Blue = low T1D GRS (<5th centile of a type 1 diabetes population (< 
0.234)), orange = medium T1D GRS (5th-50th centile of a type 1 diabetes population (>= 0.234 
& <= 0.280)), red =high T1D GRS (>50th centile of a type 1 diabetes population (> 0.280)). 
 
 
Differences in T1D GRS were associated with higher HbA1c in GADA 
positive participants but no differences in other clinical features  
The characteristics of the GADA positive and negative participants split by T1D 
GRS category are shown in Table 2. In GADA positive participants, HbA1c 
increased (p = 0.04) and BMI decreased (p = 0.01) with higher T1D GRS 
category. In GADA negative participants, clinical characteristics were similar 
across all categories of T1D GRS.   
When comparing the characteristics of GADA positive and negative participants 
(Table 2), GADA positive participants had a higher T1D GRS (median 0.251 vs 
0.231, p < 0.001) and a lower BMI (median 28.73 vs 30.48, p < 0.001) but 




Table 2: Participant characteristics by risk group. Median (IQR) or %. p values given for continuous variables are Wilcoxon-type test for trend, for categorical 
variables Pearson chi-squared. *Closest to diagnosis (median 3 years diabetes duration). †At latest follow up. ‡Centile of participants with type 1 diabetes from the 
Wellcome Trust Case Control Consortium.  
 
 <5th T1D GRS centile for 
type 1 diabetes‡ (low) 
5th–50th T1D GRS centile for 
type 1 diabetes ‡ (medium) 
>50th T1D GRS centile for 
type 1 diabetes ‡ (high) 
p-value 
GADA negative     
n (% of GADA negative) 4,484 (54%) 3,369 (40%) 475 (6%)  
Sex (% Male) 56.2% 57.0% 56.2% >0.1 
Age at diagnosis (years) 60 (52, 68) 60 (52, 68) 60 (51, 68) >0.1 
BMI (kg/m2)* 30.5 (27.3, 34.9) 30.4 (27.1, 34.6) 30.7 (27.4, 34.3) >0.1 
Duration of diabetes (years) at latest follow up  10.6 (6.1, 14.4) 10.5 (5.8, 14.1) 10.6 (6.0, 14.4) >0.1 
Duration of diabetes (years) at GADA 6.3 (3.3, 10.0) 6.0 (3.3, 10.0) 6.3 (3.6, 10.2) >0.1 
HbA1c (%)† 7.0 (6.4, 8.0) 7.0 (6.4, 8.0) 6.9 (6.4, 8.0) >0.1 
HbA1c (mmol/mol) † 53 (46, 64) 53 (46, 64) 52 (46, 64) >0.1 
Insulin treated within 5 years (%) 








GADA (units/mL) 4.9 (4.9, 5.0) 4.9 (4.9, 5.0) 4.9 (4.9, 5.0) >0.1 
     
GADA positive 
n (% of GADA positive) 96 (34%) 135 (48%) 49 (18%)  
Sex (% Male) 51.0% 57.0% 49.0% >0.1 
Age at diagnosis (years)   61 (50, 69)  59 (51, 67) 54 (49, 63) 0.06 
BMI (kg/m2)* 29.6 (26.7, 34.1) 28.7 (25.6, 32.5) 27.7 (25.4, 30.4) 0.01 
Duration of diabetes (years) at latest follow up 11.1 (9.0., 13.8) 10.4 (6.7, 14.9) 11.8 (9.1, 15.0) >0.1 
Duration of diabetes (years) at GADA 5.2 (3.1, 9.5) 5.6 (3.0, 10.1) 8.9 (4.9, 11.1) 0.01 
HbA1c (%)† 7.3 (6.6, 9.1) 7.8 (6.7, 9.0) 8.1 (7.1, 9.1) 0.04 
HbA1c (mmol/mol) † 56 (49, 76) 62 (50, 75) 66 (55, 77) 0.04 
Insulin treated within 5 years (%) 
(where observed ≥ five years) 
18.4% 27.8% 40.5% 0.03 
GADA (units/mL) 77.6 (24.3, 1191.9) 111.4 (28.8, 1354.9) 175.9 (38.6, 1218.2) >0.1 




T1D GRS and GADA are predictors of rapid insulin requirement and are 
independent of age and BMI  
Table 3 shows the Cox proportional hazards regression model for time to insulin 
(censored at 5 years) controlled for effects of cohort differences. As expected, 
the presence of GADA was a significant predictor of time to insulin (Hazard 
Ratio (HR) 3.43 [2.50, 4.71], p <0.001). T1D GRS was independently 
associated with time to insulin, but only in the presence of GADA (HR per 1 
standard deviation (SD) increase in T1D GRS 1.48 [1.15, 1.90], p = 0.002). 
These associations were independent of age at diagnosis and BMI. 
Table 3: Hazard ratios from Cox proportional regression model (adjusted for cohort) for time to 
insulin censored at 5 years (30 SNP T1D GRS).* Closest to diagnosis 
 
Variable Hazard Ratio 
 [95% CI] 
p value 
   
GADA negative  1  
GADA positive 3.43 [2.50, 4.71] <0.001 
GADA negative:T1D GRS (per 1 SD increase in T1D GRS) 1.02 [0.94, 1.12] >0.1 
GADA positive:T1D GRS (per 1 SD increase in T1D GRS) 1.48 [1.15, 1.90] 0.002 
Age at diagnosis (per 1 year) 0.97 [0.96, 0.97] <0.001 
BMI (per kg/m2 unit)* 1.00 [0.98, 1.01] >0.1 
   
 
 
A 10 SNP T1D GRS, and HLA type alone are predictive of future insulin 
requirement 
The association between the 10 SNP T1D GRS and rapid insulin requirement 
was consistent with our findings using the full 30 SNP T1D GRS. The 10 SNP 
T1D GRS was associated with rapid insulin requirement in the GADA positive 
risk groups (p < 0.001) but was not associated in the GADA negative groups 
(p=0.4) (Supplementary Figure 3). In Cox proportional hazards regression 
model (Supplementary Table 5), the 10 SNP T1D GRS was independently 




SD increase in T1D GRS 1.34 [1.05, 1.71], p = 0.02). Kaplan-Meier plots for 
HLA DR3/DR4 genotype risk groups, individually and grouped by number of at 
risk alleles, are shown in Supplementary Figures 4 and 5.  
Conclusions 
In this large study of participants with a clinical diagnosis of type 2 diabetes, we 
have found that type 1 genetic susceptibility alters the clinical implications of a 
positive GADA when predicting rapid time to insulin. GADA positive participants 
with high T1D GRS were more likely to require insulin within 5 years of 
diagnosis, with 48% progressing to insulin in this time in contrast to only 18% in 
participants with low T1D GRS. The T1D GRS was independent of and additive 
to participant’s age of diagnosis and BMI. However, T1D GRS was not 
associated with rapid insulin requirement in participants who were GADA 
negative. 
To our knowledge this is the first study to assess the association between an 
integrated assessment of type 1 genetic risk and GADA in patients with type 2 
diabetes or LADA. A key strength of this study is use of large, predominantly 
population-based, cohorts of participants diagnosed with type 2 diabetes and to 
date, is the largest cohort with measured GADA in a western population. This 
means our results are likely to reflect true associations in patients seen in 
clinical practice. An additional key strength is the use of a single laboratory and 
assay for measuring GADA across cohorts, with a very robustly defined 
threshold for positive GADA based on a large predominantly adult control 
population. We have demonstrated that our results are independent of and 




A limitation of our study is that time to insulin has been self-reported in the 
Exeter cohorts at a single visit, in contrast to other cohorts where electronic 
healthcare records were available. Insulin commencement was also based on 
clinical decision making rather than a trial protocol. Both these aspects may 
introduce imprecision but since both clinicians and participants were unaware of 
results, systematic bias would be unlikely. An additional limitation of cross-
sectional study design is that GADA was measured at a median 6.1 years 
diabetes duration, which could result in a lower prevalence than if measurement 
was undertaken at diagnosis. However, in adult populations the difference is 
likely to be small, with GADA positivity being stable over the first 6 years in 
UKPDS study participants (adult onset type 2 diabetes) (24) and a modest 
reduction in prevalence (72% to 63%) observed after 8 years in adult onset type 
1 diabetes (25). The results of this study can only be applied to white European 
populations and we do not have measurement of other islet-autoantibodies in 
this cohort - the interaction between genetic risk and other islet-autoantibodies 
would be an area of interest for future research (26). 
Our findings are consistent with previous research in a population of 
participants diagnosed with diabetes between the ages of 20 to 40 years, where 
the same T1D GRS was predictive of insulin dependent diabetes (9), and other 
work which has shown this risk score to be additive to islet-autoantibodies in 
predicting future type 1 diabetes (27). It is also consistent with previous 
research showing patients defined as LADA who have HLA type associated 
with type 1 diabetes susceptibility, have more rapid progression to insulin (8), 
and with research showing a combination of positive islet cell autoantibodies 
and high risk HLA is associated with low C-peptide in a cohort diagnosed as 




relationship between integrated genetic risk of type 1 diabetes and progression 
of type 2 diabetes or LADA has not been previously assessed, it has previously 
been shown that a type 2 diabetes genetic risk score covering 61 established 
type 2 diabetes risk variants is not associated with time to insulin (17) and that a 
69 SNP type 2 diabetes genetic risk score has very limited utility in 
discriminating patients with type 1 from type 2 diabetes (9).  
The prevalence of positive GADA in our cohorts was lower than in much of the 
previous literature, with previous multicentre studies reporting widely varying 
prevalence of positive GADA in type 2 diabetes populations ranging from 4% to 
14% (29; 30). In addition to diabetes duration, differences in the prevalence of 
GADA positivity between our and other studies may be explained by our use of 
an assay with higher specificity than used in many other studies (29-33), our 
lack of an upper age limit (with lower GADA prevalence seen at older ages (4; 
33; 34)), and our use of predominantly population cohorts not selected from 
secondary care where treatment with insulin is more frequent. We have used a 
robustly defined high specificity (97.5%) threshold to define positive GADA in 
line with current clinical laboratory practice, using a large control population. 
Detectable GADA are commonly found in healthy adult non-diabetic populations 
and therefore a threshold based on a control population is recommended to 
robustly define GADA positivity (31-33).  An additional potential reason for low 
autoantibody prevalence is that we have excluded a small number of cohort 
participants who had GADA tested in clinical practice, which may have 
influenced treatment choice. However only 47 participants were excluded of 
whom only 13 were GADA positive, so the effect on overall prevalence is small. 
Our findings have clear implications for clinical practice. The T1D GRS 




value of GADA testing. For predicting future insulin requirement in patients with 
apparent type 2 diabetes who are GADA positive, T1D GRS may be clinically 
useful and can be used as an additional test in the screening process. However, 
in patients with type 2 diabetes who are GADA negative, there is no benefit 
gained from genetic testing. This is unsurprising as the prevalence of underlying 
autoimmunity in patients with a clinical phenotype of type 2 diabetes who are 
GADA negative is likely to be extremely low, therefore most GADA negative 
participants with high T1D GRS will have non-autoimmune diabetes.  The use 
of this two-step testing approach may facilitate a precision medicine approach 
to patients with apparent type 2 diabetes; patients who are likely to progress 
rapidly are identified for targeted management which may include increased 
monitoring, early therapy intensification and/or interventions aimed at slowing 
progression (35; 36). 
The costs of analysing the T1D GRS are relatively modest and may fall further 
as genetic testing is rapidly becoming less expensive (37). This may allow 
introduction of the T1D GRS into clinical practice. While the test cost could 
potentially be reduced further by using 10 SNPs or imputing HLA type alone, 
the majority of test costs are attributable to DNA extraction, sample handling 
and test interpretation, with cost for genotyping additional SNPs as low as 8 
pence per SNP. Savings would therefore be modest and, while this study does 
not have sufficient statistical power to directly compare different risk scores in 
islet-autoantibody-positive participants, this may come at a cost of reduced test 
accuracy. The use of a risk score approach has an additional advantage over 
using HLA alone, as it provides genetic information expressed as a simple to 




While using the T1D GRS in a two stage approach may have clinical utility, 
approaches that go beyond single tests and thresholds to integrate multiple 
clinical features and biomarkers are likely to have the greatest use for clinical 
practice. The T1D GRS is additive to other predictive features such as age of 
diagnosis and BMI, and dichotomizing the test to use thresholds will lose 
predictive value. While the negative predictive value of a low T1D GRS in 
participants with GADA is high (<5th centile 92%), positive predictive values are 
modest, with the majority of high T1D GRS participants not requiring insulin by 
5 years. Therefore approaches that combine different predictive features on a 
continuous basis, using prediction models (clinical calculators), may have the 
greatest utility in accurately predicting future insulin requirement in this group, 
and are an important area for future research (38). Additional areas for future 
research include the association between T1D GRS and progression where 
multiple islet-autoantibodies have been tested, and assessment in a prospective 
setting where islet-autoantibodies have been measured at diabetes diagnosis.  
In conclusion, a Type 1 Diabetes Genetic Risk Score alters the clinical 
implications of a positive GADA test in patients with clinical type 2 diabetes, and 
is independent of and additive to clinical features. This therefore represents a 
novel test for identifying patients with rapid progression in this population. 
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Supplementary Table 1: Cohort recruitment and data collection methods summary  
 




3963 1942 1917 574 212 
Data collection 
period 
From 1998  From 1998 2007 to 2017 2011 to 2013 2013 to 2015 
 
Study design Longitudinal Longitudinal Cross-sectional Longitudinal Cross-sectional 
Setting Primary and 
secondary care  in 
Tayside, Scotland 
Primary and secondary 
care in West-Friesland, 
Netherlands 
Primary and secondary 
care in eight diabetes 
research regions, 
England and retinal 
screening clinics. 
 
Primary and secondary 
care in South West 
England 
Primary and secondary care in 
Exeter, Dundee and Oxford, 
England 
Inclusion criteria Clinical diagnosis of 
type 2 diabetes. 
Clinical diagnosis of type 
2 diabetes. 
Clinical diagnosis of 
diabetes (any type). 
Clinical diagnosis of 
type 2 diabetes. 
Clinician determined 
requirement for DPP-IV 




Clinical diagnosis of type 2 
diabetes non-insulin treated 
within 6 months of diagnosis. 
Participants were selected on 
the basis of rapid or slow 
progression to insulin therapy 
(<7, >7 years).  Age 18-90 
inclusive.  
 
Data collection Clinical measurements 
and blood collected at 
initial visit. Follow up 





collected at initial visit, 
and repeated annually. 
Blood collected at one of 
the annual visits. 
Additional health data 
collected using electronic 
medical record linkage. 
Clinical measurements 
and blood sample 
collected at visit. 
Ongoing biochemical 
data collected from 
pathology laboratories. 
Clinical measurements 
and blood taken at 
initial visit. Follow up 
clinical measurements 
and blood collected at 
three and six months. 
Clinical measures and fasting 

















Missing data/excluded participants (n = 1334) 
 Non-white European ethnicity: 97 
 Time to insulin or duration not available: 467 
GADA not available: 53 
 Failed genotyping: 670 
 Clinical GADA testing*: 47  
Insulin treated (n = 1816) Non-insulin treated (n = 6792) 
Exeter DARE eligible 
participants (n = 2964) 
 
DCS eligible participants 
(n = 2010) 
 
GoDarts eligible 
participants (n = 3994) 
 
PRIBA eligible participants  
(n = 718) 
 
MRC Progressor eligible 
participants (n = 256) 
 










Supplementary Table 2: Type 1 diabetes SNPs included in the genetic risk score with weights. 









DR3/DR4 48.18 3.87  
 
DR3/DR3 21.12 3.05  
DR4/DR4 21.98 3.09  
DR4/X 7.03 1.95  
DR3/X 4.53 1.51  
rs1264813 HLA_A_24 1.54 0.43  T 
rs2395029 HLA_B_5701 2.5 0.92  T 
rs3129889 HLA_DRB1_15 14.88 2.70  A 
rs2476601 PTPN22 1.96 0.67  A 
rs689 INS 1.75 0.56  T 
rs12722495 IL2RA 1.58 0.46  T 
rs2292239 ERBB3 1.35 0.30  T 
rs10509540 C10orf59 1.33  0.29  T 
rs4948088 COBL 1.3 0.26  C 
rs7202877   1.28 0.25  G 
rs12708716 CLEC16A 1.23 0.21  A 
rs3087243 CTLA4 1.22 0.20  G 
rs1893217 PTPN2 1.2 0.18  G 
rs11594656 IL2RA 1.19 0.17  T 
rs3024505 IL10 1.19  0.17  G 
rs9388489 C6orf173 1.17  0.16  G 
rs1465788   1.16 0.15  C 
rs1990760 IFIH1 1.16 0.15  T 
rs3825932 CTSH 1.16 0.15  C 
rs425105   1.16 0.15  T 
rs763361 CD226 1.16 0.15  T 
rs4788084 IL27 1.16 0.15  C 
rs17574546   1.14 0.13  C 
rs11755527 BACH2 1.13 0.12  G 
rs3788013 UBASH3A 1.13 0.12  A 
rs2069762 IL2 1.12 0.11  A 
rs2281808   1.11 0.10  C 




















DR3/DR4 48.18 3.87  
 
DR3/DR3 21.12 3.05  
DR4/DR4 21.98 3.09  
DR4/X 7.03 1.95  
DR3/X 4.53 1.51  
rs1264813 HLA_A_24 1.54 0.43  T 
rs2395029 HLA_B_5701 2.5 0.92  T 
rs3129889 HLA_DRB1_15 14.88 2.70  A 
rs2476601 PTPN22 1.96 0.67  A 
rs689 INS 1.75 0.56  T 
rs12722495 IL2RA 1.58 0.46  T 
rs2292239 ERBB3 1.35 0.30  T 





Supplementary Table 4: Participant characteristics stratified by cohort. Median (IQR) or % 
Kruskal-Wallis used for comparison testing continuous variables, chi-square for categorical variables 
Exeter cohorts are shown combined due to low numbers in PRIBA and MRC Progressor 
* Closest to diagnosis 
† At latest follow up  
‡ Percentage of participants observed for at least five years 
§ Centile of participants with type 1 diabetes from the Wellcome trust case control consortium. 
 
 DCS Hoorn  
(n = 1 942) 
GoDarts 
 (n = 3 963) 
Exeter studies 
(n= 2 702 ) 
p-value 
Sex (% Male) 54.6% 54.8% 60.2% <0.001 
Age at diagnosis (years) 60 (53, 67) 61 (54, 68)  59 (50, 67) <0.001 
BMI (kg/m2)* 29.5 (26.8, 33.2) 30.4 (27.2, 34.6) 31.1 (27.5, 35.7) <0.001 
Duration of diabetes (years) † 7.1 (4.3, 11.0) 12.8 (10.3, 15.7) 7.0 (3.0, 12.3) <0.001 
Duration of diabetes (years) at GADA  8.2 (5.3, 12.2) 5.1 (2.7, 8.0) 7.0 (3.0, 12.0) <0.001 
Insulin treated within 5 years (%)‡ 5.8 7.4 10.2 <0.001 
HbA1c (%)† 6.5 (6.1, 7.1) 7.2 (6.5, 8.2) 7.3 (6.6, 8.4) <0.001 
HbA1c (mmol/mol) † 48 (43, 54) 55 (48, 66) 56 (49, 68) <0.001 
GADA Positive (%) 2.2% 3.9% 3.1% <0.001 
GADA (units/mL) 2.6 (2.0, 3.7) 5.0 (5.0, 5.0) 4.9 (4.9, 4.9) <0.001 






















Supplementary Figure 3: Kaplan-Meier plot of probability of requiring insulin therapy by risk group using 10 SNP T1D GRS. Solid lines represent GADA positive 







Supplementary Table 5: Hazard ratios from Cox proportional regression model for time to insulin censored at 5 years (10 SNP T1D GRS) * Closest to diagnosis 
 
Variable Hazard Ratio [95% CI] p value 
GADA Negative  1  
GADA Positive 3.70 [2.74, 4.99] <0.001 
GADA Negative:10 SNP T1D GRS (per 1 SD change in T1D GRS) 1.04 [0.96, 1.14] >0.1 
GADA Positive:10 SNP T1D GRS (per 1 SD change in T1D GRS) 1.34 [1.05, 1.71] 0.02 
Age at diagnosis (per 1 year) 0.97 [0.96, 0.98] <0.001 






Supplementary Figure 4: Kaplan-Meier plot of probability of requiring insulin therapy by risk group using HLA DR3/DR4 alleles. Solid lines represent GADA positive 
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The rate of glycaemic deterioration in patients with clinically diagnosed type 2 
diabetes is highly variable. We aimed to develop and validate a multivariable 
prognostic model to predict rapid glycaemic progression leading to a 
requirement for insulin therapy within five years in adult patients diagnosed with 
type 2 diabetes.  
Research Design and Methods  
We examined the relationship between seven potential prognostic factors; Age 
at diagnosis, BMI, Sex, HbA1c, HDL, GAD65 autoantibodies (GADA) and a Type 
1 Diabetes Genetic Risk Score, and time to insulin therapy using survival 
analysis in 3,232 participants with clinical type 2 diabetes (onset >=35 years, 
treated without insulin from diagnosis). Separate models were developed 
without knowledge of GADA status, and in GADA positive and negative 
participants. External validation was performed in observational (Diabetes Care 
System (DCS) n = 1,241) and (for glycaemic progression on monotherapy) trial 
(ADOPT, n = 3,487) datasets. 
Results 
Area under the receiving operator curve (ROC AUC) for insulin requirement at 5 
years ranged from 0.74 (95% CI [0.71, 0.77]) (model without GADA) to 0.80 
[0.71, 0.88] (GADA positive model). Results were consistent in external 
validation (model without GADA ROC AUC 0.80 [0.75, 0.85], ADOPT 0.70 
[0.67, 0.73]). 70% of participants had <10% probability of insulin requirement at 





Prediction models integrating clinical features with biomarkers may assist 
clinicians in identifying patients with high risk of progression and those who may 






The rate of glycaemic deterioration leading to a requirement for insulin therapy 
in patients with clinically diagnosed type 2 diabetes is highly variable (1); in 
many patients, glycaemia can be successfully managed with lifestyle changes 
or oral agents for many years whilst others require insulin therapy soon after 
diagnosis (2; 3). This heterogeneity may reflect differences in underlying 
pathophysiology (4-9).  
Being able to identify which patients will rapidly progress (or conversely remain 
stable over many years) may have utility in clinical practice and research. In 
clinical practice this could facilitate prioritised monitoring and treatment 
escalation for those likely to progress rapidly, and may allow targeting of 
therapies with specific effects on glycaemic deterioration (10), however this 
approach would need to be low cost and therefore based on routinely measured 
features or inexpensive biomarkers. In research, those patients likely to rapidly 
progress could be targeted to maximise cost effectiveness of trials of 
interventions aimed at slowing diabetes progression. 
A number of clinical and genetic factors have been found to be associated with 
the rate of glycaemic deterioration leading to a requirement for insulin therapy in 
patients with clinically diagnosed type 2 diabetes (1; 4; 5; 11-18). Whilst the 
definition of failure varies between studies (initiation of pharmacologic 
treatment, requirement for second or third line treatment, or requirement for 
insulin), the association between younger age at diagnosis and rapid 
progression has been a consistent finding and is strongly associated with 
disease progression (1). Additional clinical features reported to be associated 
with future progression of type 2 diabetes include, HbA1c or fasting glucose, 
HDL, Triacylglyceride, alanine transaminase, sex, beta-cell function 




and ethnicity (1; 4; 5; 11-18). However, in a recent large study of progression to 
insulin therapy, only age at diagnosis, HDL, Triacylglyceride and BMI were 
independent predictors (11). 
The presence of GAD65 autoantibodies (GADA) or (less commonly) other islet-
autoantibodies is strongly associated with rapid progression to insulin, however 
many autoantibody-positive patients do not have early insulin requirement (13; 
19; 20). A Type 1 Diabetes Genetic Risk Score (T1D GRS) has been shown to 
be associated with faster progression to insulin but only in participants who are 
GADA positive (20). No association was found with type 2 diabetes generic risk 
(11; 21).  
Rather than relying on single features in isolation, the most effective approach 
to predicting type 2 diabetes progression is likely to be through combining 
different features, as is now common for outcome prediction in many areas of 
clinical practice. There are however, no prognostic models that combine clinical 
features and biomarkers to predict progression in individuals with a clinical 
diagnosis of type 2 diabetes. 
We aimed to develop and validate a prognostic model to predict early insulin 
requirement in adult patients newly diagnosed with type 2 diabetes. 
Methods 
We used data from existing prospective studies to develop and validate a 
multivariable prognostic model to predict progression to insulin therapy, from 






Study population  
Participants were eligible for the study (model development or validation) if they 
had a clinical diagnosis of type 2 diabetes after the age of 35 years, and were 
treated without insulin from diagnosis.  
Participants known to have had GADA testing performed either in clinical 
practice or prior to diagnosis (through a review of electronic laboratory records) 
were excluded due to the risk of the result influencing the clinician’s treatment 
decision to commence insulin (n=107).   
Development cohort 
For model development, participants were identified in the Genetics of Diabetes 
Audit and Research Tayside Study (GoDARTS) (22). GoDarts is a population 
cohort comprising of longitudinal clinical data (measured at recruitment and 
from electronic medical record linkage) of participants with a clinical diagnosis 
of type 2 diabetes recruited from primary and secondary care in Tayside, 
Scotland, UK.  Participants diagnosed with diabetes before 1st January 1994 
were excluded from our study; due to insufficient prescribing information we 
were unable to define time to insulin prior to this date. 
External validation cohort 
For external validation, participants meeting our study inclusion criteria were 
identified in the Hoorn Diabetes Care System (DCS) (23). DCS is a longitudinal 
study of participants diagnosed with type 2 diabetes recruited from primary and 
secondary care in West-Friesland, Netherlands, clinical data is collected at 




Assessment of the performance of the model in predicting shorter term 
glycaemic progression (monotherapy failure) was undertaken in 3,487 
participants in the Diabetes Outcome Progression Trial (ADOPT) (10; 24; 25), 
ADOPT is an intention to treat randomised drug efficacy trial in participants 
aged 30-75 years with recently diagnosed (< 3 years) type 2 diabetes. 
Participants were eligible for ADOPT if they had been previously managed with 
diet/exercise only and had fasting plasma glucose ranging from 126 to 240 
mg/dl (7–13 mmol/l) at screening and from 126 to 180 mg/dl (7–10 mmol/l) at 
randomisation (10).  
All participants included in this study were of white-European origin. 
Model outcome measure: Time to insulin therapy 
The primary outcome was time to insulin therapy, defined as the number of 
months between diabetes diagnosis and commencement of continuous insulin 
therapy obtained from electronic prescription records.  
In ADOPT, the primary outcome was time to monotherapy failure which was 
defined according to the study primary outcome as a confirmed level of fasting 
plasma glucose of more than 180 mg/dl (10.0 mmol/l) (10). Time to insulin could 
not be assessed in this cohort. 
Prognostic factors 
Study prognostic factors were selected based on reported independent 
associations with glycaemic progression of diabetes in previous literature (1; 11) 
and availability in study cohorts. We examined seven potential prognostic 
factors; Age at diagnosis, BMI, Sex, HbA1c, HDL, GADA and a T1D GRS. While 




with more rapid progression in the GoDARTS cohort (11) it was not included in 
our study due to limited data availability in the GoDarts participants (25% 
Triglycerides missing), high collinearity with HDL, and the need for patients to 
fast prior to measurement which limits clinical utility. To maximise potential 
utility, and account for potential different interactions between clinical features 
and progression in autoimmune and non-autoimmune diabetes, models were 
developed for routinely available predictors without knowledge of GADA status, 
and separate models then developed for both GADA positive and negative 
participants, with and without examination of T1D GRS respectively.  
BMI 
Height and weight measurements were collected at recruitment visit and used 
to calculate BMI. 
Laboratory Measurement  
HbA1c and HDL 
HbA1c values were included in the model development if collected within +/- 6 
months of reported diagnosis date. The closest available value was used for 
analysis with values prior to diagnosis excluded if in the non-diabetic range 
(<6.5% (48 mmol/mol)). HDL values were included where the sample was 
collected within 12 months of diagnosis (before or after diagnosis), with the 
closest available value used for study analysis. 
In the GoDarts cohort, HbA1c and HDL were collected from electronic medical 
record linkage as previously described (22) (or recruitment visit where this was 




In the DCS cohort, HbA1c and HDL were measured at a recruitment visit and 
were repeated annually as previously described (23). Measurement of HbA1c 
and HDL was conducted using fasting blood. HbA1c was based on the 
turbidimetric inhibition immunoassay for haemolysed whole EDTA blood (Cobas 
c501, Roche Diagnostics, Mannheim, Germany) and is expressed in 
mmol/mmol according to the International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) as well as percentage according to the Diabetes 
Control and Complications Trial (DCCT)/ National Glycohemoglobin 
Standardization (23). HDL was determined enzymatically (Cobas c501, Roche 
Diagnostics) (23). 
Measurement of HbA1c and HDL in ADOPT has been described previously (25). 
Type 1 Diabetes Genetic Risk Score (T1D GRS) 
The development of the T1D GRS has been described previously (26). In brief, 
T1D GRS consists of 30 common type 1 diabetes genetic variants (single 
nucleotide polymorphisms (SNPs)) from HLA and non-HLA loci; each variant is 
weighted by their effect size on type 1 diabetes risk from previously published 
literature, with weights for DR3/DR4-DQ8 assigned based on imputed 
haplotypes. The combined score represents an individual’s genetic 
susceptibility to type 1 diabetes. Variants used to derive the score are shown in 
Supplementary Table 1. For ease of clinical interpretation the score is 
presented in this article as the centile position of the distribution in the 
Wellcome Trust Case Control Consortium type 1 diabetes population (27).  
Genotyping in the GoDarts cohort was performed using custom genotyping 
arrays (including Immunochip, Cardio-Metabochip (Metabochip) and Human 




DCS cohort was performed with Illumina’s HumanCoreExome Array and 
imputed using IMPUTE2 (28) into the 1000 Genomes March 2012 reference 
panel. All SNPs had an INFO > 0.8. 
T1D GRS calculation was not performed if genotyping results were missing for 
either of the two alleles with the greatest weighting (DR3/DR4-DQ8 or 
HLA_DRB1_15) or if more than two of any other SNPs were missing.  
GADA 
GADA was measured for GoDarts and DCS by the Academic Department of 
Blood Sciences at the Royal Devon and Exeter Hospital using the RSR Limited 
ELISA assay (RSR Ltd, Cardiff, UK) on the Dynex DS2 ELISA Robot (Dynex 
Technologics, Worthing, UK). Sample collection for GADA measurement was a 
median diabetes duration of 4.5 years (GoDarts) and 7.2 years (DCS). The cut-
off for positivity was ≥11 units/ml, based on the 97.5th centile of 1,559 controls 
without diabetes (29). The lowest reportable value (lowest calibrant) was 5.0 
units/ml. The laboratory participates in the International Autoantibody 
Standardisation Programme. 
Missing data 
This study is a complete case analysis. To assess the appropriateness of this 
approach to deal with missing data, we first looked at the missing data patterns 
to describe the missing data (Supplementary Table 2). The percentage of 
participants in the development data meeting our inclusion criteria with missing 
data for the study prognostic factors was 18%.  
The missing data mechanism was then investigated using the predictors of 




participants with missing data to those of participants without missing data and 
can be used to assess the plausibility of the data being missing completely at 
random (MCAR). This involves using logistic models each with a binary 
outcome of missing data relating to the variable of interest (1 = missing data, 0 
= not missing), with the remaining prognostic factors treated as predictor 
variables. Significant predictor variables suggest that the data is not MCAR. 
None of the predictor variables was significant suggesting that the data was 
MCAR and therefore a complete case analysis was considered appropriate. 
Statistical analysis 
Model development 
We applied a Royston-Parmar flexible parametric survival model (RP) (30-32) 
programmed in Stata (stpm2) (33). RP models have advantages over Cox 
models; they can be used when the proportional hazards assumption is not met, 
can predict survival/failures probabilities over time for individual participants, 
and have smoothed survival and cumulative hazards functions. We followed the 
approaches of Royston and Lambert for developing and reporting our RP model 
(34). Median follow-up time was calculated using the reverse Kaplan-Meier 
method (35).  All analysis was performed in Stata/SE 15.1 (StataCorp, College 
Station, TX). 
Continuous prognostic factors 
Each continuous predictor was first modelled (univariate, Cox model) as linear, 
log-transformed and transformed using orthogonalised restricted cubic splines 
(3 knots) (36). Nonlinearity between each factor and the outcome was then 




criteria (BIC). Each continuous predictor was mean centred in the modelling to 
produce a meaningful baseline survival function. T1D GRS was normalised. 
Time-dependent covariates 
Proportional hazards for each prognostic factor (non-transformed) was checked 
visually using plots of scaled Schoenfeld residuals against time. 
Scale and baseline complexity 
Scale and baseline complexity were selected by inspecting the Akaike 
information criterion (AIC) and BIC statistics of a simple multivariable 
preliminary model consisting of all prognostic factors (categorised continuous 
(non-transformed) predictors) with varying scale (log cumulative hazard 
(hazard), log cumulative odds (odds), standard normal deviate (probit) (normal) 
and value of theta using the Aranda-Ordaz family of link functions (theta)) and 
degrees of freedom (1 to 5) (34).  
Selection of prognostic factors 
We first built a RP model including all prognostic factors without any 
transformations. We then investigated the inclusion of transformed and time 
dependent effects to improve the model fit assessed using AIC and BIC. 
Interactions between continuous variables were not assessed in the model. The 
goodness of fit of the continuous covariates included in the final model was 
assessed visually using plots of smoothed martingale residuals. 
Evaluation of model performance: Internal validation 
Bootstrapping with replacement (1,000 repetitions) was used to estimate 
optimism adjusted explained variation on the natural scale of the model (R2D) 




at five years. ROC AUC was calculated using the failure probability at five years 
and a five-year censored outcome (participants with < 5 year duration and non-
insulin treated were excluded).  
The available range of discrimination was assessed visually by plotting failure 
probabilities against time at specified centiles of the distribution of the 
prognostic index. 
Evaluation of model performance: External validation 
The model was fitted to both external datasets. The quality of the model 
predictions were evaluated using ROC AUC at five years calculated using same 
method as previously described. Calibration was assessed visually using a 
calibration plots at five years. 
GADA models   
A separate model applicable to participants with a clinical diagnosis of type 2 
diabetes who are known to be GADA positive and a model for those known to 
be GADA negative were developed and validated using the same methods as 
previously described. T1D GRS was used as a potential predictor in the GADA 
positive model only. 
Results 
For the development cohort, we identified 3,232 participants with a clinical 
diagnosis of type 2 diabetes meeting all of our inclusion criteria. A flow diagram 
describing the flow of participants through the study is shown in Supplementary 
Figure 1. Table 1 shows the characteristics for these participants. 97% (n = 
3,147) had been followed for at least five years; median follow up time, 




up), was 11.8 (95% CI [11.6, 11.9]) years. 8.8% (n =278) of those participants 




Table 1: Participant characteristics for No GADA model cohorts. 
Median (IQR) or % 
*At first visit 
†Percentage of patients observed for at least five years 
‡ measured < 6 months post diagnosis 
§ Closest to diagnosis (within 12 months pre or post diagnosis) 
|| Not followed post failure   
 
 GoDarts development 
 (n = 3,232) 
DCS Validation 
(n = 1,241) 
ADOPT validation 
(n = 3,487) 
Sex (% Male) 54.6% 54.0% 59.1% 
Age at diagnosis (years) 62 (54, 69)  61 (54, 67)  58 (51, 65) 
BMI (kg/m2)* 30.4 (27.2, 34.7) 29.5 (26.8, 33.2) 31.0 (27.8, 35.3) 
Duration of diabetes (years) at latest follow up 12.3 (9.9, 14.9) 6.3 (4.0, 10.2) Not Available||  
Insulin treated within 5 years (%)† 8.8% 8.0% Not Applicable 
Monotherapy failure by 4 years Not Applicable Not Applicable 15.1% 
HbA1c (%)‡ 7.6 (6.6, 9.5) 6.6 (6.1, 7.5) 7.2 (6.7, 7.8) 
HbA1c (mmol/mol) ‡  60 (49, 80) 48.6 (43.2, 58.5) 55.2 (49.7, 61.7) 





In univariate analysis, increased risk of progressing to insulin therapy was 
associated with younger age at diagnosis, lower HDL, higher HbA1c and being 
female; there was a U-shaped association with BMI, with risk lowest in those 
with a BMI of 30 ((Figure 1, Supplementary Figure 2 and Supplementary Table 
3).   
Figure 1: Best fit univariate association between continuous variables and progression to 
insulin therapy assessed using relative to mean centred hazard obtained from Cox models with 
95% confidence intervals. Horizontal line at hazard ratio = 1. Assumes relative effect is the 
same throughout the follow-up period (n = 3,232). 
 
Supplementary Table 4 shows the univariate R2D and C-statistic for each of the 
best fit clinical features and biomarkers. 
Covariate effects varied over time (time dependent) 
The effect of HDL, BMI and HbA1c varied over time, invalidating the assumption 
that each covariate is independent of time. Supplementary Figure 3 shows the 
effect of HDL and HbA1C reducing over the first five years and BMI increasing 




example, at diagnosis, the risk of rapid insulin requirement (hazard ratio) is 
much higher in patients with a high HbA1c compared to those patients with a 
lower HbA1c but after five years, the difference in risk between patients with 
higher and lower HbA1c measured at diagnosis is much less. These time 
dependent effects can be modelled using spline functions with the knot location 
specified at five years but have the disadvantage of creating a more complex 
model with an increased number of degrees of freedom (model parameters). 
When the model fit (AIC and BIC) was assessed with the inclusion of HDL, BMI 
and HbA1c as time dependent variables, only the inclusion of HbA1c significantly 
improved the model fit. Since HDL and BMI were weaker predictors and did not 
improve the model fit when used as time dependent effects, we decided to 
include only HbA1c as a time dependent effect. A limitation with the use of spline 
functions for dealing with time dependent covariates is that the individual model 
parameters for the time dependent splines are almost impossible to interpret 
(34). Essentially the time dependent splines represent the situation shown in the 
Supplementary Figure 3. 
Combining clinical features and biomarkers in a prognostic model 
improves model performance 
Age at diagnosis (linear), HDL (log-transformed), sex (male), BMI (3-knot 
spline) and HbA1c (log-transformed) as a time varying covariate were 
statistically significant predictors of time to insulin therapy and were included in 
the final model (Supplementary Table 5). HDL, BMI and HbA1c were time-
dependent effects (Supplementary Figure 3) but only HbA1c was included as a 
time varying covariate since using time varying covariates for HDL and BMI did 
not significantly improve the model fit. The parameter estimates for the full 




ROC AUC of the predicted probabilities for discriminating those who are insulin 
treated by five years was 0.74 [0.71, 0.77]. The explained variation (R2D) of the 
final model was modest (19% [16%, 23%]). Supplementary Table 7 shows the 
impact of each covariate in the model on R2D. HbA1c was the most important 
covariate in the model accounting for most of the explained variation (on its own 
R2D = 12%), BMI and sex added the least.  
Internal validation results suggest robust model performance  
The distribution of the model predicted probabilities for requiring insulin by 5 
years was skewed and in most cases fairly low (median (range) 5.3% (0.3 - 
62.75)) (Supplementary Figure 4). 
The model showed reasonable discrimination for requirement of insulin by 5 
years, with those in the highest deciles of predicted probability having the 
highest risk (18% predicted to require insulin for the 90th centile compared with 
1.6% in the lowest decile), (Supplementary Figure 5). The model calibration was 
good (Supplementary Figure 6). 
Results of the bootstrap internal validation showed low levels of optimism 
(Supplementary Table 8). 
Similar model performance in external validation cohort 
1,241 participants in the DCS study and 3,487 in ADOPT met criteria for 
external validation (Supplementary Figures 7 & 8). Table 1 shows the 
characteristics for the DCS and ADOPT participants included in the external 
validation. 
The ROC AUC at 5 years for the DCS external validation cohort was 0.80 [0.75, 




although probabilities were slightly underestimated overall (5.7% expected to be 
insulin treated within 5 years v 6.5% observed), with the model fitting less well 
at the extremes.  
To deal with a shorter follow up duration in ADOPT (four year treatment period 
(10)), we evaluated the model using the ADOPT external validation cohort at 
four years. ROC AUC at four years was 0.70 [0.67, 0.73]. Consistent with the 
different outcome assessed (monotherapy failure as opposed to insulin 
requirement) the expected probabilities were lower than the observed outcome 
(expected/observed = 0.27), we therefore recalibrated the model using a 




Figure 2A: DCS external validation calibration plot of expected versus observed failure probabilities at t = 5 years.  
Figure 2B: Re-calibrated ADOPT validation calibration plot of expected versus observed failure probabilities at t = 4 years.    
Dashed grey line is reference line where observed = expected probabilities. Black filled circles are risk groups using deciles of expected probabilities, vertical grey 































A GADA positive model showed good performance in internal validation 
We identified 131 participants who were GADA positive in the development data 
meeting all of our inclusion criteria (Supplementary Table 9). The final model 
consisted of age at diagnosis (log-transformed and TVC), BMI (log-
transformed), HbA1c (log-transformed) and sex (Supplementary Table 10). The 
parameter estimates for the full model are shown in Supplementary Table 11.   
ROC AUC at five years was 0.80 [0.71, 0.88]. R2D was reasonable (33% [18%, 
46%]). HbA1c was the most important factor in the model (on its own R2D = 16%) 
(Supplementary Table 12). Internal validation suggested low levels of optimism 
(Supplementary Table 13). 
Due to small sample size (n = 28 and n = 138 GADA positive participants 
meeting inclusion criteria in DCS and ADOPT respectively, of whom only 9 and 
18 met the study glycaemic failure definition), external validation could not be 
performed.  
A GADA negative model has similar discrimination performance to the 
main model 
We identified 3,101 participants who were GADA negative in the development 
data meeting all of our inclusion criteria (Supplementary Table 14). The final 
model consisted of age at diagnosis (linear), HbA1c (log-transformed and TVC), 
HDL (log-transformed) and sex (Supplementary Table 15). The parameter 
estimates for the full model are shown in Supplementary Table 16. ROC AUC at 
five years was 0.73 [0.69, 0.76]. R2D was modest (22% [18%, 26%]) with HbA1c 
again the strongest predictor (R2D 14%). Internal validation showed low levels of 




We identified 1,213 participants who were GADA negative in the DCS external 
validation cohort satisfying our inclusion criteria (Supplementary Table 14). The 
calibration plot at five years (Supplementary Figure 9) shows that the range of 
probabilities is again narrow. The model showed reasonable calibration but 
underestimated in the higher risk groups. There was a slight increase in ROC 
AUC at 5 years (ROC AUC 0.76 [0.70, 0.82]) when compared to the internal 
validation results.  
We also identified 3,208 participants in the ADOPT data (Supplementary Table 
14). ROC AUC at four years was 0.71 [0.68, 0.74]. After adjusting the model to 
reflect the difference in outcome incidence (baseline hazard (intercept) update), 
the results of the calibration (Supplementary Figure 10) were very similar to the 
results of the ADOPT external validation of the main model.  
The majority of participants who have low model probabilities may be 
unlikely to benefit from GADA testing 
Figure 3 shows the probability of a positive GADA test (3A) and how much 
difference a GADA positive result makes to a patients probability of progressing 
to insulin within five years (3B). Participants with higher model probability have 
far higher likelihood of testing GADA positive (3A), and have higher rates of 
rapid insulin requirement if they test positive for GADA (3B). In contrast the vast 
majority of participants who have low model probability have a low likelihood of 
a positive GADA test, and low likelihood of rapid progression even if they test 
positive, for example 70% of participants have model probability ≤10%, this 
group had only a 3% GADA positive rate in the development dataset and only 





Figure 3A: Percentage of GADA positive participants by model probability of five year insulin requirement without GADA testing (no GADA measurement model). 
Development (GoDarts) cohort n = 3232.  
Figure 3B: Proportion of GADA positive participant progressing to insulin within five years (95% CI) in the GoDarts and DCS cohorts (n = 151), by risk of five year 
insulin requirement without GADA testing (no GADA measurement model). 




























We have developed, evaluated and externally validated prognostic models 
combining clinical features and biomarkers to provide estimates of a patient’s 
risk of progression to insulin therapy within five years of diagnosis.  
All models had a ROC AUC > 0.7 and performed similarly in external cohorts 
providing confidence in the validity of the models. The performance of our 
models is similar to those of other existing prognostic models routinely used in 
clinical practice for example in cardiovascular disease and mortality prediction 
(39; 40). The initial poor calibration of the models in ADOPT is expected due to 
the use of a different outcome (moderate glycaemia on monotherapy, in 
contrast to insulin treatment used for model development), however this was 
addressed by a simple recalibration of the model. Models were highly predictive 
of a participant being GADA positive, with those who had low model probability 
having very low rates of GADA positivity, and GADA positive participants in this 
group only low probability of 5 year insulin requirement. 
To our knowledge, this is the first study to develop a prognostic model for 
progression to insulin therapy in adult participants with type 2 diabetes. A key 
strength of this study is our use of a population cohort (GoDarts) for model 
development, this means that our results are likely to be a true representation of 
patients seen in primary care. Additional key strengths are the availability of 
clinical features at diagnosis, our systematic approach to model development 
(34) and our use of separate cohorts for external validation. We have used both 
unambiguous definitions of the prognostic factors and reproducible 
measurements which means our models are usable in clinical practice (41). We 




to the presence of statistically significant interactions between GADA and each 
of BMI, T1D GRS and HDL, inclusions of these interactions would have resulted 
in a highly complex model. 
Limitations of this study include that insulin commencement was based on 
clinical decision making rather than a trial protocol (1), we have however 
addressed this by externally validating the models in ADOPT using a trial 
glucose threshold.  In addition the models have been developed on a white 
European population, validating these models in other ethnicities is therefore an 
important area of future work. An additional limitation of our study is that GADA 
was measured at a median 4.9 years diabetes duration, which could result in a 
lower prevalence than if measurement was undertaken at diagnosis. However, 
in adult populations the error is likely to be small, with GADA positivity being 
stable over the first six years in UKPDS study participants (42). In addition we 
did not have sufficient external data to externally validate the GADA positive 
model. Lastly we were not able to use the most recently published Type 1 
Diabetes Genetic Risk Score (which has modestly improved performance), due 
to unavailability of all the relevant SNPs in our cohorts (43). 
We have previously shown that the T1D GRS is independently associated with 
rapid progression to insulin in patients diagnosed with type 2 diabetes who were 
GADA positive, using a larger cohort of 8,608 participants (20). In this study, 
T1D GRS was not statistical significant in the GADA positive model when 
adjusted for the other clinical features and biomarkers. This may reflect a 
smaller cohort, more advanced modelling to optimize use of other features, and 




Our models have the potential to facilitate the management of patients 
diagnosed with type 2 diabetes by allowing identification of individuals who have 
a high probability of rapid glycaemic progression and may benefit from more 
intensive treatment or monitoring. A potential related role is in assisting targeted 
GADA testing to the minority of patients who have higher risk of islet antibody 
positivity, and in whom a positive antibody will be associated with high rates of 
progression. While we have focused on five year insulin requirement our use of 
the flexible parametric survival models means that survival probabilities can be 
calculated for any time point. We envisage that the model will be implemented 
as a dynamic web-based tool similar to that used in a cancer survival model 
(44) and may potentially be used at diagnosis alongside recently published 
prediction models for diabetes classification (45). 
In conclusion, prediction models integrating clinical features with biomarkers 
may assist clinicians in identifying patients with high risk of progression and 
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Supplementary Table 1: Type 1 diabetes SNPs included in the genetic risk score with weights. 










DR3/DR4 48.18 3.87  
 
DR3/DR3 21.12 3.05  
DR4/DR4 21.98 3.09  
DR4/X 7.03 1.95  
DR3/X 4.53 1.51  
rs1264813 HLA_A_24 1.54 0.43  T 
rs2395029 HLA_B_5701 2.5 0.92  T 
rs3129889 HLA_DRB1_15 14.88 2.70  A 
rs2476601 PTPN22 1.96 0.67  A 
rs689 INS 1.75 0.56  T 
rs12722495 IL2RA 1.58 0.46  T 
rs2292239 ERBB3 1.35 0.30  T 
rs10509540 C10orf59 1.33  0.29  T 
rs4948088 COBL 1.3 0.26  C 
rs7202877   1.28 0.25  G 
rs12708716 CLEC16A 1.23 0.21  A 
rs3087243 CTLA4 1.22 0.20  G 
rs1893217 PTPN2 1.2 0.18  G 
rs11594656 IL2RA 1.19 0.17  T 
rs3024505 IL10 1.19  0.17  G 
rs9388489 C6orf173 1.17  0.16  G 
rs1465788   1.16 0.15  C 
rs1990760 IFIH1 1.16 0.15  T 
rs3825932 CTSH 1.16 0.15  C 
rs425105   1.16 0.15  T 
rs763361 CD226 1.16 0.15  T 
rs4788084 IL27 1.16 0.15  C 
rs17574546   1.14 0.13  C 
rs11755527 BACH2 1.13 0.12  G 
rs3788013 UBASH3A 1.13 0.12  A 
rs2069762 IL2 1.12 0.11  A 
rs2281808   1.11 0.10  C 









Supplementary Table 2: Missing data pattern (n = 4,001). 1 means complete. Table only 
includes predictor variables that had missing data. 
 
Percent missing  HDL HbA1c 
82% 1 1 
6% 0 0 
6% 1 0 









Missing data/excluded patients (n = 876) 
 Clinical GADA testing*: 107  
 HbA1c or HDL not measured: 769 
 
Insulin treated (n = 825) Non-insulin treated (n = 2,407) 
GoDarts eligible patients (n = 4,108) 
 
Complete case (n = 3,232) 
GADA positive n = 131 





Supplementary Figure 2: Univariate association between continuous variables in Model 1 and 
insulin treated outcome assessed using relative to mean centred hazard obtained from Cox 
models with 95% confidence intervals. Black solid lines are linear model, black dashed lines are 
3 knot models, dash-dot lines are log transformed. Horizontal line at hazard ratio = 1. Assumes 




Supplementary Table 3: Selection of functional forms for continuous prognostic factors. 
Obtained from Cox models. N=2407 used in calculating BIC. 
 
 Linear Log-transformed 3-knot spline 
 AIC BIC AIC BIC AIC BIC 
Age at Diagnosis 12387.72 12393.51 12390.97 12396.75 12391.94 12415.09 
BMI 12495.06 12500.84 12495.84 12501.62 12477.11 12500.26 
HbA1c 12324.11 12329.89 12310.86 12316.64 12302.48 12325.63 
HDL 12473.46 12479.25 12464.39 12470.17 12455.04 12478.19 
 
 
Supplementary Table 4: Performance of univariate associations with progression to insulin 
therapy using simple Cox model. 
 
Prognostic factor Adjusted R2D [95% CI] C-statistic [95% CI] 
Age at diagnosis (linear) 0.08 [0.05, 0.11] 0.61 [0.59, 0.63] 
BMI (3-knot spline) 0.01 [0.00, 0.02] 0.54 [0.51, 0.56] 
HbA1c (log-transformed) 0.12 [0.09, 0.16] 0.66 [0.64, 0.67] 
HDL (log-transformed) 0.03 [0.01, 0.04] 0.57 [0.54, 0.59] 






Supplementary Table 5: Hazard Ratios of the four covariates in the RP model (normal scale 
with 3 d.f.) for time to insulin. 
 * Centered variables. † Log-transformed. ‡Derived spline variables for BMI. Full model including 
derived spline variables for the baseline normal cumulative hazard, derived spline variables for 
the time-dependent effect of HbA1c and intercept is shown in separate table.  
 
Variable Hazard Ratio  [95% CI] P value 
HbA1c (mmol/mol)*† 2.66 [2.31, 3.06] <0.001 
Age at diagnosis (years)* 0.98 [0.97, 0.98] <0.001 
Sex (male) 0.87 [0.78, 0.95] 0.004 
HDL (mmol/mol)* † 0.74 [0.62, 0.89] 0.001 
BMI_1*‡ 0.95 [0.91, 1.00] 0.056 
BMI_2*‡ 0.93 [0.89, 0.97] 0.001 
BMI_3*‡ 1.09 [1.04, 1.14] <0.001 





Supplementary Figure 3: Univariate analysis smoothed Schoenfeld residuals against time 
plots. Dashed reference lines at 1 (null effect) and estimated value of HR. Trends in the running 






Supplementary Table 6: Model coefficients for the RP model (normal scale with 3 d.f.) for 
model replication purpose. 
 * Centered variables. † Log-transformed. ‡Derived spline variables for BMI. §Derived spline 
variables for the baseline normal cumulative hazard. ||Derived spline variables for the time-
dependent effect of Hba1c. HbA1c is centered on 66 mmol/mol (8.2%), BMI on 31 kg/m2, Age is 
centered on 61 years and HDL on 1.2 mml/mol. BMI knots at knots 16.20, 27.20, 30.40, 34.70, 
66.20. 
 
Variable Beta coefficient [95% CI] P value 
HbA1c (mmol/mol)*† 0.9770372 [0.8365849, 1.11749] <0.001 
Age at diagnosis (years)* -0.0218331 [-0.0267874, -0.0168788] <0.001 
Sex (male) -0.1438583 [-0. 2413587, -0.0463578] 0.004 
HDL (mmol/mol)* † -0.3005002 [-0.4800388, -0.1209615] 0.001 
BMI_1*‡ -0.046877 [-0.0950246, 0.0012707] 0.056 
BMI_2*‡ -0.0745811 [-0.1189969, -0.0301652] 0.001 
BMI_3*‡ 0.0829741 [0.0393008, 0.1266475] <0.001 
BMI_4*‡ -0.0214095 [-0.0662199, 0.023401] 0.349 
rcs1§  0.46694 [0.4379549, 0.4959251] < 0.001 
rcs2§ -0.1295396 [-0.1515924, -0.1074868] < 0.001 
rcs3§ -0.0278038 [-0.045251, -0.0103567] 0.002 
rcsHbA1c1|| -0.0820199 [-0.154833, -0.0068254] 0.032 
rcsHbA1c2|| 0.0623191 [0.0097391, 0.1148992] 0.020 





Supplementary Table 7: Effects of removing variables on explained variation (R2D). The effect 
of removing one covariate singularly is shown in the second and third columns. The effect of 
removing covariates cumulatively in descending order of importance is shown in the fourth and 
fifth columns. The effect of removing covariates cumulatively in ascending order of importance 
is shown in the sixth and seventh columns. 
 
Variable removed Single Cumulative (greatest first) Cumulative (least first) 
 R2D R2D R2D order 
Full model 0.19 0.19 0.19  
HbA1c 0.09 0.09   
Age at diagnosis 0.15 0.04 0.12 4 
HDL 0.19 0.00 0.18 3 
BMI 0.19 0.00 0.18 2 

















Supplementary Figure 4: Distribution of predicted failure probabilities of all patients in 







Supplementary Figure 5: Failure probabilities (first five years from diagnosis) at the 10th, 20th 
…90th deciles of the prognostic index (linear predictor). 10th centile (low risk) is the lowermost 








Supplementary Figure 6: GoDarts internal validation calibration plot plot of expected versus 
observed failure probabilities at t = 5 years.  
Dashed grey line is reference line where observed = expected probabilities. Black filled circles 
are risk groups using deciles of expected probabilities, vertical grey solid lines are 95% CIs. 




Supplementary Table 8 Model performance results for the internal validation 
 
Performance parameter Internal validation (1,000 bootstrap) 
Apparent (SD) Test (SD) Optimism 
Explained variation (R2D) (1) 0.199 (0.021) 0.191 (0.009) 0.008 













Missing data/excluded patients (n = 761) 
 Clinical GADA testing*: 0 
 HbA1c, BMI or HDL not measured: 761 
Insulin treated (n = 1,072) Non-insulin treated (n = 169) 
DCS eligible patients (n = 2,002) 
 
Complete case (n = 1,241) 
GADA positive n = 28 










Missing data/excluded patients (n = 144) 
 HbA1c, BMI or HDL not measured: 144 
 Monotherapy failure* (n = 525) No monotherapy failure* (n = 2,962) 
ADOPT eligible patients (n = 3,619) 
 
Complete case (n = 3,487) 
GADA positive n = 138 
GADA negative n = 3,208 





Supplementary Table 9: Patient characteristics for GADA positive development cohorts. 
Median (IQR) or % 
* At first visit 
†Percentage of patients observed for at least five years 
‡ measured < 6 months post diagnosis 
§ Closest to diagnosis (within 12 months pre or post diagnosis) 
|| Centile of participants with type 1 diabetes from the Wellcome Trust Case Control Consortium.  
 
 GoDarts Development 
 (n = 131) 
Sex (% Male) 48.9% 
Age at diagnosis (years) 62 (56, 70)  
BMI (kg/m2)* 28.7 (25.7, 32.7) 
Duration of diabetes (years) at latest follow up 12.5 (10.2, 14.9) 
Failure within 5 years (%)† 30.2% 
HbA1c (%)‡ 8.6 (6.9, 10.8) 
HbA1c (mmol/mol) ‡  71.0 (52.0, 95.0) 
HDL (mmol/L) §  1.2 (1.0, 1.5) 
Duration of diabetes (years) at GADA 4.9 (2.1, 6.9) 
T1D GRS|| 6.8 (1.1, 37.5) 
 
 
Supplementary Table 10: Hazard Ratios of the four covariates in the GADA positive model 
(hazard scale with 1 d.f.) for time to insulin. * Centered variables. † Log-transformed. Full model 
including derived spline variables for the baseline normal cumulative hazard, derived spline 
variables for the time-dependent effect of HbA1c and intercept for model replication purpose is 
shown in separate table.  
 
Variable Hazard Ratio  [95% CI] P value 
HbA1c (mmol/mol)*† 3.55 [1.68, 7.47] 0.001 
Age at diagnosis (years)* † 0.07 [0.02, 0.32] 0.001 
Sex (male) 0.58 [0.34, 0.96] 0.036 





Supplementary Table 11: Model coefficients for the GADA positive model (hazard scale with 1 
d.f.) for model replication purpose. 
 * Centered variables. † Log-transformed. §Derived spline variables for the baseline hazard 
cumulative hazard. ||Derived spline variables for the time-dependent effect of age at diagnosis. 
HbA1c is centered on 75 mmol/mol, Age at diagnosis is centered on 61 years, BMI is centered 
on 29 kg/m2.  
 
Variable Beta coefficient [95% CI] P value 
HbA1c (mmol/mol)*† 1.266847 [0.5230154, 2.010679]  0.001 
Age at diagnosis (years)* † -2.605545 [-4.086671, -1.124419] 0.001 
Sex (male) -0.5520431 [-1.066946, -0.0371403] 0.036 
BMI (kg/m2) *† -2.859483 [-4.181024,  -1.507469] < 0.001 
rcs1§ 1.028493 [0.8105269, 1.246459] < 0.001 
rcsAge1|| -1.521259 [-2.796028, -0.2464909] 0.019 
rcsAge2|| 0.153941 [-0.5701638, 0.8780459] 0.677 
Intercept -0.9048484 [-1.257163, -0.5525342]  
 
 
Supplementary Table 12: Effects of removing variables on explained variation (R2D) on the 
GADA positive model. The effect of removing one covariate singularly is shown in the second 
and third columns. The effect of removing covariates cumulatively in descending order of 
importance is shown in the fourth and fifth columns. The effect of removing covariates 
cumulatively in ascending order of importance is shown in the sixth and seventh columns. 
 
Variable removed Single Cumulative (greatest first) Cumulative (least first) 
 R2D R2D R2D order 
Full model 0.326 0.326 0.326  
HbA1c 0.249 0.249  4 
BMI 0.203 0.059 0.161 3 
Age at diagnosis 0.229 0.006 0.232 2 




Supplementary Table 13: Model performance results for the internal validation 
(GADA positive model) 
 
Performance parameter Internal validation (1,000 bootstrap) 
Apparent (SD) Test (SD) Optimism 
Explained variation (R2D) (1) 0.355 (0.099) 0.328 (0.035) 0.027 





Supplementary Table 14: Patient characteristics for GADA negative cohorts. Median (IQR) or % 
* At first visit 
†Percentage of patients observed for at least five years 
‡ measured < 6 months post diagnosis 
§ Closest to diagnosis (within 12 months pre or post diagnosis)  
|| Not followed post failure. 
 
 GoDarts Development 
 (n = 3,101) 
DCS Validation 
(n = 1,213) 
ADOPT Validation 
(n = 3,208) 
Sex (% Male) 54.8% 54.3% 59.2% 
Age at diagnosis (years) 62 (54, 69)  61 (54, 67)  58 (51, 65)  
BMI (kg/m2)* 30.5 (27.2, 34.8)  29.5 (26.8, 33.2) 31.0 (27.8, 35.3) 
Duration of diabetes (years) at latest follow up 12.3 (9.9, 15.0) 6.3 (4.0, 10.2) Not Available|| 
Insulin treated within 5 years (%)† 7.9% 7.1% 14.9% 
HbA1c (%)‡ 7.6 (6.6, 9.4) 6.6 (6.1, 7.5)  7.2 (6.7, 7.8) 
HbA1c (mmol/mol) ‡  60.0 (49.0, 79.0) 48.6 (43.2, 58.5) 55.2 (49.7, 61.7) 
HDL (mmol/L) §  1.15 (0.99, 1.36) 1.15 (0.99, 1.36) 1.2 (1.0, 1.4) 





Supplementary Table 15: Hazard Ratios of the four covariates in the GADA negative model 
(odds scale with 2 d.f.) for time to insulin. * Centered variables. † Log-transformed. Full model 
including derived spline variables for the baseline odds cumulative hazard and intercept for 
model replication purpose is shown in separate table.  
 
Variable Hazard Ratio  [95% CI] P value 
HbA1c (mmol/mol)*† 5.52 [4.26, 7.15] <0.001 
Age at diagnosis (years)*  0.96 [0.95, 0.97] <0.001 
Sex (male) 0.77 [0.65, 0.92] 0.004 




Supplementary Table 16: Model coefficients for the RP GADA negative model (odds scale with 
2 d.f.) for model replication purpose. 
 * Centered variables. † Log-transformed. ‡Closest to diagnosis. §Derived spline variables for the 
baseline normal cumulative hazard. ||Derived spline variables for the time-dependent effect of 
HbA1c. HbA1c is centered on 66 mmol/mol (8.2%), Age centered on 61 years and HDL on 1.2 
mml/mol.  
 
Variable Beta coefficient [95% CI] P value 
HbA1c (mmol/mol)*† 1.707518 [1.448497, 1.966538]  <0.001 
Age at diagnosis (years)*  -0.0395409 [-0.048312, -0.0307698] <0.001 
Sex (male) -0.2552507 [-0.4289788, -0.0815225] 0.004 
HDL (mmol/L)  *†‡ -0.6422273 [-0.9718084, -0.3126463] < 0.001 
rcs1§ 0.9315873 [0.8557963, 1.007378] < 0.001 
rcs2§ -0.1583448 [-0.2177518, -0.0989377] < 0.001 
rcsHbA1c|| -0.3280567 [-0.5007058, -0.1554076] < 0.001 
rcsHbA1c|| 0.0955222 [-0.0272555, 0.2182999] 0.127 
Intercept -1.580503 [-1.711754, -1.449251]  
 
 
Supplementary Table 17: Model performance results for the internal validation (GADA 
negative model) 
 
Performance parameter Internal validation (1,000 bootstrap) 
Apparent (SD) Test (SD) Optimism 
Explained variation (R2D) (1) 0.219 (0.025) 0.215 (0.015) 0.004 





Supplementary Figure 9: DCS external validation (GADA negative model) calibration plot of 
expected versus observed failure probabilities at t = 5 years. Dashed grey line is reference line 
where observed = expected probabilities. Black filled cricles are risk groups using deciles of 






Supplementary Figure 10: ADOPT external validation (GADA negative model) calibration plot 
of expected versus observed failure probabilities at t = 4 years. Dashed grey line is reference 
line where observed = expected probabilities. Black filled cricles are risk groups using deciles of 
expected probabilities, vertical grey solid lines are 95% CIs. Grey solid line is lowess smoother.  
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The work presented in this thesis has investigated the development of clinical 
prediction models to assist with the classification and care of patients diagnosed 
with diabetes in clinical practice.  
The first two studies of this thesis investigate the development and validation of 
a diagnostic model for identifying type 1 diabetes requiring rapid insulin therapy 
in young adults. We first developed a multivariable diagnostic model combining 
five clinical features and biomarkers (age of diagnosis, BMI, GADA and IA-2 
islet-autoantibodies, T1D GRS) using logistic regression. Performance was 
assessed using both internal and external validation; the results indicated that 
the model had high discrimination and calibration ability. In the next study, we 
used the same dataset to assess if machine learning would have superior 
performance over logistic regression in this setting. We built comparative 
models using five commonly used supervised machine learning algorithms 
(Gradient Boosting Machine, Support Vector Machine, K-Nearest Neighbours, 
Neural Network and Random Forest) and compared their performance to that of 
logistic regression. In this setting, there was no performance gain in using 
machine learning.  
The remaining studies investigated glycaemic deterioration in patients 
diagnosed with type 2 diabetes. We first discovered that a genetic risk score 
(T1D GRS) can be used to identify patients with rapid glycaemic deterioration 
requiring insulin treatment over and above GADA testing. We went on to 
develop and externally validate a multivariable prognostic model built using 
Royston-Parmar flexible parametric survival analysis (RP) to identify patients 
with a high risk of rapid progression. Performance of the model was modest 




The remainder of this chapter gives an overview of the main findings of this 
thesis and discusses the work’s conclusions, implications, limitations and 





Discussion of chapter 2: Development and validation of multivariable 
clinical diagnostic models to identify type 1 diabetes requiring rapid 
insulin therapy in adults aged 18 to 50 
Misclassification of diabetes subtype is common particularly in young adult 
patients where, due to increasing rates of obesity, discriminating between type 
1 and young-onset type 2 diabetes can be challenging. Current guidance on 
diabetes classification at diagnosis focuses on aetiopathological definitions 
rather than the patient’s treatment requirements, with no clear criteria for use in 
clinical practice. There is no single diagnostic test that can robustly classify 
diabetes at diagnosis and no clinical prediction models are available to assist 
clinical decision making.   
In this study we developed and validated a diagnostic model to classify type 1 
diabetes at diagnosis using a robust definition based on the requirement for 
rapid insulin therapy. 
Conclusions 
A diagnostic model combining clinical features and biomarkers has a higher 
accuracy for identifying type 1 diabetes with rapid insulin requirement than 
using single features in isolation. 
Implication of findings 
This study delivers a diagnostic model that has the potential to be used in 
clinical practice to assist clinicians to accurately identify patients with type 1 





The development of multiple models with different combinations of the five 
predictors means that the model still retains utility in situations where 
autoantibody and/or genetic testing is either not indicated or not available; the 
model can be still be used in at least one form. For example, genetic but not 
autoantibody data is available in many biobanks but in clinical care, genetic 
testing is not yet routinely performed. This development approach allows a 
staged approach to classification of diabetes; the clinical features-only model 
can be used to identify patients with diagnostic uncertainty who may benefit 
most from additional testing without incurring any financial cost.  
In addition to aiding clinical decision-making, the model could facilitate a triage-
based approach to diabetes subtype diagnosis; probabilities derived on clinical 
features alone could be used as criteria for requesting autoantibody or genetic 
testing. It could also be used as a tool for evidence-based classification in 
diabetes research where it could be incorporated into the participant selection 
process. 
The model is presented in a website (beta version available at 
https://www.diabetesgenes.org/t1dt2d-prediction-model/) (Figure 1) which 











There have not to our knowledge been any other published studies proposing a 
diagnostic model for classifying type 1 and type 2 diabetes at diagnosis. A 
recent study examining the frequency of type 1 diabetes has however 
highlighted the need for improved diabetes classification in older adults (1). 
A clustering algorithm comprising of five diabetes subgroups has recently been 
published; one cluster being defined by the presence of GADA positivity only 
regardless of other features (severe autoimmune diabetes (SAID) cluster), and 
the other four based on GADA negativity and differences in age at diagnosis, 
BMI, HbA1c and HOMA 2 (type 2-like clusters) (2) but did not show that the 
clusters could be used to inform treatment decisions (3). Whilst this cluster 
model has limitations, it does identify a future direction for diabetes prediction 
models where the focus shifts from classification of diabetes to predicting other 
aspects of the disease such as complications and treatment responses.  
A new improved T1D GRS has been published subsequent to our study (T1D 
GRS2) (4). The new T1D GRS2 includes 67 SNP’s compared to 30 in T1D GRS 
and has greater performance. An area of future work would be to update the 
model with the new T1D GRS2.  
We followed up this study in Chapter 3 to compare the performance of machine 
learning algorithms to that of logistic regression. 
Limitations 
The limitations of this work are predominantly related to the use of existing 
cross-sectional data to build the models: ideally we would have carried out a 




data to assess development of severe insulin deficiency and insulin 
requirement. 
The use of existing data meant that we were limited to modelling only the 
features that were available in the datasets. The cross-sectional nature of the 
data meant that predictors that present at diagnosis such as presentation 
glycaemia, ketosis, or weight loss were not available in the datasets. It also 
meant that predictor variables were for most participants measured some years 
post diagnosis; since BMI and islet-autoantibodies change over time in adult 
onset diabetes (5), the model predictions are likely to be under-estimated.  Data 
such as date of diagnosis and time to insulin were self-reported by the patient 
rather than obtained from patient medical records which may have introduced 
error when assigning the outcome.  
There are two limitations connected to the use of C-peptide as our gold 
standard outcome. Firstly, an issue with stored samples for participants in the 
DARE cohort prior to February 2010 (when immediate freezing of aliquoted 
samples was introduced) restricted the availability of C-peptide data in DARE 
participants before this date: sample degradation and poor sample collection 
can cause falsely low values (6). Secondly, we did not consider renal 
impairment in the participants, which may cause falsely high values (7).  
Both GADA and IA-2 titres (concentrations) were dichotomised for use as 
predictors in the model. We did not use them as continuous predictors because 
the rounding of titres lower or above the levels of assay detection causes peaks 
at either end in the continuous distribution and because titre values are not 
normally available in clinical practice; results are normally reported simply as 




The datasets used to develop the model predominantly consisted of white-
European participants, which meant that we did not have sufficient data to 
include ethnicity as a predictor in the model. The model does not therefore 
reflect differences in prevalence in certain ethnic subgroups (8) and restricts the 
use of the model to a white-European population. Another limitation related to 
the use of the model is that is unsuitable for extrapolation beyond the ages of 
18 and 50 years. 
Finally, we were unable to externally validate all combinations of the model as 
IA-2 islet-autoantibodies and T1D GRS were not available in the external 
dataset. 
Future research 
The main direction of future research is to implement the model into clinical 
practice. This will involve additional validation and expanding the use of the 
model into other ethnicities and age groups.  
Important areas of future research are updating the existing predictor 
coefficients using data measured at diagnosis and assessing the performance 
of the model with the inclusion of additional features available only at diagnosis. 
This data will be available in the Getting the Right Classification and Treatment 
From Diagnosis in Adults With Diabetes (StartRight) study (9). StartRight is a 
new prospective observational study of newly diagnosed adult participants 
designed to assess the relationship of clinical features and biomarkers to 
diabetes subtype.  
There is an opportunity to perform prospective external validations using the 
StartRight study (9) and United Kingdom prospective diabetes study (UKPDS) 




updating of the model. UK Biobank is a long-term national project to build a 
detailed resource for health researchers consisting of data and stored samples 
on more than 500,000 UK volunteers aged 40-69 years when recruited (11). It 
now contains GP medical records and there are plans to include C-peptide 
measurement.  
An assessment of the clinical usefulness of the model would be an interesting 
addition to this study and would be useful for implementing the model into 
clinical use. Follow up research could include a health economic and 
implementation study (12) to evaluate the impact of the model in clinical use. 
For example, a study to evaluate differences in classification or outcomes could 








Discussion of chapter 3: Logistic regression has similar performance to 
optimised machine learning algorithms in a clinical setting: application to 
the classification of type 1 and type 2 diabetes in young adults 
The previous chapter suggested that a diagnostic model to classify type 1 
diabetes at diagnosis built using logistic regression achieved good performance. 
In this study we compared the discrimination and calibration performance of five 
machine learning algorithms to logistic regression using our diabetes 
classification model from the previous chapter as an example. 
Conclusions 
Optimised machine algorithms performed no better than logistic regression to 
classify type 1 and type 2 diabetes in young adults.  
Implication of findings 
A recent systematic review study found no evidence of superior performance of 
machine learning over logistic regression and concluded that improvements in 
methodology and reporting of comparison studies are needed (13).  In our study 
we demonstrated the application of a methodological approach and provided 
our code to allow our approach to be replicated in future comparison studies 
(Appendix 2). 
This study demonstrates the utility of comparing machine learning to traditional 
regression modelling when developing and selecting clinical prediction models, 
and re-iterates the need to validate models on external data. In our diabetes 
setting, we provided confidence that machine learning would not have yielded 






There are no studies that have published a performance comparison of a 
diabetes classification model. 
Limitations 
An essential aspect of this model comparison study was the external validation, 
which we would ideally have carried out using with all five predictors.  It is a 
severe limitation that the lack of IA-2 and T1D GRS in the external dataset 
meant that the only external validation that we were able to perform involved 
using just three of the predictor variables: Age at diagnosis, BMI and GADA. 
This is a very small number of predictors for machine learning algorithms even 
in medicine (between 5 and 20 predictors is more relevant). Machine learning is 
generally associated with processing large numbers of predictors but in 
medicine, with the possible exception of image data, a few meaningful 
predictors is more common. It is possible that a comparison of a model 
comprising of more variables and the use of a larger sample size might have 
given enough power to the machine learning for it to outperform logistic 
regression. 
Furthermore, logistic regression may have been slightly disadvantaged in our 
comparison by not considering non-linearity. 
Future research 
The methodological approach that we have applied to our study could be used 
as a framework for independent researchers to externally validate other studies 




use our framework to examine other comparison studies identified as having a 
risk of bias in the recent systematic review (13). 
Future research to address the main limitations of this study could include 
adding more predictors and an assessment of a more flexible logistic regression 
model with splines or fractional polynomials. A logistic regression model with 
interactions would also be of interest especially if the number of predictors were 
increased. The effect of the use of SMOTE for class imbalance on risk 




Discussion of chapter 4: A Type 1 Diabetes Genetic Risk Score can 
identify patients with GAD65 autoantibody positive type 2 diabetes that 
rapidly progress to insulin therapy 
The rate of glycaemic progression in patients with clinically diagnosed type 2 
diabetes is highly variable. There may be clinical utility in identifying patients 
who are most likely to rapidly progress to requiring insulin therapy, enabling 
clinicians to prioritise high risk patients for more frequent monitoring and 
treatment escalation.  
GADA has been associated with rapid glycaemic deterioration, but the 
predictive value of this test is limited in patients with type 2 diabetes. Previous 
research has suggested that type 1 diabetes genetic variants in the HLA region 
are associated with rapid progression to insulin therapy in patients with clinically 
diagnosed type 2 diabetes who are positive GADA (14). 
We used survival analysis to investigate if a diagnostic test for type 1 diabetes 
genetic variants (T1D GRS) could identify rapid progression to insulin therapy in 
adult patients with a clinical diagnosis of type 2 diabetes over and above GADA 
testing. 
Conclusions 
We found that participants who were GADA positive and had a high T1D GRS 
progressed to insulin therapy more rapidly than the other GADA positive 
participants. There was no difference in the rate of progression by T1D GRS in 
participants who were GADA negative.  
Our finding that GADA is associated with time to insulin in patients clinically 




what we add to previous knowledge is our finding that T1D GRS is 
independently associated with time to insulin in this population, but only in the 
presence of GADA.  
Implication of findings 
T1D GRS alters the clinical implications of a positive GADA test when predicting 
time to insulin requirement in patients with a clinical diagnosis of type 2 
diabetes. There is no prognostic value in genetic testing for patients who are 
GADA negative; genetic testing should be indicated in clinical practice only for 
patients who are GADA positive to more accurately assess their risk of requiring 
rapid insulin therapy. The use of this two-step testing approach may facilitate a 
precision medicine approach to treating patients diagnosed with type 2 
diabetes. Our findings could also be applied to participant selection for future 
type 2 diabetes clinical trials investigating immune intervention or other 
interventions to slow progression. 
Whilst original reports of the T1D GRS focused on aiding discrimination 
between type 1 and type 2 diabetes (17) it has also been used in subsequent 
studies for other applications such as discriminating monogenic and type 1 
diabetes (18) and predicting progression of islet-autoimmunity (19). The use of 
T1D GRS in our study adds another novel practical application of its use to the 
literature: to assist identification of patients diagnosed with type 2 diabetes who 
will require early insulin therapy over and above GADA testing. 
Our results support the findings of a recent study that suggested the presence 
of GADA in patients clinically diagnosed with type 2 diabetes is indicative of two 
heterogeneous populations with very different phenotypes (20). The first 




susceptibility to type 1 diabetes and require rapid insulin therapy. The second is 
a non-autoimmune diabetes: the GADA result is a false positive which will be 
common with islet-autoantibody testing in low prior prevalence populations (type 
2 diabetes not requiring initial insulin).  
The presence of genetic susceptibility to type 1 diabetes may increase the 
likelihood that a patient who is GADA positive has true underlying type 1 
diabetes, rather than being a false positive result. 
Subsequent work 
Although this study has been cited by studies relating to the use of genetics in 
diabetes (21, 22), there have not to our knowledge been any other published 
studies investigating the use of GADA and T1D GRS to identify patients 
diagnosed with type 2 diabetes requiring early insulin therapy. 
We followed up this study by using GADA and T1D GRS in the development of 
a multivariable prognostic model to predict rapid insulin requirement in adult 
patients diagnosed with type 2 diabetes requiring early insulin therapy (chapter 
5).  
Limitations 
The main limitation of this study is our reliance on using initiation of insulin 
therapy based on a clinical decision rather than trial protocol to define the 
endpoint. This is problematic because there is likely to be variation in the 
decision to initiate insulin therapy between both clinician and patient which may 
have introduced inertia bias. Clinicians were unaware of the patients T1D GRS 
and immunology test results at the date of treatment decision so systematic 




were unable to distinguish between relative or absolute requirement for insulin 
as C-peptide was not routinely measured in this cohort.  
In the Cox proportional hazards regression analysis, we discovered a 
statistically significant association between year of diagnosis and time to insulin 
consistent with previous studies (23) reflecting changes in prescribing patterns 
over time, specifically an increasing delay of insulin therapy initiation (24). Our 
results were not adjusted for year of diagnosis but this finding may be an 
important consideration in future work. 
There were several limitations relating to the use of Exeter-based cohorts. 
Firstly, the use of self-reported time to insulin in the Exeter based cohorts may 
have introduced imprecision. Our use of complete-case analysis meant that we 
excluded a large number of DARE participants because GADA was missing; 
GADA testing was only performed in the study for participants who were 
younger at diagnosis and stored serum was not available for all participants 
meaning that we could not perform additional GADA testing for all participants 
where GADA was missing. Most of the 3,542 participants excluded from our 
analysis were from the DARE cohort, there were statistically significant 
differences in the clinical features of these excluded participants but they were 
not considered clinically relevant. 
To achieve sufficient numbers, we had to combine several cohorts from 
different studies - ideally we would have used a single cohort. There were two 
limitations related to the use of a combined dataset; statistically significant 
differences in GADA prevalence, diabetes duration and HbA1c between cohorts 




these limitations by including study of origin as a strata variable in the Cox 
proportional hazards regression analysis. 
Another limitation is the measurement of GADA post diagnosis. This limitation 
has been discussed earlier in this discussion in relation to chapter 2 and is not 
repeated here. In addition to GADA, IA-2 has previously been associated with 
time to insulin in patients diagnosed with type 2 diabetes (25) but we were 
unable to assess the interaction between IA-2 (or any other islet-autoantibody) 
and T1D GRS in our study as this data was not available. 
In our Cox proportional hazards regression analysis, the relationship between 
the continuous covariates and progression to insulin was assumed to be linear. 
This may be an invalid assumption and should be considered in any future 
research. 
The implications of our findings are not generalisable to patients who are of 
non-white European ethnicity or are younger than 35 years at diagnosis. 
Future research 
There is an opportunity for this study to be repeated in a new prospective study 
in which GADA is measured at diabetes diagnosis and initiation of insulin is 
based on a trial protocol. Our study could be extended in this new prospective 
setting to investigate the use of other islet-autoantibodies such as IA-2 and 
ZnT8. The findings from a study using IA-2 would be of particular interest for 
LADA diagnosis which is currently based on GADA only.  
A follow up study to assess whether prior likelihood of autoimmune diabetes 
alters the association between clinical features and biomarkers, and 




performing survival analysis for different age and BMI subgroups. It would also 
be of clinical interest to examine if the interaction between GADA and T1D GRS 
was consistent at different ages. Our primary outcome was short term 
progression to insulin therapy (5 years), a secondary outcome that could be 
investigated in future research is long term progression to insulin in those 
participants who did not require insulin therapy by five years. Future research 
could be based on the new improved T1D GRS2 (4) which was published 
subsequent to our study and incorporating different centiles for GADA positivity. 
An important area for future research would be to apply our findings to the 
development of a prognostic model to predict rapid insulin requirement in 
individual patients diagnosed with type 2 diabetes. The use of a prediction 
model combining multiple predictors including GADA and T1D GRS is likely to 







Discussion of chapter 5: Predicting early insulin requirement in adults 
diagnosed with type 2 diabetes: development and external validation of a 
multivariable survival model. 
Chapter 4 identified genetic susceptibility to type 1 diabetes, measured using 
T1D GRS, alters the implications of a positive GADA result in patients 
diagnosed with type 2 diabetes and could be used to identify patients at high 
risk of rapid progression to insulin therapy.  
A previous Diabetes UK-funded Diabetes Remission Clinical Trial (DiRECT) 
study found other clinical features and biomarkers in addition to GADA and T1D 
GRS that were independently associated with progression to insulin in patients 
diagnosed with type 2 diabetes (23). We combine our findings from chapter 4 
and findings from the DiRECT study to develop and validate a multivariable 
prognostic model to predict rapid insulin requirement from diagnosis in 
individual adult participants diagnosed with type 2 diabetes. 
Conclusions 
The rate of glycaemic deterioration from first diagnosis defined by requirement 
for insulin therapy is generally slow and fairly constant in the majority of patients 
diagnosed with type 2 diabetes. Prognostic models integrating clinical features 
and biomarkers have the potential to identify those patients at high risk of rapid 
progression to insulin. High HbA1c measured at diagnosis is the strongest 
predictor of rapid progression.  
Implication of findings 
Identifying patients at high risk of rapid progression to insulin has utility in both 




patient’s progression to insulin can be used to optimise their treatment and set 
monitoring priorities. In research, patients likely to rapidly progress could be 
targeted to maximise the cost effectiveness of clinical trials of interventions 
aimed at slowing diabetes progression. 
Use of the model as a triage-based tool for identifying of patients who would 
benefit most from GADA testing or those patients who are more likely to be 
GADA positive has significant clinical interest. Firstly, there is a financial benefit 
in testing only a minority of patients who will benefit most from additional 
testing. Currently one of the reasons why GADA testing is not indicated 
routinely for patients with type 2 diabetes is that it would be too expensive to 
test everyone given the huge incidence of this disease. Secondly, altering the 
number of GADA tests performed by only testing those patients who are more 
likely to be GADA positive (increasing the prior likelihood) will have the benefit 
of increasing the positive predicted value of the test. 
Subsequent work 
There have not to our knowledge been any other published studies proposing a 
prognostic model for identifying early insulin requirement in adults diagnosed 
with type 2 diabetes.   
Limitations 
The measuring of GADA post diagnosis in the GoDarts and DCS cohorts may 
have resulted in some false negatives since GADA levels decrease over time 
(26). This would have no impact on our main model but may have caused 
estimation bias in our GADA models due to the classification of participants by 




The development of separate GADA models has an advantage in terms of 
clinical utility but resulted in a small numbers of participants available to build 
the GADA positive model (n = 131) and wide confidence intervals in the model 
estimates. In addition, we were unable to perform external validation of the 
GADA positive model for the same reason. We were unable to use DARE 
Exeter-based cohort to increase our sample size as HbA1c measured at 
diagnosis was not available for the majority of participants. 
In contrast to our findings in chapter 4, T1D GRS was not statistical significant 
in the GADA model when adjusted for the other clinical features and 
biomarkers, this may have been a power issue in this small dataset or it could 
be that the combined features are capturing a prior likelihood effect (identifying 
the GADA false positives) much better than T1D GRS in our previous study. 
Much larger studies would be needed to increase the number of GADA positive 
participants to allow the T1D GRS to be re-assessed and external validation of 
the model to be performed. It would be useful to investigate the effect of the 
new T1D GRS2 (4).  
The use of separate GADA models dealt with the presence of statistically 
significant interactions between GADA and each of BMI, T1D GRS and HDL. 
Future work could investigate interactions between the continuous predictor 
variables and assess the impact of including any required interaction terms on 
model performance, the practicality of implementing a potentially complex 
model would also need to be assessed. 
The predictor variables included in the models are based on features and 
biomarkers which are routinely measured or inexpensive to measure in the U.K. 




and availability of the tests are likely to vary. The findings of this study can only 
be applied to participants of white- European ethnicity. 
The main limitation of our study is that insulin initiation was based on clinical 
decision making rather than a trial protocol. There is uncontrollable extraneous 
variability in both the time of diagnosis and the length of time before insulin 
initiation and therefore neither the start nor the endpoint of the survival period is 
fixed in relation to any underlying progress of the disease. Many patients with 
type 2 diabetes are diagnosed whilst in the early stages of the disease by 
routine testing; otherwise, because hyperglycaemia develops gradually, a 
patient may go undiagnosed for many years before experiencing classic 
diabetes symptoms.  
In clinical practice, clinical inertia may affect insulin initiation decisions (27, 28); 
decisions to initiate insulin therapy may also be influenced by factors other than 
high HbA1c (29). In patient-centred care approaches, there will inevitably be 
between patient variations in the decision to start insulin with many patients 
having a strong preference to avoid insulin initiation (30, 31). There may be also 
be between clinician/practice variability in the prescribing patterns (32) and/or 
compliance to the HbA1c level guidelines at which insulin is initiated (31, 33). 
We did not have HbA1c measured at time of insulin initiation so we were unable 
to check if insulin was initiated according to guidelines. 
We assessed the performance of the model in ADOPT clinical trial data (34); 
this dataset had the advantage of an outcome event defined using a trial 
protocol but the disadvantage of being based on a different diabetes outcome 




model using a prospective trial where biomarkers could be measured at time of 
diagnosis and insulin initiation.  
Drug therapy prior to insulin initiation was not available in the datasets so we 
were unable to adjust for the adequacy of glycaemic control in different 
therapies (32, 35-39). Number of visits and inadequate monitoring (40) may 
have affected time to insulin initiation but we did not have the data to check this.  
At a population level, glycaemic control is improving over time (41) with the time 
to insulin initiation increasing (24). This may be explained by the introduction of 
newer oral agents over time (24). All of these will have an impact on the 
predictions when using time to insulin initiation as the outcome. Our finding that 
earlier year of diagnosis was associated with higher rates of glycaemic 
deterioration was consistent with previous studies (16, 23). Year of diagnosis 
was not adjusted for in our model since its practical implementation would have 
been difficult. Our failure to adjust for calendar year of diagnosis in the model 
may have resulted in over-estimated predictions. This limitation should be 
considered when implementing the model for clinical use, possibly by applying 
periodic adjustments.   
We decided to use RP to develop our model as it is a preferred approach in 
situations where individual predictions are required and there is a need to 
incorporate the time-dependent effects (42, 43). We encountered limitations in 
the usability of the model arising from the inclusion of time-dependent effects; 
the beta-coefficients are difficult to interpret and publishing the model is more 
complex.  
Data was not available for other islet-autoantibodies in our development dataset 




incorporate IA-2 and/or ZnT8 into the models as this is likely to increase 
performance but their inclusion would likely involve re-designing the model.  
674 patients in our development cohort died before they had progressed to 
insulin therapy; we did not investigate the impact or adjust for competing risks in 
our model which means that the model coefficients may be over-stated. A 
competing risks analysis would be an interesting area for future research. 
Future research 
The Innovative Medicines Initiative Diabetes Research on Patient Stratification 
(DiRECT) study (44) may be a potentially valuable resource for future research 
aimed at either updating or validating the model although its usefulness is 
limited by a relatively short follow up time. DiRECT is a large study collecting 
biomarkers associated with glycaemic deterioration in participants recently 
diagnosed with type 2 diabetes. Participants are recruited close to diagnosis 
and followed-up for between 18 and 36 months, clinical features and 
biomarkers are collected at baseline and repeated at two follow up visits. A 
further area of research would be to use DiRECT or similar studies to assess 
whether the addition of further genetic, metabolomic or proteomic data improves 
the model performance over and above the simple clinical features and clinical 
biomarkers currently used. 
A study comparing the performance and clinical utility of our model to identify 
patients with rapid progression to insulin to that of the type 2 diabetes 
subgroups derived by Ahlqvist et al in the recently published cluster analysis (2) 
would be interesting future research.  
Another area of future research would involve using the risk predictions from 




investigate whether targeted interventions can be a cost-effective approach for 
managing type 2 diabetes outcomes. Related future research could include 
process evaluation of the model using clinician focus groups or questionnaires 
and performing decision curve analysis to describe the clinical effects of the 
model.  
There is the option in future research to address this research question as a 
binary regression problem – the event outcome being insulin initiation by five 
years. It would be interesting to compare both the performance of the two 






This thesis demonstrates that routinely measured clinical features and 
biomarkers can be used in multivariable prediction models to aid clinical 
decisions regarding the classification and care of adult patients diagnosed with 
diabetes.  
The importance and challenges of both correctly classifying patients with 
diabetes according to their treatment requirements at diagnosis and identifying 
patients with type 2 diabetes who are likely to rapidly progress to insulin have 
been highlighted in this thesis: clinical prediction models to identify patients 
likely to develop diabetes (45) or to identify MODY (46) have been published 
but there are currently no published clinical prediction models that address 
these two challenges. 
For classification of type 1 and type 2 diabetes, the studies in this thesis identify 
five diagnostic predictors that can be used at diagnosis, in varying 
combinations, to accurately predict a patient’s individual risk of type 1 diabetes 
requiring early insulin therapy. The studies in this thesis also identify clinical 
features and biomarkers that can be combined to predict risk of rapid glycaemic 
deterioration, from diagnosis, in patients with type 2 diabetes.  
This thesis is concerned with the application of statistics to develop valid clinical 
prediction models that can be used in clinical practice. Methodologically, the 
systematic approach applied to the model development and validation 
undertaken in this thesis has been statistically robust and has followed 
methodological literature and published guidelines on how to perform prediction 
research (47). An important focus of this thesis is the clinical utility of these 




implemented in the models. Future work is now required to make these models 
ready for implementation into clinical practice. 
The models developed in this thesis could be used to implement a personalised 
approach to managing patients with diabetes in clinical practice: evidence-
based predictions obtained from the models can be used to inform treatment 
decisions in conjunction with clinical expertise. In addition, predictions could be 
used to implement triage-based protocols for additional islet-autoantibody of 
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Appendix 1:  
R Code for creating diabetes 






## Create classification model shiny app   





# Define UI for application that returns a probability 
ui <- fluidPage( 
useShinyjs(), 
titlePanel("Type 1/Type 2 diabetes classification model BETA Version"), 
h4("This model is designed to differentiate type 1 from type 2 diabetes. If a 
diagnosis of monogenic diabetes is being considered please use the ", 
tags$a(href="https://www.diabetesgenes.org/mody-probability-calculator/", 
target="_blank", "MODY calculator")), 
h4("Please enter the age and BMI, other biomarkers are optional"), 
div(id="form", 
# Sidebar layout with a input and output definitions 
sidebarLayout( 
sidebarPanel( 
#Numeric input control for Age 
textInput(inputId = "age", label = "Enter age at diagnosis (yrs) (min 18, max 
50)", placeholder = "min is 18, max is 50" 
 ), 
h5(tags$strong("Enter BMI OR enter height and weight in boxes below, then 
press 'Use Height and Weight'")), 
# Set BMI using text box 
numericInput(inputId = "BMI",value = NULL,label = tags$div(HTML(paste("Enter 
BMI (kg/m",tags$sup(2),") (min 17.5, max 70)",sep =""))), min = 17.5, max = 70, 
step = 0.5),  
#inputs to calculate BMI if required 
#height 
textInput(inputId ="Height", label ="Height (cm)"), 
#weight 
textInput(inputId ="Weight", label = "Weight (kg)"), 
#allows the user to select BMI input type 





selectInput("Ethnicity", "Ethnicity: Model is currently only available for white-
ethnicities", choices = c("White-European")), 
radioButtons("GADA", "Select GADA status:", c("Positive" = "1", "Negative" = 
"0","Not tested" = ""), selected = ""),  
# Selector for choosing IA2 
radioButtons("IA2", "Select IA-2 status:", c("Positive" = "1", "Negative" = "0", 
"Not tested" = ""), selected = ""), 
#Numeric input control for T1D GRS 
textInput(inputId = "GRS",value = "", label = "Enter T1D GRS centile of type 1 
diabetes population*", placeholder = "Enter centile between 0 and 1" ), width = 
5), 
# Outputs 












conditionalPanel(condition =  "(input.GADA == '') && (input.IA2 == '') && 
(input.GRS =='')" ,textOutput("mod1Prob"),                    





condition =  "(input.GADA != '') && (input.IA2 == '') && (input.GRS =='')" , 
textOutput("mod2Prob"), 







conditionalPanel(condition =  "(input.GADA != '') && (input.IA2 != '') && 
(input.GRS =='')" , 
textOutput("mod3Prob"), 




conditionalPanel(condition =  "(input.GADA != '') && (input.IA2 != '') && 
(input.GRS !='')" , 
textOutput("mod4Prob"), 




conditionalPanel(condition =  "(input.GADA == '') && (input.IA2 != '') && 
(input.GRS=='')", 
textOutput("mod5Prob"), 




conditionalPanel( condition =  "(input.GADA == '') && (input.IA2 == '') && 
(input.GRS !='')", 
textOutput("mod8Prob"), 




conditionalPanel(condition =  "(input.GADA == '') && (input.IA2 != '') && 
(input.GRS !='')", 
textOutput("mod6Prob"), 







conditionalPanel(condition =  "(input.GADA != '') && (input.IA2 == '') && 
(input.GRS !='')", 
textOutput("mod7Prob"), 





tabPanel("Model information", paste("This model is designed to assist 
classification of diabetes in patients diagnosed aged 18 to 50. It was developed 
in a white UK population and therefore predictions may not be applicable to 
other populations. Type 1/type 2 diabetes is defined using a gold standard 
based on measured endogenous insulin secretion (C-peptide) and early insulin 
requirement (see diabetes definition tab). The development of the model is 
described in XXXX")), 
tabPanel("Diabetes definition", h5(" For model development diabetes type was 
defined as follows:",tags$br(), "Type 1 - Insulin requirement with 3 years of 
diagnosis and severe endogenous insulin deficiency (non-fasting C-peptide 
<200pmol/L)", tags$br(), "Type 2 - Absence of insulin requirement within 3 
years of diagnosis, or (where early insulin treatment) substantial retained 
endogenous insulin secretion after 5 years diabetes duration (non-fasting C-
peptide >600pmol/L)")) 
), 




h5("*Type 1 Diabetes Genetic Risk Score (30 SNP), Oram RA, Patel K, Hill A, 
Shields B, McDonald TJ, Jones A, Hattersley AT, Weedon MN: A Type 1 
diabetes genetic risk score can aid discrimination between Type 1 and Type 2 
diabetes in young adults. Diabetes care 2016;39:337-344") 
) 
# Define server function  
server <- function(input, output, session) { 
output$txt1 = renderText({ 





output$txt2 = renderText({ 
if(input$GADA =="1") { 
paste("GADA: Positive") 




output$txt3 = renderText({ 
if(input$IA2 =="1") { 
paste("IA-2: Positive") 




output$txt4 = renderText({ 
if (!(is.null(input$age)||input$age =='')){ 
paste("Age at diagnosis: ", input$age)} 
}) 
output$txt5 = renderText({ 
if(!(is.null(input$BMI)||input$BMI =='' ||is.na(input$BMI))){ 








output$txt6 = renderText({ 
if(input$GRS !=""){ 








updateNumericInput(session, "BMI", value = 
paste(round(as.numeric(input$Weight)/((as.numeric(input$Height)/100)^2),1))) 
output$txt7 = renderText({ 





==''||is.na(input$Height)) & !(is.null(input$Weight)||input$Weight 
==''||is.na(input$Weight)) & (round(input$BMI)) != 
round(as.numeric(input$Weight)/((as.numeric(input$Height)/100)^2))){ 




model1pred = function (){37.9391 + (-5.085444 *log(as.numeric(input$age))) + 
(-6.342471 * log(input$BMI)) 
} 
output$mod1Prob = renderText({ 
if (is.null(input$age)||input$age =='' ) { paste ("Please enter age between 18 and 
50 (inclusive)") 
} 
else if ((as.numeric(input$age)<18 || as.numeric(input$age)>50)){ paste("Please 
enter valid age, minimum age is 18, maximum is 50") 
} 
else if (is.null(input$BMI)||input$BMI ==''||is.na(input$BMI) ) { paste ("Please 
enter valid BMI OR use the height and weight inputs") 
} 
else if (input$BMI <17.5 || input$BMI >70) { paste ("Please enter valid BMI 
value, minimum BMI is 17.5, maximum is 70") 
} 
else {if (round((exp(model1pred())/(1+exp(model1pred())))*100)>99){ 

















model2pred = function () { -0.9833514 + (0.9433088*model1pred()) + ( 
3.113623*as.numeric(input$GADA)) 
}  
output$mod2Prob = renderText({if (is.null(input$age)||input$age =='' ) { paste 
("Please enter age between 18 and 50 (inclusive)") 
} 
else if ((as.numeric(input$age)<18 || as.numeric(input$age)>50)){ paste("Please 
enter valid age, minimum age is 18, maximum is 50") 
} 
else if (is.null(input$BMI)||input$BMI ==''||is.na(input$BMI) ) { paste ("Please 
enter valid BMI OR use the height and weight inputs") 
} 
else if (input$BMI <17.5 || input$BMI >70) { paste ("Please enter valid BMI 
value, minimum BMI is 17.5, maximum is 70") 
} 
else {if (round((exp(model2pred())/(1+exp(model2pred())))*100)>99) 
{paste("The probability of type 1 diabetes based on your selected inputs is > 
99%") 
} else if(round((exp(model2pred())/(1+exp(model2pred())))*100)<1){paste("The 
probability of type 1 diabetes based on your selected inputs is < 1%") 
}  
else {paste("The probability of type 1 diabetes based on your selected inputs 







AntiStatus1 = function () { 







AntiStatus2 = function (){ 







AntiStatus3 = function (){ 






model3pred = function (){ -1.280086  + (0.9166205*model1pred()) + (3.082366 
* AntiStatus1()) + (3.494462* AntiStatus2()) + (4.350717 * AntiStatus3()) 
} 
output$mod3Prob = renderText({ if (is.null(input$age)||input$age =='' )  
{paste ("Please enter age between 18 and 50 (inclusive)") 
} 
else if ((as.numeric(input$age)<18 || as.numeric(input$age)>50)){ paste("Please 





else if (is.null(input$BMI)||input$BMI =='' ||is.na(input$BMI)) { paste ("Please 
enter valid BMI OR use the height and weight inputs") 
} 
else if (input$BMI <17.5 || input$BMI >70) { paste ("Please enter valid BMI 
value, minimum BMI is 17.5, maximum is 70") 
} 
else {if (round((exp(model3pred())/(1+exp(model3pred())))*100)>99){ 




probability of type 1 diabetes based on your selected inputs is < 1%") 
}  
else {paste("The probability of type 1 diabetes based on your selected inputs 




model4pred = function (){-7.7859  + (0.8766028*model3pred()) + (30.11052 * 
(((qnorm(as.numeric(input$GRS) ))*0.025569)+0.278778)) 
} 
output$mod4Prob = renderText({if (is.null(input$age)||input$age =='' ) { paste 
("Please enter age between 18 and 50 (inclusive)") 
} 
else if ((as.numeric(input$age)<18 || as.numeric(input$age)>50)){ paste("Please 
enter valid age, minimum age is 18, maximum is 50") 
} 
else if (is.null(input$BMI)||input$BMI ==''||is.na(input$BMI) ) { paste ("Please 
enter valid BMI OR use the height and weight inputs") 
} 
else if (input$BMI <17.5 || input$BMI >70) { paste ("Please enter valid BMI 
value, minimum BMI is 17.5, maximum is 70") 
} 
else {if (round((exp(model4pred())/(1+exp(model4pred())))*100)>99){paste("The 
probability of type 1 diabetes based on your selected inputs is > 99%") 
}  
else if(round((exp(model4pred())/(1+exp(model4pred())))*100)<1){ paste("The 





else {paste("The probability of type 1 diabetes based on your selected inputs 




model5pred = function (){ -0.3553344 + (3.194096*as.numeric(input$IA2)) + 
(0.9916812*model1pred()) 
}  
output$mod5Prob = renderText({if (is.null(input$age)||input$age =='' ) { paste 
("Please enter age between 18 and 50 (inclusive)") 
} 
else if ((as.numeric(input$age)<18 || as.numeric(input$age)>50)){ paste("Please 
enter valid age, minimum age is 18, maximum is 50") 
} 
else if (is.null(input$BMI)||input$BMI ==''||is.na(input$BMI)) { paste ("Please 
enter valid BMI OR use the height and weight inputs") 
}     
else if (input$BMI <17.5 || input$BMI >70) { paste ("Please enter valid BMI 
value, minimum BMI is 17.5, maximum is 70") 
} 
else {if (round((exp(model5pred())/(1+exp(model5pred())))*100)>99){paste("The 
probability of type 1 diabetes based on your selected inputs is > 99%") 
}  
else if(round((exp(model5pred())/(1+exp(model51pred())))*100)<1){paste("The 
probability of type 1 diabetes based on your selected inputs is < 1%") 
}  
else {paste("The probability of type 1 diabetes based on your selected inputs 











output$mod6Prob = renderText({if (is.null(input$age)||input$age =='' ) { paste 
("Please enter age between 18 and 50 (inclusive)") 
} 
else if ((as.numeric(input$age)<18 || as.numeric(input$age)>50)){ paste("Please 
enter valid age, minimum age is 18, maximum is 50") 
} 
else if (is.null(input$BMI)||input$BMI =='' ||is.na(input$BMI)) { paste ("Please 
enter valid BMI OR use the height and weight inputs") 
} 
else if (input$BMI <17.5 || input$BMI >70) { paste ("Please enter valid BMI 
value, minimum BMI is 17.5, maximum is 70") 
} 
else {if (round((exp(model6pred())/(1+exp(model6pred())))*100)>99){paste("The 
probability of type 1 diabetes based on your selected inputs is > 99%") 
}  
else if(round((exp(model6pred())/(1+exp(model6pred())))*100)<1){paste("The 
probability of type 1 diabetes based on your selected inputs is < 1%") 
}  
else {paste("The probability of type 1 diabetes based on your selected inputs 
is", 








output$mod7Prob = renderText({if (is.null(input$age)||input$age =='' ) { paste 
("Please enter age between 18 and 50 (inclusive)") 
} 
else if ((as.numeric(input$age)<18 || as.numeric(input$age)>50)){ paste("Please 
enter valid age, minimum age is 18, maximum is 50") 
} 
else if (is.null(input$BMI)||input$BMI ==''||is.na(input$BMI)) { paste ("Please 





else if (input$BMI <17.5 || input$BMI >70) { paste ("Please enter valid BMI 
value, minimum BMI is 17.5, maximum is 70") 
} 
else {if (round((exp(model7pred())/(1+exp(model7pred())))*100)>99){ 




probability of type 1 diabetes based on your selected inputs is < 1%") 
}  
else {paste("The probability of type 1 diabetes based on your selected inputs 
is", 








output$mod8Prob = renderText({if (is.null(input$age)||input$age =='' ) { paste 
("Please enter age between 18 and 50 (inclusive)") 
} 
else if ((as.numeric(input$age)<18 || as.numeric(input$age)>50)){ paste("Please 
enter valid age, minimum age is 18, maximum is 50") 
}     
else if (is.null(input$BMI)||input$BMI =='' ||is.na(input$BMI)) { paste ("Please 
enter valid BMI OR use the height and weight inputs") 
}     
else if (input$BMI <17.5 || input$BMI >70) { paste ("Please enter valid BMI 
value, minimum BMI is 17.5, maximum is 70") 
} 
else {if (round((exp(model8pred())/(1+exp(model8pred())))*100)>99){paste("The 
probability of type 1 diabetes based on your selected inputs is > 99%") 
}  
else if(round((exp(model8pred())/(1+exp(model8pred())))*100)<1){paste("The 





else {paste("The probability of type 1 diabetes based on your selected inputs 
is", round((exp(model8pred())/(1+exp(model8pred())))*100), "%") 
}  
}   
}) 
} 
# Create the Shiny app object 






Appendix 2:  
R Code for machine learning 







## Create combined machine learning comparison  
## original author - ferratlauric@gmail.com - September 2018 
## adapted by Anita Lynam - g26482@hotmail.co.uk - July 2019 
############################################################# 
























































library(dplyr) # for data manipulation 
library(purrr) # for functional programming (map) 











setwd("Your file path here") 
#name the data files 
dataFile1 <- "Your stata test data file.dta" 
dataFile2 <- "Your stata validation.dta" 
#load Stata datasets 
dataset_test <- read.dta13(dataFile1) 
dataset_val <-  read.dta13(dataFile2) 
#create a datset containing a subset of variables to include in the model 
myvars <- c("Your outcome variable","Your covariate 1","Your covariate 
2","Your covariate 3")   
dataset_test <- dataset_test[myvars] 
############################## 
# 2 - Set up the model training  
############################## 
#set seed for reproductivity 
seedchoice <- 7  
# model formulas 
# Add as many covariates as required 
formula.model4 <- formula("Your outcome variable ~ Your covariate 1 + Your 
covariate 2 + Your covariate3 + ....") 
# Data need to be put in a good shape to be used in the caret framework: 
# factorise string data and mumeric data which need to be factorised 
# no missing data (always possible to impute when it is not the case) 
#identify factor variables and view the levels 
is.fact2 <- sapply(dataset_test, is.factor) 
factors2.df <- dataset_test[, is.fact2] 
lapply(factors2.df, levels) 
is.fact3 <- sapply(dataset_val, is.factor) 
factors3.df <- dataset_val[, is.fact3] 
lapply(factors3.df, levels) 
#amend class to factor for training and validation datasets 
Yourcovariate3 <- myvars[4] 
Youroutcomevariable <- myvars[1] 






dataset_val[,Yourcovariate3] <- as.factor(dataset_val[,Yourcovariate3]) 
dataset_val[,Youroutcomevariable] <- 
as.factor(dataset_val[,Youroutcomevariable]) 
#rename the levels of the facor variable. This is required to run the training 
models for each of the five imputed datasets 
feature6.names <- names(dataset_test) 
for (f in feature6.names)  { 
  if (class(dataset_test[[f]]) == "factor")  { 
    levels6 <- unique(c(dataset_test[[f]])) 
    dataset_test[[f]] <- factor(dataset_test[[f]], 
                                labels = make.names(levels6)) 
        } 
} 
feature7.names <- names(dataset_val) 
for (f in feature7.names)  { 
  if (class(dataset_val[[f]]) == "factor")  { 
    levels7 <- unique(c(dataset_val[[f]])) 
    dataset_val[[f]] <- factor(dataset_val[[f]], 
                               labels = make.names(levels7)) 
        } 
} 
#create standardised variables for the continuous variables 
Yourcovariate1 <- myvars[2] 
Yourcovariate2 <- myvars[3] 
Std_Yourcovariate1 <- paste0("Std_",Yourcovariate1) 
Std_Yourcovariate2 <- paste0("Std_",Yourcovariate2) 
 
dataset_test[,Std_Yourcovariate1] <- (dataset_test[,Yourcovariate1] - 
mean(dataset_test[,Yourcovariate1]))/sd(dataset_test[,Yourcovariate1])   
dataset_test[,Std_Yourcovariate2] <- (dataset_test[,Yourcovariate2] - 
mean(dataset_test[,Yourcovariate2]))/sd(dataset_test[,Yourcovariate2]) 





dataset_val[,Std_Yourcovariate2] <- (dataset_val[,Yourcovariate2] - 
mean(dataset_val[,Yourcovariate2]))/sd(dataset_val[,Yourcovariate2]) 
# prepare training scheme  
#routines, fits each model and calculates a resampling based performance 
measure. 
# The traincontrol function controls the computational nuances of the train 
function 
# repeatedcv (repeated cross validation) method is a resampling method 
Control that creates multiple versions of the folds and aggregates the results 
# number is the k number of folds for the repeatedcv 
# repeats is the number of complete sets of folds to compute 
# The summmary funcion is a function to compute performance metrics across 
resamples.  
# twoClassSummary computes sensitivity, specificity and the area under the 
ROC curve 
# sampling is the type of additional sampling that is conducted after resampling  
# (usually to resolve class imbalances).  
# SMOTE (Chawla et. al. 2002) is a well-known algorithm to fight unbalanced 
classification problem.  
# The general idea of this method is to artificially generate new examples of the 
minority class using  
# the nearest neighbors of these cases. Furthermore, the majority class 
examples are also under-sampled,  
# leading to a more balanced dataset. 
#for use in default and grid search optimised models 
control <- trainControl(method = "repeatedcv", number = 10, repeats = 
5,classProbs = TRUE,summaryFunction = twoClassSummary, sampling = 
"smote", savePredictions = TRUE) 
#for use in random search optimised models 
control_Rand_Search <- trainControl(method = "repeatedcv", number = 10, 
repeats = 5,classProbs = TRUE,summaryFunction = twoClassSummary, 
sampling = "smote", savePredictions = TRUE, search = "random") 
############################## 
# 3 - Train the models  
############################## 
# The train function sets up a grid of tuning parameters for a number of 
classification and regression  




# train the Gradient bootstrap Machine model (Stochastic Gradient Boosting) 
# utils::browseVignettes("gbm") 
# verbose is an argument of the gmb package, indicating whether or not to print 
out progress and  
# performance indicators 
#build all the Gbm (Stochastic gradient boosting model) models 
#tuning parameters: n.trees (number of  iterations), interaction depth 
(complexity), shrinkage (learning rate), n.minobsinnode (min number of training 
det damples in a node to commence splitting) 
#learning rate shrinks the contribution of each tree by learning_rate 
getModelInfo()$gbm$parameters 
#Shrinkage: the smaller the number, the better the predictive value, the more 
trees required, and the more computational cost. 
#the smaller the shrinkage, the more trees you should have 
# Fetch max Value for interaction.depth  
floor(sqrt(NCOL(dataset_test))) 
#set up the grid 
gbmGrid <-  expand.grid(interaction.depth = c(1, 3, 6, 9, 10), 
                        n.trees = c(10, 50,100,150,500),  
                        shrinkage = seq(from = 0.01, to = 0.1, by = 0.01), 
                        n.minobsinnode = c(5,10,15,20))  
#tune the hyper-parameters using  Grid Search 
set.seed(seedchoice) 
modelGbm_CC_GADA_Lr <- train(formula.model4, data = dataset_test, method 
= "gbm", trControl = control, verbose = FALSE,metric = 
'ROC',tuneGrid=gbmGrid) 
#random search independently draws from a uniform density from the same 
configuration space as would be spanned by a regular grid, 
#we do not use random hyperparameter search for gbm models as it may be 
inefficients  
# train the SVM model 
# Support Vector Machines with Radial Basis Function Kernel (SVM classifier 
using a non-linear kernel) 
#RBF is a reasonable first choice, it can handle nonlinear relationships 
#C is the penalty parameter of the error term. It controls the trade off between 




#larger values of C focus attention more on (correctly classified) points near the 
decision boundary (wiggly boundary), while smaller values involve data further 
away (wider margins). 
#sigma the radius/spread/decision boundary of the kernel 
#When gamma is low, the 'curve' of the decision boundary is very low and thus 
the decision region is very broad.  
#When gamma is high, the 'curve' of the decision boundary is high, which 
creates islands of decision-boundaries around data points. 
#using training dataset and default parameters 
getModelInfo()$svmRadial$parameters 
svmGrid <-  expand.grid(sigma = c(0.01, 0.1, 1, 10, 100), 
                        C = seq(from = 0.1, to = 1, by = 0.05))  
#using training dataset and tune the hyper-parameters using Caret Grid Search 
set.seed(seedchoice) 
modelSvm_CC_GADA_Lr <- train(formula.model4, data = dataset_test, method 
= "svmRadial", trControl = control, verbose = TRUE,metric = 
'ROC',tuneGrid=svmGrid) 
# train the Random forest model 
#parameter mtry is the number of variables available for splitting at each tree 
node 
#The default is the square root of the number of predictor variables (rounded 
down) 
#as we are only using three variables we do not optimise the parameters 




#using training dataset and default parameters 
set.seed(seedchoice) 
modelRf_CC_GADA <- train(formula.model4, data = dataset_test, method = 'rf', 
trControl = control,metric = 'ROC') 
# train a logistic regression model 
#using training dataset 
#there are no tuning parameters for glm method within caret 
set.seed(seedchoice) 
modelLG_CC_GADA <- train(formula.model4, data = dataset_test, method = 
"glm", family = "binomial", trControl = control,metric = 'ROC') 





#size parameter is the number of units in hidden layer (nnet fit a single hidden 
layer neural network)  
#decay parameter is the regularization parameter to avoid over-fitting 
nnetGrid <-  expand.grid(size = seq(from = 1, to = 10, by = 1), decay = c(0.5, 
0.1, 0.01, 0.001, 0.0001, 0.00001, 0.000001, 0.0000001)) 
#tune the hyper-parameters using Caret Grid Search 
set.seed(seedchoice) 
modelnnet_CC_GADA_Lr <- train(formula.model4, data = dataset_test, method 
= "nnet", trControl = control,metric = 'ROC', tuneGrid = nnetGrid) 
# train a k-nearest-neighbours 
#based on euclidean distance 
getModelInfo()$knn$parameters 
#k parameter is the number of neighbours.  
knnGrid <-  expand.grid(k = seq(from = 1, to = 100, by = 1)) 
#tune the hyper-parameters using Caret Grid Search 
set.seed(seedchoice) 
modelknn_CC_GADA_Lr <- train(formula.model4, data = dataset_test, method 
= "knn", trControl = control,metric = 'ROC', tuneGrid = knnGrid) 







# collect resamples 
#compare the models for the CC existing GADA model (hyperparameter grid 
search) for comparison 
#no grid search for RF or LG models 
results_grid_CC_GADA <- resamples(list(LogisticRegression = 
modelLG_CC_GADA, StochasticGradientBoosting = 
modelGbm_CC_GADA_Lr, SupportVectorMachine = modelSvm_CC_GADA_Lr, 
NeuralNetwork = modelnnet_CC_GADA_Lr,RandomForest = 






#check character string for the performance measure used to sort or computing 
the between-model correlations 
results_grid_CC_GADA$metrics 
#visualizing resampling results across models 
xyplot(results_grid_CC_GADA, what = "BlandAltman") 
# boxplots of results and save as pdf 
pdf("Your file name.pdf") 
bwplot(results_grid_CC_GADA) 
dev.off() 
# dot plots of results (includes 95% CI) 
# average performance value (with two-sided confidence limits) for each model 
pdf("Your file name.pdf") 
dotplot(results_grid_CC_GADA) 
dev.off() 
#trellis scatterplot of results 
pdf("Your file name.pdf") 
splom(results_grid_CC_GADA) 
dev.off() 
#test for a difference in the average resampled area under the ROC curve 
diffs <- diff(results_grid_CC_GADA, metric = "ROC") 
summary(diffs) 
#calculate the 95% CI for the resampling ROC AUC 
test  <- results_grid_CC_GADA$values 
 
m <- mean(test$`RandomForest~ROC`) 
s <- sd(test$`RandomForest~ROC`) 
l <- length(test$`RandomForest~ROC`) 
m+c(-1.96,1.96)*s/sqrt(length(l)) 
 
m <- mean(test$`LogisticRegression~ROC`) 
s <- sd(test$`LogisticRegression~ROC`) 
l <- length(test$`LogisticRegression~ROC`) 





m <- mean(test$`StochasticGradientBoosting~ROC`) 
s <- sd(test$`StochasticGradientBoosting~ROC`) 
l <- length(test$`StochasticGradientBoosting~ROC`) 
m + (c(-1.96,1.96)*(s/sqrt(length(l)))) 
 
m <- mean(test$`SupportVectorMachine~ROC`) 
s <- sd(test$`SupportVectorMachine~ROC`) 
l <- length(test$`SupportVectorMachine~ROC`) 
m + (c(-1.96,1.96)*(s/sqrt(length(l)))) 
 
m <- mean(test$`NeuralNetwork~ROC`) 
s <- sd(test$`NeuralNetwork~ROC`) 
l <- length(test$`NeuralNetwork~ROC`) 
m + (c(-1.96,1.96)*(s/sqrt(length(l)))) 
 
m <- mean(test$`KNearestNeighbours~ROC`) 
s <- sd(test$`KNearestNeighbours~ROC`) 
l <- length(test$`KNearestNeighbours~ROC`) 
m + (c(-1.96,1.96)*(s/sqrt(length(l)))) 
################################# 
# 4 - Perform external validation  
################################# 
#for the Gbm grid search model (validation) 
probsTestGbmGridVal <- predict(modelGbm_CC_GADA_Lr, 
newdata=dataset_val, type = "prob") 
dataset_val <- data.frame(dataset_val,probsTestGbmGridVal$X2) 
predTestGbmGridVal <- log(as.numeric(probsTestGbmGridVal$X2)/(1-
as.numeric(probsTestGbmGridVal$X2))) 
#then create a roc object and calculate the ROC on the validation dataset 
roc_objTestGbmGridval <- roc(dataset_val[,Youroutcomevariable], 
predTestGbmGridVal) 






#for the Svm grid search model (validation) 
probsTestSvmGridVal <- predict(modelSvm_CC_GADA_Lr, 
newdata=dataset_val, type = "prob") 
dataset_val <- data.frame(dataset_val,probsTestSvmGridVal$X2) 
predTestSvmGridVal <- log(as.numeric(probsTestSvmGridVal$X2)/(1-
as.numeric(probsTestSvmGridVal$X2))) 
#then create a roc object and calculate the ROC on the validation dataset 
roc_objTestSvmGridval <- roc(dataset_val[,Youroutcomevariable], 
predTestSvmGridVal) 
AUC_objTestSvmGridval <- auc(roc_objTestSvmGridval) 
AUC_objTestSvmGridval 
ci.auc(roc_objTestSvmGridval) 
#for the knn grid search model (validation) 
probsTestknnGridVal <- predict(modelknn_CC_GADA_Lr, 
newdata=dataset_val, type = "prob") 
dataset_val <- data.frame(dataset_val,probsTestknnGridVal$X2) 
probsTestknnGridVal$X2[probsTestknnGridVal$X2 == 1] <- 0.999999 
probsTestknnGridVal$X2[probsTestknnGridVal$X2 == 0] <- 0.000001 
predTestknnGridVal <- log(as.numeric(probsTestknnGridVal$X2)/(1-
as.numeric(probsTestknnGridVal$X2))) 
#then create a roc object and calculate the ROC on the validation dataset 
roc_objTestknnGridval <- roc(dataset_val[,Youroutcomevariable], 
predTestknnGridVal) 
AUC_objTestknnGridval <- auc(roc_objTestknnGridval) 
AUC_objTestknnGridval 
ci.auc(roc_objTestknnGridval) 
#for the nnet grid search model (validation) 
probsTestnnetGridVal <- predict(modelnnet_CC_GADA_Lr, 
newdata=dataset_val, type = "prob") 
dataset_val <- data.frame(dataset_val,probsTestnnetGridVal$X2) 
predTestnnetGridVal <- log(as.numeric(probsTestnnetGridVal$X2)/(1-
as.numeric(probsTestnnetGridVal$X2))) 
#then create a roc object and calculate the ROC on the validation dataset 





AUC_objTestnnetGridval <- auc(roc_objTestnnetGridval) 
AUC_objTestnnetGridval 
ci.auc(roc_objTestnnetGridval) 
#for the RF model (validation) 
probsTestRfVal <- predict(modelRf_CC_GADA, newdata=dataset_val, type = 
"prob") 
dataset_val <- data.frame(dataset_val,probsTestRfVal$X2) 
probsTestRfVal$X2[probsTestRfVal$X2 == 1] <- 0.999999 
probsTestRfVal$X2[probsTestRfVal$X2 == 0] <- 0.000001 
predTestRfVal <- log(as.numeric(probsTestRfVal$X2)/(1-
as.numeric(probsTestRfVal$X2))) 
#then create a roc object and calculate the ROC on the validation dataset 
roc_objTestRfval <- roc(dataset_val[,Youroutcomevariable], predTestRfVal) 
AUC_objTestRfval <- auc(roc_objTestRfval) 
AUC_objTestRfval 
ci.auc(roc_objTestRfval) 
#for the logistic regression model (validation) 
probsTestlgVal <- predict(modelLG_CC_GADA, newdata=dataset_val, type = 
"prob") 
dataset_val <- data.frame(dataset_val,probsTestlgVal$X2) 
predTestLGVal <- log(as.numeric(probsTestlgVal$X2)/(1-
as.numeric(probsTestlgVal$X2))) 
#then create a roc object and calculate the ROC on the validation dataset 
roc_objTestLGval <- roc(dataset_val[,Youroutcomevariable], predTestLGVal) 
AUC_objTestLGval <- auc(roc_objTestLGval) 
AUC_objTestLGval 
ci.auc(roc_objTestLGval) 
#plot the roc curves 
plot(roc_objTestRfval, col = "gray85",main = "",add=FALSE) 
plot(roc_objTestLGval, col = "gray45", add = TRUE) 
plot(roc_objTestSvmGridval, co = "black", add = TRUE) 
plot(roc_objTestGbmGridval, col = "gray85",  lty = 3, add = TRUE) 
plot(roc_objTestnnetGridval, col = "black",lty = 3, add = TRUE) 





AUC <- c(AUC_objTestLGval, AUC_objTestGbmGridval, 
AUC_objTestSvmGridval, AUC_objTestRfval, AUC_objTestnnetGridval, 
AUC_objTestknnGridval) 
ValResults <- data.frame(model, AUC) 
#use prediction-recall curve to validate the models 
#calculate the AUPRC for the validation dataset 
prRFVal <- pr.curve(1-
dataset_val$probsTestRfVal.X2,dataset_val$probsTestRfVal.X2, curve = 
TRUE) 
prLGVal <-  pr.curve(1-
dataset_val$probsTestlgVal.X2,dataset_val$probsTestlgVal.X2, curve = TRUE)  
prSVMVal <- pr.curve(1-
dataset_val$probsTestSvmGridVal.X2,dataset_val$probsTestSvmGridVal.X2, 
curve = TRUE)  
prGBMVal <- pr.curve(1-
dataset_val$probsTestGbmGridVal.X2,dataset_val$probsTestGbmGridVal.X2, 
curve = TRUE)  
prNNVal <- pr.curve(1-
dataset_val$probsTestnnetGridVal.X2,dataset_val$probsTestnnetGridVal.X2, 
curve = TRUE) 
prKNNVal <- pr.curve(1-
dataset_val$probsTestknnGridVal.X2,dataset_val$probsTestknnGridVal.X2, 
curve = TRUE) 







# plot PR curve for the test curve in red, without legend 
plot(prRFVal, color = "gray85",auc.main=FALSE, main = "")  
plot( prLGVal, color = "gray45", add = TRUE) 
plot( prSVMVal, color = "black", add = TRUE) 
plot( prGBMVal, color = "gray85", lty = 3, add = TRUE) 
plot( prNNVal, color = "black", lty = 3, add = TRUE) 




#plot the calibration plots with loess smoother  
#for logistic regression 
#create 10 risk groups 
dataset_val %>% mutate(quintile=ntile(dataset_val$probsTestlgVal.X2,10)) -> 
dataset_val_10 
Youroutcomevariable_num <- paste(Youroutcomevariable,"num") 
dataset_val_10[as.numeric(dataset_val_10[,Youroutcomevariable])== 
1,Youroutcomevariable_num] <- 0 
dataset_val_10[as.numeric(dataset_val_10[,Youroutcomevariable])== 
2,Youroutcomevariable_num] <- 1 
#average the observed and expected probabilities of patients in each risk group  
obs <- aggregate(as.numeric(dataset_val_10[,Youroutcomevariable_num]), 
list(dataset_val_10$quintile),mean) 
exptd <- aggregate(dataset_val_10$probsTestlgVal.X2, 
list(dataset_val_10$quintile),mean) 
obsn <- aggregate(as.formula(paste0(Youroutcomevariable ,"~ quintile")), 
dataset_val_10, length) 
#CIs for scatter points 
lci <- obs - (1.96*(((obs*(1-obs))/obsn[,Youroutcomevariable])^.5)) 
lci[lci<0]<- 0 
uci <- obs + (1.96*(((obs*(1-obs))/obsn[,Youroutcomevariable])^.5)) 
uci[uci>1]<- 1 
LR_Cali_Plot = data.frame(exptd$x,obs$x, uci$x, lci$x) 
ggplot(LR_Cali_Plot, aes(x= exptd$x, y=obs$x)) + 
   geom_point(size = 2) +  
   geom_smooth(method=loess, se=FALSE, col = "black", lwd = 1) + 
  geom_abline(slope=1, intercept=0, lty=2 ) + 
 scale_x_continuous(name = "Expected", breaks = c(0.0, 
0.2,0.4,0.6,0.8,1.0),limits = c(0,1)) + 
scale_y_continuous(name = "Observed", breaks = c(0.0, 
0.2,0.4,0.6,0.8,1.0),limits = c(0,1)) + 
   geom_errorbar(aes(ymin=lci$x, ymax=uci$x), width=0.02) + 
   theme_bw() 
#for SVM 








== 1,Youroutcomevariable_num] <- 0 
dataset_val_10_SVM[as.numeric(dataset_val_10_SVM[,Youroutcomevariable])
== 2,Youroutcomevariable_num] <- 1 




exptd_SVM <- aggregate(dataset_val_10_SVM$probsTestSvmGridVal.X2, 
list(dataset_val_10_SVM$quintile),mean) 
obsn_SVM <- aggregate(as.formula(paste0(Youroutcomevariable ,"~ quintile")), 
dataset_val_10_SVM, length) 
#CIs for scatter points 
lci_SVM <- obs_SVM- (1.96*(((obs_SVM*(1-
obs_SVM))/obsn_SVM[,Youroutcomevariable])^.5)) 
lci_SVM[lci_SVM<0]<- 0 
uci_SVM <- obs_SVM + (1.96*(((obs_SVM*(1-
obs_SVM))/obsn_SVM[,Youroutcomevariable])^.5)) 
uci_SVM[uci_SVM>1]<- 1 
SVM_Cali_Plot <- data.frame(exptd_SVM$x,obs_SVM$x, uci_SVM$x, 
lci_SVM$x) 
ggplot(SVM_Cali_Plot, aes(x= exptd_SVM$x, y=obs_SVM$x)) + 
   geom_point(size = 2) +  
   geom_smooth(method=loess, se=FALSE, col = "black", lwd = 1) + 
   geom_abline(slope=1, intercept=0, lty=2 ) + 
scale_x_continuous(name = "Expected", breaks = c(0.0, 
0.2,0.4,0.6,0.8,1.0),limits = c(0,1)) + 
scale_y_continuous(name = "Observed", breaks = c(0.0, 
0.2,0.4,0.6,0.8,1.0),limits = c(0,1)) + 
   geom_errorbar(aes(ymin=lci_SVM$x, ymax=uci_SVM$x), width=0.02) + 
   theme_bw() 
#for Random Forest     
#create 10 risk groups 






1,Youroutcomevariable_num] <- 0 
dataset_val_10_RF[as.numeric(dataset_val_10_RF[,Youroutcomevariable])== 
2,Youroutcomevariable_num] <- 1 




exptd_RF <- aggregate(dataset_val_10_RF$probsTestRfVal.X2, 
list(dataset_val_10_RF$quintile),mean) 
obsn_RF <- aggregate(as.formula(paste0(Youroutcomevariable ,"~ quintile")), 
dataset_val_10_RF, length) 
#CIs for scatter points 
lci_RF <- obs_RF- (1.96*(((obs_RF*(1-
obs_RF))/obsn_RF[,Youroutcomevariable])^.5)) 
lci_RF[lci_RF<0]<- 0 
uci_RF = obs_RF + (1.96*(((obs_RF*(1-
obs_RF))/obsn_RF[,Youroutcomevariable])^.5)) 
uci_RF[uci_RF>1]<- 1 
RF_Cali_Plot <- data.frame(exptd_RF$x,obs_RF$x, uci_RF$x, lci_RF$x) 
ggplot(RF_Cali_Plot, aes(x= exptd_RF$x, y=obs_RF$x)) + 
   geom_point(size = 2) +  
   geom_smooth(method=loess, se=FALSE, col = "black", lwd = 1) + 
   geom_abline(slope=1, intercept=0, lty=2 ) + 
scale_x_continuous(name = "Expected", breaks = c(0.0, 
0.2,0.4,0.6,0.8,1.0),limits = c(0,1)) + 
scale_y_continuous(name = "Observed", breaks = c(0.0, 
0.2,0.4,0.6,0.8,1.0),limits = c(0,1)) + 
   geom_errorbar(aes(ymin=lci_RF$x, ymax=uci_RF$x), width=0.02) + 
   theme_bw() 
#for GBM    










== 2,Youroutcomevariable_num] <- 1 




exptd_GBM <- aggregate(dataset_val_10_GBM$probsTestGbmGridVal.X2, 
list(dataset_val_10_GBM$quintile),mean) 
obsn_GBM <- aggregate(as.formula(paste0(Youroutcomevariable ,"~ quintile")), 
dataset_val_10_GBM, length) 
#CIs for scatter points 
lci_GBM <- obs_GBM- (1.96*(((obs_GBM*(1-
obs_GBM))/obsn_GBM[,Youroutcomevariable])^.5)) 
lci_GBM[lci_GBM<0]<- 0 
uci_GBM <- obs_GBM + (1.96*(((obs_GBM*(1-
obs_GBM))/obsn_GBM[,Youroutcomevariable])^.5)) 
uci_GBM[uci_GBM>1]<-1 
GBM_Cali_Plot = data.frame(exptd_GBM$x,obs_GBM$x, uci_GBM$x, 
lci_GBM$x) 
ggplot(GBM_Cali_Plot, aes(x= exptd_GBM$x, y=obs_GBM$x)) + 
   geom_point(size = 2) +  
   geom_smooth(method=loess, se=FALSE, col = "black", lwd = 1) + 
   geom_abline(slope=1, intercept=0, lty=2 ) + 
scale_x_continuous(name = "Expected", breaks = c(0.0, 
0.2,0.4,0.6,0.8,1.0),limits = c(0,1)) + 
scale_y_continuous(name = "Observed", breaks = c(0.0, 
0.2,0.4,0.6,0.8,1.0),limits = c(0,1)) + 
   geom_errorbar(aes(ymin=lci_GBM$x, ymax=uci_GBM$x), width=0.02) + 
   theme_bw() 
#for KNN   





== 1,Youroutcomevariable_num] <- 0 
dataset_val_10_KNN[as.numeric(dataset_val_10_KNN[,Youroutcomevariable])








exptd_KNN <- aggregate(dataset_val_10_KNN$probsTestknnGridVal.X2, 
list(dataset_val_10_KNN$quintile),mean) 
obsn_KNN <- aggregate(as.formula(paste0(Youroutcomevariable ,"~ quintile")), 
dataset_val_10_KNN, length) 
#CIs for scatter points 
lci_KNN <- obs_KNN- (1.96*(((obs_KNN*(1-
obs_KNN))/obsn_KNN[,Youroutcomevariable])^.5)) 
lci_KNN[lci_KNN<0]<- 0 
uci_KNN = obs_KNN + (1.96*(((obs_KNN*(1-
obs_KNN))/obsn_KNN[,Youroutcomevariable])^.5)) 
uci_KNN[uci_KNN>1]<- 1 
KNN_Cali_Plot <- data.frame(exptd_KNN$x,obs_KNN$x, uci_KNN$x, 
lci_KNN$x) 
ggplot(KNN_Cali_Plot, aes(x= exptd_KNN$x, y=obs_KNN$x)) + 
   geom_point(size = 2) +  
   geom_smooth(method=loess, se=FALSE, col = "black", lwd = 1) + 
   geom_abline(slope=1, intercept=0, lty=2 ) + 
scale_x_continuous(name = "Expected", breaks = c(0.0, 
0.2,0.4,0.6,0.8,1.0),limits = c(0,1)) + 
scale_y_continuous(name = "Observed", breaks = c(0.0, 
0.2,0.4,0.6,0.8,1.0),limits = c(0,1)) + 
   geom_errorbar(aes(ymin=lci_KNN$x, ymax=uci_KNN$x), width=0.02) + 
   theme_bw() 
#for NN   





1,Youroutcomevariable_num] <- 0 
dataset_val_10_NN[as.numeric(dataset_val_10_NN[,Youroutcomevariable])== 
2,Youroutcomevariable_num] <- 1 







exptd_NN <- aggregate(dataset_val_10_NN$probsTestnnetGridVal.X2, 
list(dataset_val_10_NN$quintile),mean) 
obsn_NN <- aggregate(as.formula(paste0(Youroutcomevariable ,"~ quintile")), 
dataset_val_10_NN, length) 
#CIs for scatter points 
lci_NN <- obs_NN- (1.96*(((obs_NN*(1-
obs_NN))/obsn_NN[,Youroutcomevariable])^.5)) 
lci_NN[lci_NN<0]<- 0 
uci_NN <- obs_NN + (1.96*(((obs_NN*(1-
obs_NN))/obsn_NN[,Youroutcomevariable])^.5)) 
uci_NN[uci_NN>1]<- 1 
NN_Cali_Plot <- data.frame(exptd_NN$x,obs_NN$x, uci_NN$x, lci_NN$x) 
ggplot(NN_Cali_Plot, aes(x= exptd_NN$x, y=obs_NN$x)) + 
   geom_point(size = 2) +  
   geom_smooth(method=loess, se=FALSE, col = "black", lwd = 1) + 
   geom_abline(slope=1, intercept=0, lty=2 ) + 
scale_x_continuous(name = "Expected", breaks = c(0.0, 
0.2,0.4,0.6,0.8,1.0),limits = c(0,1)) + 
scale_y_continuous(name = "Observed", breaks = c(0.0, 
0.2,0.4,0.6,0.8,1.0),limits = c(0,1)) + 
   geom_errorbar(aes(ymin=lci_NN$x, ymax=uci_NN$x), width=0.02) + 
   theme_bw() 
#calcluate Calibration slope for each model 
glm(formula(paste0(Youroutcomevariable," ~ predTestGbmGridVal")), 
family=binomial, data=dataset_val) 
glm(formula(paste0(Youroutcomevariable," ~ predTestSvmGridVal")), 
family=binomial, data=dataset_val) 
glm(formula(paste0(Youroutcomevariable," ~ predTestknnGridVal")), 
family=binomial, data=dataset_val) 
glm(formula(paste0(Youroutcomevariable," ~ predTestnnetGridVal")), 
family=binomial, data=dataset_val) 
glm(formula(paste0(Youroutcomevariable," ~ predTestRfVal")), family=binomial, 
data=dataset_val) 





#calcluate Calibration in the large for each model 
#predicted risks are understated if _b[_cons] > 0 or overstated if _b[_cons] < 0 
glm(formula(paste0(Youroutcomevariable," ~  offset(predTestGbmGridVal)")), 
family=binomial, data=dataset_val) 
glm(formula(paste0(Youroutcomevariable," ~  offset(predTestSvmGridVal)")), 
family=binomial, data=dataset_val) 
glm(formula(paste0(Youroutcomevariable," ~  offset(predTestknnGridVal)")), 
family=binomial, data=dataset_val) 
glm(formula(paste0(Youroutcomevariable," ~  offset(predTestnnetGridVal)")), 
family=binomial, data=dataset_val) 
glm(formula(paste0(Youroutcomevariable," ~  offset(predTestRfVal)")), 
family=binomial, data=dataset_val) 
glm(formula(paste0(Youroutcomevariable," ~  offset(predTestLGVal)")), 
family=binomial, data=dataset_val) 
#calcluate overall misCalibration for each model 
#the slope coefficient beta of the linear predictors reflects the deviations from 
the ideal slope of 1.  
#If p is significant then there is deviation from zero 
mc1 <- glm(formula(paste0(Youroutcomevariable," ~  predTestGbmGridVal+ 
offset(predTestGbmGridVal)")), family=binomial, data=dataset_val) 
mc2 <- glm(formula(paste0(Youroutcomevariable," ~  predTestSvmGridVal + 
offset(predTestSvmGridVal)")), family=binomial, data=dataset_val) 
mc3 <- glm(formula(paste0(Youroutcomevariable," ~  predTestknnGridVal + 
offset(predTestknnGridVal)")), family=binomial, data=dataset_val) 
mc4 <- glm(formula(paste0(Youroutcomevariable," ~  predTestnnetGridVal + 
offset(predTestnnetGridVal)")), family=binomial, data=dataset_val) 
mc5 <- glm(formula(paste0(Youroutcomevariable," ~  predTestRfVal + 
offset(predTestRfVal)")), family=binomial, data=dataset_val) 
mc6 <- glm(formula(paste0(Youroutcomevariable," ~  predTestLGVal + 











predMatrixVal <- data.frame(dataset_val$probsTestGbmGridVal.X2 









MVal <- cor(predMatrixVal) 
corrplot(MVal, method="number",tl.cex = 1) 
#create a variable importance dataframe 
# Svm and KNN do not have built-in variable importance score 
Model <- c('Logistic Regression','Stochastic Gradient Boosting', 'Neural 
Network', 'Random Forest') 
# calculate the variable importance scores 
# varImp function provides the variable importance 
LGImp <- varImp(modelLG_CC_GADA, scale = FALSE) 
LGImp 
gmbImp <- varImp(modelGbm_CC_GADA_Lr, scale = FALSE) 
gmbImp 
nnetImp <- varImp(modelnnet_CC_GADA_Lr, scale = FALSE) 
nnetImp 
rfImp <- varImp(modelRf_CC_GADA, scale = FALSE) 
rfImp 
#manually divide each variable importance scores by max to scale 
Yourcovariate1 <- c(insert your variance importance scores here) 
Yourcovariate2 <- c(insert your variance importance scores here) 
Yourcovariate3 <- c(insert your variance importance scores here) 
#build the DF with the scaled variable importance scores 
varImpDF = data.frame(Model,Yourcovariate1,Yourcovariate2,Yourcovariate3) 
#build the plots of the variable importance ranks 





coord_flip()+ ylab("Scaled variable importance score")+  xlab("") + ggtitle("Your 
covariate 1") + scale_y_continuous(expand = c(0, 0)) +theme(axis.text.y = 
element_blank(),axis.ticks.y = element_blank() ) 
plotVarImp2 <- ggplot(data = varImpDF, aes(x = Model, y = 
varImpDF$Yourcovariate2))+geom_bar(stat="identity",width=0.06)+ 
coord_flip()+ ylab("Scaled variable importance score")+ xlab("") + ggtitle("Your 
covariate 2") + scale_y_continuous(expand = c(0, 0)) +theme(axis.text.y = 
element_blank(),axis.ticks.y = element_blank() ) 
plotVarImp3 <- ggplot(data = varImpDF, aes(x = Model, y = 
varImpDF$Yourcovariate3))+geom_bar(stat="identity",width=0.06)+ 
coord_flip()+ ylab("Scaled variable importance score")+  xlab("") + ggtitle("Your 
covariate 3") + scale_y_continuous(expand = c(0, 0)) +theme(axis.text.y = 
element_blank(),axis.ticks.y = element_blank() ) 





grid.arrange(plotVarImp1, plotVarImp2, plotVarImp3,ncol = 3) 
################################# 
# 5 - save the objects for future use 
################################# 
save(dataset_test,dataset_val,ValResults,control,modelLG_CC_GADA,modelRf
_CC_GADA, modelSvm_CC_GADA_Lr, modelGbm_CC_GADA_Lr, 
modelnnet_CC_GADA_Lr,modelknn_CC_GADA_Lr, varImpDF, 
results_grid_CC_GADA,gmbImp, rfImp, nnetImp,dataset_val_10, file = "Your 
Machine Learning Objects.RData") 
 
 
 
 
